INFORMATION FOR AUTHORS

The Canadian Journal of Neurological Sciences publishes original articles in neurology, neurosurgery and basic neurosciences. Manuscripts are considered for publication with the understanding that they, or the essence of their content, have not been published elsewhere except in abstract form and are not under simultaneous consideration by another journal. A cover letter that states the above must accompany the submission. Articles undergo peer review. Manuscripts should be submitted to: Douglas Zochodne, M.D., Editor, Canadian Journal of Neurological Sciences, 7015 Macleod Trail SW, Suite 709, Calgary, AB, Canada T2H 2K6

Manuscript Preparation via Regular Mail

• Submit five high quality copies of the manuscript and original illustrations. Papers will be accepted in English or French. Text should be formatted in Microsoft Word (saved as RFT files) or Quark Xpress. Manuscripts must be double spaced throughout including references, tables and legends for illustrations. Margins of at least 25mm should be left on all sides.

• After a paper has been reviewed, the author will be requested to submit four copies of the revised manuscript, including illustrations. Supply a CD containing the article *saved in an RTF format*. Identify clearly first author's name, file name, word processing program and version, and system (i.e. PC or Mac). Clearly indicate the order and importance of headings.

• For detailed instructions regarding style and layout refer to "Uniform requirements for manuscripts submitted to biomedical journals". Copies of this document may be obtained on the website www.icmje.org, but the main points are summarized here. Articles should be submitted under conventional headings of introduction, methods and materials, results, discussion, but other headings will be considered if more suitable. Clinical trials must be reported in Consort format (www.cjns.org). Pages of text should be numbered consecutively.

Manuscript Preparation via Electronic Mail

• Electronic submission is now available. Papers will be accepted in English or French. Text should be formatted in Microsoft Word (saved as RFT files) or Quark Xpress. Store illustrations as separate files - do NOT integrate them into your text. Export line drawings/vector graphics as TIF, or EPS format. Use Photoshop for processing and retouching scanned half-tone images. Save the original scan and the processed version. Export black and white or colour images as TIF or EPS format in their anticipated size in print. Do NOT send pictures embedded in a Word document.

• Papers will be accepted in English or French. Manuscripts must be double spaced throughout including references, tables and legends for illustrations. Margins of at least 25mm should be left on all sides.

• Scanned line drawings must be digitalized with a resolution of at least 800, better 1000 dpi (dots per inch) after scaling.

• Clearly label name and address of corresponding author. Set up a folder with all files and label as Journal Submission, attach and submit to address below.

• Scanned half-tone images should be digitalized with a final resolution of at least 300 dpi, a 12 bit grayscale accuracy and a density range of 2.8.

Screen values must lie between 5% and 95%. Scanned color illustrations must be digitalized in RGB mode with a resolution of at least 300 dpi, a 32 bit accuracy and a density range of 2.8.

To Submit Manuscripts Electronically:

authorsubmissions@cjns.org

• *A title page* should identify the title of the article which should be no more than 80 characters including spaces; name of institution(s) from which the work originated; and the name, address, telephone, and fax number of the corresponding author.

• Abstract Original Articles should be accompanied by an abstract of 250 words or less on a separate page, preferably in English and French, although the Journal will provide translation if required. Abstracts of original articles should consist of four paragraphs headed: *Background* (or objective), Methods, Results and Conclusions. Review articles should be accompanied by an abstract of 150 words or less.

• Acknowledgements including recognition of financial support should be typed on a separate page at the end of the text.

• The SI system (système international d'unités) should be used in reporting all laboratory data, even if originally reported in another system. An *Ethics approval statement* must be provided, if applicable. Temperatures are reported in degrees celsius. English language text may use either British or American spelling, but should be consistent throughout.

• References should be numbered in the order of their citation in the text. Those cited only in tables and legends for illustrations are numbered according to the sequence established by the first identification in the text of a particular table or illustration. Titles of journals should be abbreviated according to the style used in Index Medicus. References should list the names of up to six authors; if there are more, cite the first six, then et al. Provide the full title, year of publication, volume number and inclusive pagination for journal articles. For any reference cited as "in press", five copies of the article must accompany the author's manuscript. Do not reference unpublished or "submitted" papers; these can be mentioned in the body of the text and authors must provide five copies of "submitted" manuscripts. Avoid "personal communications" and, if necessary, include them in the body of the text, not among the references. Reference citations should not include unpublished presentations or other non-accessible material. Books or chapter references should also include the place of publication and the name of the publisher. Examples of correct forms of reference follow:

Journals

Rose ME, Huerbin MB, Melick J, Marion DW, Palmer AM, Schiding JK, et al. Regulation of interstitial excitatory amino acid concentrations after cortical contusion injury. Brain Res. 2002;935(1-2):40-6.

Chapter in a book

Meltzer PS, Kallioniemi A, Trent JM. Chromosome alterations in human solid tumors. In: Vogelstein B, Kinzler KW, editors. The genetic basis of human cancer. New York: McGraw-Hill; 2002. p. 93-113.

• *Illustrations (regular mail)* Submit five original sets of illustrations. We will not return illustrations; therefore, authors should keep negatives for all photographs. Submit high quality glossy black and white photographs preferably 127 x 173 mm (5" x 7"). This includes graphs and diagrams.

(continued)

Do NOT send photocopies of illustrations. Original artwork and radiographs should not be submitted. The additional cost of coloured illustrations must be borne by the author; quotations are available upon request from the Journal office. Identify each figure with a label at the back indicating top, figure number and first author. Letters and arrows applied to the figures to identify particular findings should be professional appliques suitable for publication. Photomicrographs should include a calibration bar with a scale indicated on the figure or in the legend. Legends for illustrations should be typed on a separate page from the illustrations.

• *Tables* Type tables double-spaced on pages separate from the text. Provide a table number and title for each. Particular care should be taken in the preparation of tables to ensure that the data are presented clearly and concisely. Each column should have a short or abbreviated heading. Place explanatory matter in footnotes, not in the heading. Do not submit tables as photographs.

• *Review articles* on selected topics are also published. They are usually invited, but unsolicited reviews will be considered.

• Letters to the Editor concerning matters arising in recent articles are welcome. Letters should be limited to two double-spaced pages and may include one illustration and a maximum of four references.

• **Permissions and Releases** Any non-original material (quotations, tables, figures) must be accompanied by written permission from the author and the copyright owner to reproduce the material in the Journal. Permission must be for **print** and **electronic** media. Photographs of recognizable persons must be accompanied by a signed release from the legal guardian or patient authorizing publication. **Case reports** should include signed consent from the patient being reported.

· Conflict of Interest Authors who have non-scientific or non-academic gain whether it be financial or other from publishing their article are responsible for declaring it to the Editor. Any financial interest, research grant, material support, or consulting fee associated with the contents of the manuscript must be declared to the Editor. These guidelines apply to each author and their immediate families. Conflicts of interest are not necessarily wrong nor do they necessarily change the scientific validity of research or opinion, but the Journal and readers should be aware of the conflict. If the Editor considers the conflict to compromise the validity of the paper, it will not be accepted for publication. Authors, editorial staff and reviewers are asked to declare any relationship that would be considered as a conflict of interest whether or not they believe that a conflict actually exists. Information that the Journal receives about conflict or potential conflict will be kept confidential unless the Editor or Associate Editor considers it to be important to readers. Such conflicts will be published in the author credits or as a footnote to the paper, with knowledge of the authors.

NEUROLOGIST WANTED: NORTH VANCOUVER

Neurologist wanted to join a 2 person practice in North Vancouver. This pleasantly furnished office is fully computerized with a state-of-the-art electronic medical system. It is located a short walk from Lions Gate Hospital. The new neurologist would be expected to apply for privelages at the Hospital and contribute to the (very reasonable) call schedule shared with the Burnaby General Hospital neurologists. There is remuneration for being on call.

The full compliment of neurologists at Lions Gate Hospital is 4, and there are 4 neurosurgeons. There is an excellent radiology department with contemporary CT and MRI equipment, a fully equipped ICU as well as a Neuroscience Critical Care Unit and Ward. The "Neuro team" is close-knit and collegial and provides a pleasurant, stimulating and educational group to be part of.

Vancouver's North Shore, lying between the sea and the mountains, is a lovely part of the city in which to live.

Contact: Dr. John Stewart Phone: Office 604-924-4002 Cell: 604-970-0036 Fax: 604-924-4006 Email: john.stewart@telus.net

AGGRENOX

Dipyridamole/Acetylsalicylic Acid Capsules

200 mg Extended Release Dipyridamole/25 mg Immediate Release Acetylsalicylic Acid (ASA) Therapeutic Classification: Antiplatelet Agent

SUMMARY PRODUCT INFORMATION

Route of Administration	Dosage Form / Strength	Clinically Relevant Nonmedicinal Ingredients
oral	capsules, 200mg/25 mg	Non-medicinal ingredients (in alphabetical order): acacia, aluminium stearate, colloidal silicon dioxide, corn starch, dimethicone, hydroxypropyl methylcellulose, hydroxypropyl methylcellulose phthalate, lactose monohydrate, methacrylic acid copolymer, microcrystalline cellulose, povidone, stearic acid, sucrose, talc, tartaric acid, titanium dioxide, and triacetin. The capsule shell contains gelatine, red iron oxide and yellow iron oxide, titanium dioxide and water.

INDICATIONS AND CLINICAL USE

AGGRENOX is indicated for

• the prevention of stroke in patients who have had a previous stroke or a transient ischemic attack (TIA).

Pediatrics (< 18 years of age): Safety and effectiveness of AGGRENOX in pediatric patients has not been studied. Therefore, AGGRENOX should not be used in pediatric patients.

ASA should not be used in children or teenagers for viral infections, with or without fever, because of the risk of Reye's syndrome with concomitant use of ASA in certain viral illnesses.

CONTRAINDICATIONS

- · Patients who are hypersensitive to this drug or to any ingredient in the formulation or component of the container.
- For a complete listing, see the Dosage Forms, Composition and Packaging section of the product monograph.

 Due to the ASA component, AGGRENOX is also contraindicated in patients with known allergy to nonsteroidal anti-
- inflammatory drug products and in patients with the syndrome of asthma, rhinitis and nasal polyps. • Patients with rare hereditary problems of fructose intolerance and/or galactose intolerance (e.g. galactosaemia)
- should not take this medicine. AGGRENOX contains approximately 23 mg sucrose and 106 mg of lactose per maximum recommended daily dose.

WARNINGS AND PRECAUTIONS

General

ALCOHOL WARNING

Patients who consume three or more alcoholic drinks every day should be counselled about the bleeding risks involved with chronic, heavy alcohol use while taking AGGRENOX, due to the ASA component.

If a patient is to undergo elective surgery, consideration should be given to discontinue AGGRENOX 10 days prior to surgery to allow for the reversal of the effect.

BLEEDING

As any antiplatelet agents, which cause bleeding, the use of AGGRENOX may increase the risk of bleeding such as skin haemorrhage, gastrointestinal bleeding and intracerebral haemorrhage. The addition of other antiplatelet agents (e.g. Clopidogrel, Ticlopidine) to AGGRENOX may further increase the risk of serious bleeding. Even though no study has been conducted, such combination is not recommended.

Due to the ASA component, the concomitant use of AGGRENOX with either selective serotonin reuptake inhibitors (SSRIs) or conticosteroids can increase the gastrointestinal bleeding.

This product contains 106 mg of lactose and 22.5 mg sucrose per maximum recommended daily dose. Patients with rare hereditary problems of fructose intolerance and/ or galactose intolerance e.g. galactosaemia should not take this medicine.

Carcinogenesis and Mutagenesis

CARCINOGENESIS

In carcinogenicity studies in rats and mice with the combination of dipyridamole and ASA at the ratio of 1:6 over a period of 125 and 105 weeks respectively, no significant tumorigenic effect was observed at maximum doses of 450 mg/kg (corresponding to a share of 75 mg/kg of dipyridamole, 9 times the maximum recommended daily human dose for a 50 kg person on a mg/kg basis [or 1.5-2.1 times on a mg/m2 basis]), and 375 mg/kg ASA, 375 times the maximum recommended daily human dose for a 50 kg person on a mg/kg basis (or 58-83 times on a mg/m2 basis).

Cardiovascular

AGGRENOX should be used with caution in patients with severe coronary artery disease (e.g. unstable angina or recently sustained myocardial infarction), due to the vasodilatory effect of the dipyridamole component. Chest pain may be aggravated in patients with underlying coronary artery disease who are receiving dipyridamole. Patients being treated with AGGRENOX should not receive additional intravenous dipyridamole. If pharmacological stress testing with intravenous dipyridamole for coronary artery disease is considered necessary, then AGGRENOX should be discontinued twenty-four hours prior to testing, otherwise the sensitivity of the intravenous stress test could be limited.

For stroke or TIA patients for whom ASA is indicated to prevent recurrent myocardial infarction (MI) or angina pectoris, the dose of ASA in AGGRENOX has not been proven to provide adequate treatment for these cardiac indications.

Gastrointestinal

PEPTIC ULCER DISEASE

Patients with a history of active peptic ulcer disease should avoid using AGGRENOX, which can cause gastric mucosal irritation, and bleeding, due to the ASA component.

Gl side effects include stomach pain, heartburn, nausea, vomiting, diarrhoea, and gross Gl bleeding. Although minor upper Gl symptoms, such as dyspepsia, are common and can occur anytime during therapy, physicians should remain alert for signs of ulceration and bleeding, even in the absence of previous Gl symptoms. Physicians should inform patients about the signs and symptoms of Gl side effects and what steps to take if they occur.

<u>Hematologic</u>

AGGRENOX should be used with caution in patients with inherited (haemophilia) or acquired (liver disease or vitamin K deficiency) bleeding disorders, due to the fact that even low doses of ASA can inhibit platelet function leading to an increase in bleeding time.

Hepatic/Biliary/Pancreatic

Due to the ASA component, AGGRENOX should be avoided in patients with severe hepatic insufficiency.

Renal

Due to the ASA component, AGGRENOX should be avoided in patients with severe renal failure (glomerular filtration

rate less than 10 mL/min).

Sexual Function/Reproduction

Fertility studies with dipyridamole revealed no evidence of impaired fertility in rats at oral dosages of up to 1250 mg/kg, 156 times the maximum recommended human dose on a mg/kg basis for a 50 kg person (or 35 times on a mg/m2 basis). ASA inhibits ovulation in rats.

Special Populations

Pregnant Women: There are no adequate and well-controlled studies of AGGRENOX in pregnant women. Because animal reproduction studies are not always predictive of human response. AGGRENOX should be given during the first two trimesters of pregnancy only if the potential benefit to the mother justifies the potential risk to the fetus. Due to the ASA component, AGGRENOX should not be prescribed during the third trimester of pregnancy.

Nursing Women: Dipyridamole and ASA are excreted in human breast milk in low concentrations. Therefore, caution should be exercised when AGGRENOX is administered to a nursing woman.

Pediatrics (< 18 years of age): Safety and effectiveness of AGGRENOX in pediatric patients has not been studied. Therefore, AGGRENOX should not be used in pediatric patients.

ASA should not be used in children or teenagers for viral infections, with or without fever, because of the risk of Reye's syndrome with concornitant use of ASA in certain viral illnesses.

Monitoring and Laboratory Tests

ASA has been associated with elevated hepatic enzymes, blood urea nitrogen and serum creatinine, hyperkalemia, proteinuria and prolonged bleeding time. Over the course of the 24-month study (ESPS2), patients treated with AGGRENOX showed a decline (mean change from baseline) in hemoglobin of 0.25 g/dl, hematocrit of 0.75%, and erythrocyte count of 0.13x106/mm³.

ADVERSE REACTIONS

Clinical Trial Adverse Drug Reactions

Because clinical trials are conducted under very specific conditions the adverse reaction rates observed in the clinical trials may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse drug reaction information from clinical trials is useful for identifying drug-related adverse events and for approximating rates.

A 24-month, multicenter, double-blind, randomized study (ESPS2) was conducted to compare the efficacy and safety of AGGRENOX with placebo, extended release digyridamole alone and ASA alone. The study was conducted in a total of 6602 male and female patients who had experienced a previous ischemic stroke or transient ischemia of the brain within three months prof to randomization. Discontinuation due to adverse events in ESPS2 was 27.8% for AGGRENOX, 28.2% for extended release digyridamole. 23.2% for ASA, and 23.7% for placebo.

Table 2 presents the incidence of adverse events that occurred in 1% or more of patients treated with AGGRENOX where the incidence was also greater than those patients treated with placebo.

Table 2: INCIDENCE OF ADVERSE EVENTS IN ESPS2 REPORTED BY > 1% OF PATIENTS DURING AGGRENOX TREATMENT WHERE THE INCIDENCE WAS GREATER THAT THOSE TREATED WITH PLACEBO

	Individual Treatment Group					
	AGGRENOX	ER-DP Alone	ASA Alone	placebo		
Total Number of Patients	N=1650	N=1654	N =1649	N =1649		
Total Number (%) of Patients With at Least One On-Treatment Adverse Event	1319 (79.9%)	1305 (78.9%)	1323 (80.2%)	1304 (79.1%)		
Body System/Preferred Terr	n	• • • • • • • • • • • • • • • • • • • •				
Any Bleeding** Severity of bl	eeding:***					
Mild	84 (5.1%)	53 (3.2%)	82 (5.0%)	52 (3.2%)		
Moderate	33 (2.0%)	18 (1.1%)	33 (2.0%)	15 (0.9%)		
Severe	23 (1.4%)	4 (0.2%)	19 (1.2%)	5 (0.3%)		
Fatal	4 (0.2%)	2 (0.1%)	1 (0.1%)	2 (0.1%)		
Body as a Whole – General	Disorders					
Pain	105 (6.4%)	88 (5.3%)	103 (6.2%)	99 (6.0%)		
Fatigue	95 (5.8%)	93 (5.6%)	97 (5.9%)	90 (5.5%)		
Back Pain	76 (4.6%)	77 (4.7%)	74 (4.5%)	65 (3.9%)		
Accidental Injury	42 (2.5%)	24 (1.5%)	51 (3.1%)	37 (2.2%)		
Malaise	27 (1.6%)	23 (1.4%)	26 (1.6%)	22 (1.3%)		
Asthenia	29 (1.8%)	19 (1.1%)	17 (1.0%)	18 (1.1%)		
Syncope	17 (1.0%)	13 (0.8%)	16 (1.0%)	8 (0.5%)		
Cardiovascular Disorders, G	eneral					
Cardiac Failure	26 (1.6%)	17 (1.0%)	30 (1.8%)	25 (1.5%)		
Central & Peripheral Nervou	is System Disorders	5				
Headache	647 (39.2%)	634 (38.3%)	558 (33.8%)	543 (32.9%)		
Convulsions	28 (1.7%)	15 (0.9%)	28 (1.7%)	26 (1.6%)		
Gastro-Intestinal System Di	sorders	_				
Dyspepsia	303 (18.4%)	288 (17.4%)	299 (18.1%)	275 (16.7%)		
Abdominal Pain	289 (17.5%)	255 (15.4%)	262 (15.9%)	239 (14.5%)		
Nausea	264 (16.0%)	254 (15.4%)	210 (12.7%)	232 (14.1%)		
Diarrhoea	210 (12.7%)	257 (15.5%)	112 (6.8%)	161 (9.8%)		
Vomiting	138 (8.4%)	129 (7.8%)	101 (6.1)	118 (7.2%)		
Hemorrhage Rectum	26 (1.6%)	22 (1.3%)	16 (1.0%)	13 (0.8%)		
Melena	31 (1.9%)	10 (0.6%)	20 (1.2%)	13 (0.8%)		
Haemorrhoids	16 (1.0%)	13 (0.8%)	10 (0.6%)	10 (0.6%)		
GI Hemorrhage	20 (1.2%)	5 (0.3%)	15 (0.9%)	7 (0.4%)		
Musculo-Skeletal System D	isorders					
Arthralgia	91 (5.5%)	75 (4.5%)	91 (5.5%)	76 (4.6%)		
Arthritis	34 (2.1%)	25 (1.5%)	17 (1.0%)	19 (1.2%)		
Arthrosis	18 (1.1%)	22 (1.3%)	13 (0.8%)	14 (0.8%)		
Myalgia	20 (1.2%)	16 (1.0%)	11 (0.7%)	11 (0.7%)		

Table 2: INCIDENCE OF ADVERSE EVENTS IN ESPS2 REPORTED BY > 1% OF PATIENTS DURING AGGRENOX

	Individual Treatment Group				
	AGGRENOX	ER-DP Alone	ASA Alone	placebo	
Total Number of Patients	N=1650	N=1654	N =1649	N =1649	
Total Number (%) of Patients With at Least One On-Treatment Adverse Event	1319 (79.9%)	1305 (78.9%)	1323 (80.2%)	1304 (79.1%)	
Neoplasm					
Neoplasm NOS	28 (1.7%)	16 (1.0%)	23 (1.4%)	20 (1.2%)	
Platelet, Bleeding & Clotting	Disorders				
Hemorrhage NOS	52 (3.2%)	24 (1.5%)	46 (2.8%)	24 (1.5%)	
Epistaxis	39 (2.4%)	16 (1.0%)	45 (2.7%)	25 (1.5%)	
Purpura	23 (1.4%)	8 (0.5%)	9 (0.5%)	7 (0.4%)	
Psychiatric Disorders					
Amnesia	39 (2.4%)	40 (2.4%)	57 (3.5%)	34 (2.1%)	
Confusion	18 (1.1%)	9 (0.5%)	22 (1.3%)	15 (0.9%)	
Anorexia	19 (1.2%)	17 (1.0%)	10 (0.6%)	15 (0.9%)	
Somnolence	20 (1.2%)	13 (0.8%)	18 (1.1%)	9 (0.5%)	
Red Blood Cell Disorders					
Anaemia	27 (1.6%)	16 (1.0%)	19 (1.2%)	9 (0.5%)	
Respiratory System Disorde	rs				
Coughing	25 (1.5%)	18 (1.1%)	32 (1.9%)	21 (1.3%)	
Upper Respiratory Tract Infection	16 (1.0%)	9 (0.5%)	16 (1.0%)	14 (0.8%)	

Note: ER-DP = Extended Release Dipyridamole 400 mg/day; ASA = Acetylsalicylic Acid 50 mg/day.

Note: The dosage regimen for all treatment groups is b.i.d.

** Bleeding at any site, reported during follow-up and within 15 days after eventual stroke or treatment cessation.

* Severity of bleeding: mild = requiring no special treatment; moderate = requiring specific treatment but no blood transfusion: severe = requiring blood transfusion

Note: NOS = not otherwise specified

Less Common Clinical Trial Adverse Drug Reactions (<1%)

Adverse reactions that occurred in less than 1% of patients treated with AGGRENOX in the ESPS2 study and that were medically judged to be possibly related to either dipyridamole or ASA are listed below

Body as a Whole: allergic reaction, fever

Cardiovascular: hypotension, flushing

Central Nervous System: coma, dizziness, paraesthesia Gastrointestinal: pastritis, ulceration and perforation

Hearing & Vestibular Disorders: tinnitus, and deafness. Patients with high frequency hearing loss may have difficulty perceiving tinnitus. In these patients, tinnitus cannot be used as a clinical indicator of salicylism Heart Rate and Rhythm Disorders: tachycardia, palpitation, arrhythmia, supraventricular tachycardia

Liver and Billary System Disorders: cholelithiasis, jaundice, abnormal hepatic function

Metabolic & Nutritional Disorders: hyperglycemia, thirst

Platelet, Bleeding and Clotting Disorders: haematoma, gingival bleeding, cerebral hemorrhage, intracranial hemorrhage, subarachnoid hemorrhage

Note: There was one case of pancytopenia recorded in a patient within the AGGRENOX treatment group, from which the patient recovered without discontinuation of AGGRENOX.

Psychiatric Disorders: agitation

Reproductive: uterine hemorrhage

Respiratory: hypernea, asthma, bronchospasm, haemoptysis, pulmonary edema Special Senses: taste loss

Skin and Appendages Disorders: pruritus, urticaria Urogenital: renal insufficiency and failure, hematuria

Abnormal Hematologic and Clinical Chemistry Findings

Over the course of the 24-month study (ESPS2), patients treated with AGGRENOX showed a decline (mean change from baseline) in hemoglobin of 0.25 g/dl, hematocrit of 0.75%, and erythrocyte count of 0.13x106/mm³.

Post-Market Adverse Drug Reactions

The following is a list of additional adverse reactions that have been reported either in the literature or are from postmarketing spontaneous reports for either dipyridamole or ASA.

Body as a Whole: hypothermia, migraine-like headache (especially at the beginning of treatment)

Cardiovascular: angina pectoris, worsening of symptoms of coronary heart diseas Central Nervous System: cerebral edema

Fluid and Electrolyte: hyperkalemia, metabolic acidosis, respiratory alkalosis

Gastrointestinal: pancreatitis, Reyes Syndrome

Hearing and Vestibular Disorders: hearing loss

Hypersensitivity: acute anaphylaxis, laryngeal edema

Liver and Billiary System Disorders: hepatitis, incorporated into gallstones

Musculoskeletal: mabdomyolysis

Metabolic & Nutritional Disorders: hypoglycemia, dehydration

Blood, Platelet, Bleeding and Clotting Disorders: prolongation of the prothrombin time, prolongation of bleeding time, increased bleeding during and after surgery, disseminated intravascular coagulation, coagulopathy, thrombocytopenia Reproductive: prolonged pregnancy and labour, stillbirths, lower birth weight infants, antepartum and postpartum bleeding

Respiratory: tachypnea

Skin and Appendages Disorders: rash, alopecia, angioedema, skin haemorrhages such as contusion, ecchymosis and haematoma

Urogenital: interstitial nephritis, papillary necrosis, proteinuria

DRUG INTERACTIONS

Drug-Drug Interactions

<u>Overview</u>

When AGGRENOX is used in combination with acetylsalicylic acid or with warfarin the statements regarding precautions, warnings and tolerance for these preparations must be observed. Because of the increased risk of bleeding, the concomitant administration of benario, or warfarin with AGGRENOX should be undertaken with caution The drugs listed in this table are based on either drug interaction case reports or studies, or potential interactions due to the expected magnitude and seriousness of the interaction (i.e., those identified as contraindicated).

Table 3- Established or Potential Drug-Drug Interactions

The following days interactions	Effect are associated with the Dipyridamole compo	Clinical comment
ADENOSINE	Dipyridamole has been reported to increase the plasma levels and cardiovascular effects of adenosine.	Adjustment of adenosine dosage may be necessary.
CHOLINESTERASE INHIBITORS	The dipyridamole component of AGGRENOX may counteract the anticholinesterase effect of cholinesterase inhibitors, thereby potentially aggravating myasthenia gravis.	Patients should be advised to consult a physician if any worsening of the disease occurs.
The following drug interactions	are associated with the ASA component of A	1
ACETAZOLAMIDE	Due to the ASA component, concurrent use of AGGRENOX and acetazolamide can lead to high serum concentrations of acetazolamide (and toxicity) due to competition at the renal tubule for secretion.	Adjustment of acetazolamide dosage may be necessary.
Alcohol USE (Chronic)	Gastro-intestinal bleeding may increase when acetylsalicylic acid is administered concomitantly during chronic alcohol use.	Patients should be advised to consult a physician if any signs or symptoms of bleeding occur.
angiotensin converting Enzyme (ACE) inhibitors	Due to the indirect effect of the ASA component on the renin-angiotensin conversion pathway, the hyponatremic and hypotensive effects of ACE inhibitors may be diminished by concomitant administration of AGGRENOX.	Patients should be advised to consult a physician if any signs or symptoms of decreased renal function such as oedema, or increase in blood pressure occur.
Anticoagulant Therapy (Heparin and Warfarin	Patients on anticoagulation therapy are at increased risk for bleeding because of drug-drug interactions and effects on platelets. ASA can displace warfarin from protein binding sites, leading to prolongation of both the prothrombin time and the bleeding time. The ASA component of AGGRENOX can increase the anticoagulant activity of heparin, increasing bleeding risk. Acetylsalicylic acid has been shown to enhance the effect of anticoagulants (e.g. coumarin derivatives and heparin) which may result in an increased risk of bleeding.	Patients should be advised to consult a physician if any signs or symptoms of bleeding occur.
ANTIPLATELET DRUGS (CLOPIDOGREL, TICLOPIDINE)	Acetylsalicylic acid has been shown to enhance the effect of antiplatelet drugs (e.g. clopidogrel, tickopidine) which may result in an increased risk of bleeding.	Patients should be advised to consult a physician if any signs or symptoms of bleeding occur.
anticonvulsants	The ASA component of AGGRENOX can displace protein-bound phenytoin and valproic acid, leading to a decrease in the total concentration of phenytoin and an increase in serum valproic acid levels. Acetylsalicylic acid has been shown to enhance the effect of valproic acid which may result in an increased risk of rare, but often fatal hepatotoxicity.	Adjustment of phenytoin or valproic acid dosage may be necessary.
BETA BLOCKERS	The hypotensive effects of beta blockers may be diminished by the concomitant administration of AGGRENOX due to inhibition of renal prostaglandins by ASA, leading to decreased renal blood flow, and salt and fluid retention.	Patient should be advised to consult a physician if any signs or symptoms of decreased renal function such as oedema, or increase in blood pressure occur.
Corticosteroids	Gastro-intestinal bleeding increase when acetylsalicylic acid is administered concomitantly with corticosteroids.	Patient should be advised to consult a physician if any signs or symptoms of bleeding occur.
DIURETICS	The effectiveness of diuretics in patients with underlying renal or cardiovascular disease may be diminished by the concomitant administration of AGGRENOX due to inhibition of renal prostaglandins by ASA, leading to decreased renal blood flow and salt and fluid retention	Patient should be advised to consult a physician if any signs or symptoms of decreased renal function such as oedema occur.
IBUPROFEN	The concomitant administration of ibuprofen in healthy volunteers shortened the platelet aggregation inhibitory effect of ASA.	
METHOTREXATE	The ASA component of AGGRENOX can inhibit renal clearance of methotrexate, leading to bone marrow toxicity, especially in the elderly or renally impaired.	Adjustment of methotrexate dosage may be necessary.
NONSTEROIDAL ANTI- INFLAMMATORY DRUGS (NSAIDS)	Due to the ASA component, the concurrent use of AGGRENOX with other NSAIDs may increase bleeding or lead to decreased renal function. Gastro-intestinal bleeding increases when acetylsailcylic acid is administered concomitantly with NSAIDs.	Patient should be advised to consult a physician if any signs or symptoms of bleeding occur.

	Effect	Clinical comment	
ORAL HYPOGLYCAEMICS	AGGRENOX may increase the effectiveness of oral hypoglycemic drugs, leading to hypoglycaemia.	Patient should be advised to consult a physiclan if any signs or symptoms of hypoglycaemia occur.	
SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS)	Selective serotonin reuptake inhibitors (SSRIs) may increase the risk of bleeding.	Patient should be advised to consult a physician if any signs or symptoms of bleeding occur.	
URICOSURIC AGENTS (PROBENECID AND SULFINPYRAZONE) AND NATRIURETIC AGENTS	The ASA component of AGGRENOX antagonizes the uricosuric action of uricosuric agents. ASA decreased the natriuretic effect of spironolactone in healthy volunteers.	Patient should be advised to consult a physician if any signs or symptoms of decreased renal function such as oedema occur.	

Drug-Herb interaction

Pharmacokinetic studies to determine the effect of herb or food have not been conducted with AGGRENOX.

Drug-laboratory interactions

Pharmacokinetic studies to determine the effect of laboratory interactions have not been conducted with AGGRENOX Drug-lifestyle Interactions

Pharmacokinetic studies to determine the effect of lifestyle have not been conducted with AGGRENOX.

DOSAGE AND ADMINISTRATION

Dosing Considerations

For oral administration.

Recommended Dose and Dosage Adjustment

The recommended dose of AGGRENOX is one capsule twice daily, one in the morning and one in the evening, with or without food.

Administration

The capsules should be swallowed whole without chewing.

OVERDOSAGE

Because of the dose ratio of dipyridamole to ASA, overdosage of AGGRENOX is likely to be dominated by signs and symptoms of dipyridamole overdose. For real or suspected overdose, a Poison Control Center should be contacted immediately. Careful medical management is essential.

DIPYRIDAMOLE

SYMPTOMS

Based upon the known hemodynamic effects of dipyridamole, symptoms such as feeling warm, flushes, sweating, restlessness, feeling of weakness and dizziness may occur. A drop in blood pressure and tachycardia might also be observed.

TREATMENT

Symptomatic treatment is recommended, possibly including a vasopressor drug. Gastric lavage should be considered. Since dipyridamole is highly protein bound, dialysis is not likely to be of benefit.

ASA

SYMPTOMS

In mild overdosage these may include rapid and deep breathing, nausea, vomiting, vertigo, tinnitus, flushing, sweating, thirst and tachycardia. In more severe cases acid base disturbances including respiratory alkalosis and metabolic acidosis can occur. Severe cases may show fever, hemorrhage, excitement, confusion, convulsion or coma, and respiratory failure.

TREATMENT

It consists of prevention and management of acid-base and fluid and electrolyte disturbances. Renal clearance is increased by increasing urine flow and by alkaline diuresis but care must be taken in this approach not to aggravate further the metabolic acidosis that develops and the hypokalemia. Acidemia should be prevented by administration of adequate sodium containing fluids and sodium bicarbonate. Hypoglycemia is an occasional accompaniment of salicylate overdosage and can be managed by administration of glucose solutions. If a hemorrhagic diathesis is evident, give vitamin K. Haemodalysis may be useful in complex acid base disturbances particularly in the presence of abormal renal function.

ACTION AND CLINICAL PHARMACOLOGY

Mechanism of Action

Blood platelets participate actively in the pathogenesis of atherosclerolic lesions and thrombosis which is the principle cause of most strokes and transient ischernic attacks (TIAs). Platelets are believed to adhere to denuded, dysfunctional endothelium and to release mitogenic substances, such as platelet-derived growth factor (PDGF), that foster the lesion's progression to rupture and thrombosis. The antithrombotic action of AGGRENOX is the result of the additive antiplatelet effects of dipyridamole and acetylsalicylic acid (ASA).

DIPYRIDAMOLE

Dipyridamole inhibits the uptake of adenosine into platelets, endothelial cells and erythrocytes in vitro and in vivo; the inhibition occurs in a dose dependent manner at therapeutic plasma concentrations (0.5-1.9 µg/mL). This inhibition results in an increase in local concentrations of adenosine which acts on the platelet A2-receptor thereby stimulating platelet adenylate cyclase and increasing platelet cyclic.³, 5-adenosine monophosphate (cAMP) levels. Via this mechanism, platelet aggregation is inhibited in response to various stimuli such as platelet activating factor (PAF), collagen and adenosine diphosphate (ADP). Reduced platelet aggregation reduces platelet consumption towards normal levels.

Dipyridamole also inhibits phosphodiesterase (PDE) in various tissues. While the inhibition of cAMP-PDE is weak, therapeutic levels of dipyridamole inhibit cyclic-3', 5'-guanosine monophosphate-PDE (cGMP-PDE), thereby augmenting the increase in cGMP produced by EDPF (endothelium-derived relaxing factor, now identified as nitric oxide). AcA

ASA inhibits platelet aggregation by irreversible inhibition of platelet cyclo-oxygenase and thus inhibits the generation of thromboxane A2, a powerful inducer of platelet aggregation and vasoconstriction. In studies of platelet activity inhibition, 25 mg ASA was administered b.i.d. to 5 subjects for 2.5 days. Complete inhibition of collagen-induced aggregation was achieved by the 5th dose of ASA, and maximal effect persisted up to 2-3 days following stoppage of drug.s

Pharmacokinetics

There are no significant interactions between ASA and dipyridamole. The kinetics of the components are unchanged by their co-administration as AGGRENOX. AGGRENOX is not interchangeable with the individual components of ASA and dipyridamole.

DIPYRIDAMOLE

Absorption: The dissolution and absorption of dipyridamole from AGGRENOX capsules is independent of the pH of the gastrointestinal tract. Peak plasma levels are achieved in 1.5-2 hours after administration. The absolute bioavailability of dipyridamole from AGGRENOX is about 70%. With a daily maintenance dose of 400 mg of the extended release formulation, peak plasma levels at steady state are between 1.5-3 µg/mL and trough levels are between 0.4-0.8 µg/mL.

Pharmacokinetic studies to determine the effect of food have not been conducted with AGGRENOX

Distribution: Due to its high lipophilicity, dipyridamole distributes to many organs; however it has been shown that the drug does not cross the blood brain barrier to any significant extent.

Metabolism: Dipyridamole is metabolized in the liver. In plasma, about 80% of the total amount is present as parent compound and 20% as monoglucuronide.

Excretion: Most of the glucuronide metabolite (about 95%) is excreted via bile into the feces, with some evidence of enterohepatic circulation. Renal excretion of parent compound is negligible and urinary excretion of the glucuronide metabolite is low (about 5%). The dominant half-life for elimination after oral or intravenous administration is about 40 minutes.

Special Populations and Conditions

Geriatrics: Plasma concentrations (determined as area under the curve, AUC) of dipyridamole in healthy elderly subjects (> 65 years) are about 30-50% higher than in subjects younger than 55 years, on treatment with AGGRENOX. The difference is caused mainly by reduced clearance.

Hepatic Insufficiency: Patients with mild to severe hepatic insufficiency show no change in plasma concentrations of dipyridamole compared to healthy volunteers, but show an increase in the pharmacologically inactive monoglucuronide metabolite. Dipyridamole can be dosed without restriction as long as there is no evidence of liver failure.

Renal Insufficiency: Renal excretion of dipyridamole is very low (about 5%). In patients with creatinine clearances ranging from about 15 mL/min to > 100 mL/min, no changes were observed in the pharmacokinetics of dipyridamole or its glucuronide metabolite.

ASA

Absorption: The rate of absorption of ASA from the gastrointestinal tract is dependent on the dosage form, the presence or absence of food, gastric pH, and other physiologic factors. Since ASA produces its pharmacodynamic effect via the irreversible acetylating of platelets, the time course of its pharmacodynamic activity is not dependent on the pharmacokinetics of ASA but rather on the lifespan of the platelets (approximately 8-10 days). Therefore, small differences in the pharmacokinetics of ASA, such as variations in its absorption rate or in elimination, are largely irrelevant to its pharmacokinetics of ASA such as variations in its absorption rate or in elimination, are largely irrelevant to its pharmacokinetics of ASA such as variations in its absorption rate or in elimination, sailcylic acid in the liver and the gastrointestinal wall, with 50%-75% of an administered dose reaching the systemic circulation as intact ASA. Peak plasma levels of ASA are achieved 0.5-1 hour after administration of a 50 mg ASA daily dose from AGGRENOX (given as 25 mg b i.d.). Peak mean plasma concentration at steady state is 319 ng/mL (175-463 ng/mL).

Distribution: ASA is poorly bound to plasma proteins and its apparent volume of distribution is low (10 L). At low plasma concentrations (< 100 µg/mL), approximately 90% of salicylic acid is bound to albumin. Salicylic acid is widely distributed to all tissues and fluids in the body including the central nervous system, breast milk, and fetal tissues. Early signs of salicylate overdose (salicylism), including thmitus (ringing in the ears), occur at plasma concentrations approximating 200 µg/mL. (See ADVERSE REACTIONS, OVERDOSAGE)

Metabolism: ASA is rapidly hydrolyzed in plasma to salicylic acid, with a half-life of 15-30 minutes. Plasma levels of ASA are essentially undetectable 1-2 hours after dosing and peak salicylic acid concentrations occur within 1-2 hours of administration of ASA. Salicylate metabolism is saturable and total body clearance decreases at higher serum concentrations due to the limited ability of the liver to form both salicyluric acid and phenolic glucuronide. Following toxic doses (10-20 g), the plasma half-life may be increased to over 20 hours.

Excretion: The elimination of salicylic acid follows first order kinetics at lower doses, with a resultant half-life of approximately 2-3 hours. Renal excretion of unchanged drug depends upon urmary pH. As urinary pH rises above 6.5, the renal clearance of free salicylate increases from < 5% to > 80%. Alkalinization of the urine is a key concept in the management of salicylate overdose. (See OVERDOSAGE) Following therapeutic doses, about 10% is excreted as salicylic acid and 75% as salicyluric acid, in urine.

Special Populations and Conditions

Hepatic Insufficiency: Due to the ASA component, AGGRENOX is to be avoided in patients with severe hepatic insufficiency.

Renal Insufficiency: Due to the ASA component, AGGRENOX is to be avoided in patients with severe renal failure (glomerular filtration rate less than 10 mt/min).

STORAGE AND STABILITY

Store at 15 to 30°C.

SPECIAL HANDLING INSTRUCTIONS

Protect from excessive moisture.

DOSAGE FORMS, COMPOSITION AND PACKAGING

Each hard gelatine capsule contains 200 mg dipyridamole as extended release pellets (a mixture of two release rate pellets), and 25 mg ASA as an immediate release sugar coated tablet.

AGGRENOX is available as a hard gelatine capsule, with a red cap and an ivory-coloured body, containing yellow extended release pellets incorporating dipyridamole and a round white tablet incorporating immediate-release ASA. The capsule body is imprinted in red with the Boehringer Ingelheim logo and with "01A".

Non-medicinal ingredients (in alphabetical order): acacia, aluminium stearate, colloidal silicon dioxide, corn starch, dimethicone, hydroxypropyl methylcellulose, hydroxypropyl methylcellulose phthalate, lactose monohydrate, methacrylic acid copolymer. microcrystalline cellulose, povidone, stearic acid, sucrose, talc, tartaric acid, titanium dioxide, and triacetn.

The capsule shell contains gelatine, red iron oxide and yellow iron oxide, titanium dioxide and water AGGRENOX is supplied in polypropylene tubes containing 60 capsules.



ASA /Extended Release Dipyridamole



HAAB RED



Concentrate for solution for intravenous infusion 300 mg/15 mL

THERAPEUTIC CLASSIFICATION:

Selective adhesion molecule inhibitor

TYSABRI should be used by physicians who have of multiple scierosis and who have familiarized themselves with the efficacy/safety profile of the drug.

SUMMART PRODUCT INFORMATION	
Route of Administration Intravenous infusion	
Deserve From / Charles all	

sage Form / Strength Concentrate for solution / 300 mg per 15 mL **Clinically Relevant Nonmedicinal Ingredients**

There are no clinically relevant nonmedicinal ingredients. For a complete listing of nonmedicinal ingredients see Dosage Forms, Composition and Packaging section.

DESCRIPTION

TYSABRI™ (natalizumab) is a recombinant humanized IgG4k monoclonal antibody selective for cx4-integrin. Natalizumab is produced in murine myeloma cells The molecular weight of natalizumab is 149 kilodaltons, TYSABRI is supplied as a sterile, colourless, clear to slightly opalescent concentrate for solution for intravenous (IV) infusion

INDICATIONS AND CLINICAL USE

TYSABRI^w (natalizumab) is indicated as monotherapy (i.e., single diseasemodifying agent) for the treatment of patients with the relapsing-remitting form of multiple sclerosis (MS) to reduce the frequency of clinical exacerbations, to decrease the number and volume of active brain lesions identified on magnetic resonance imaging (MRI) scans and to delay the progression of physical disability. TYSABRI is generally recommended in MS patients who have had an inadequate response to, or are unable to tolerate. other therapies for multiple sclerosis.

Safety and efficacy in patients with chronic progressive multiple sclerosis, and in genatric and pediatric patients, have not been established.

The efficacy and safety of TYSABRI for a treatment duration beyond 2 years has not been determined.

TYSABRI should be used by physicians who have sufficient knowledge of multiple scierosis and who have familiarized themselves with the efficacy/safety profile of TYSABRI.

Generatrics (>65 years of age) Clinical studies of TYSABRI did not include sufficient numbers of patients aged 65 years and over to determine whether they respond differently than younger patients

Pediatrics (<18 years of are)

Safety and effectiveness of TYSABRI in pediatric patients with multiple sclerosis have not been studied.

CONTRAINDICATIONS

Patients who are hypersensitive to this drug or to any ingredient in the formulation or component of the container. For a complete listing, see the Dosage Forms, Composition and Packaging section of the Product Monograph. Pati nts who have or have had progressive multifocal leukoencephalopathy (PMI)

Patients who are immunocompromised, including those immunocompromised due to immunosuppressant or antineoplastic therapies, or immunodeficiencies (HIV, leukemias, lymphomas, etc.)

WARNINGS AND PRECAUTIONS

•Treatment with TYSABRI™ (natalizumab) has been associated with an increased risk of progressive multifocal leukoencephalopathy (PML). PML can cause disability or death (see Warnings and Precautions Immune; Contraindications; Adverse Reactions).

Healthcare professionals should monitor patients on TYSABRI for any new sign or symptom that may be suggestive of PML. TYSABRI dosing should be withheld immediately at the first sign or symptom suggestive of PML.

Before initiation of treatment with TYSABRI™ (natalizumab), a recent magnetic resonance image (MRI) should be available. This MRI may be helpful in differentiating subsequent MS symptoms from PML. For diagnosis of PML, an evaluation that includes a gadolinium-enhanced magnetic resonance imaging (MRI) scan of the brain and, when indicated, cerebrospinal fluid analysis for JC viral DNA are recommended (see Warnings and Precautions, Immune).

Patients who are prescribed TYSABRI should enroll in the Tysabri Care Program " - a registry of Canadian patients. This program ensures that appropriate physicians and infusion centres are able to prescribe or infuse the product.

TYSABRI has been associated with hypersensitivity reactions, which occurred at an incidence of 4%, including serious systemic reactions (e.g., anaphylaxis), which occurred at an incidence of < 1%. These reactions usually occurred within 2 hours of the start of the infusion. Symptoms associated with these reactions included urticaria, dizziness, fever, rash, rigors, pruritus, nausea, flushing, hypotension, dyspnea and chest pain. Generally, these reactions are associated with antibodies to TYSABRI. If a hypersensitivity reaction occurs, discontinue administration of TYSABRI immediately and initiate appropriate therapy

Although not seen in clinical trials with TYSABRI, there is a potential for aggravation of infection or latent infection becoming activated in patients receiving TYSABRI. In clinical trials, most patients did not interrupt treatment with TYSABRI during an infection (see Adverse Reactions, Infections).

econsis and Matagenesis

No clastogenic or mutagenic effects of natalizumab were observed in the Ames human chromosomal aberration assays. Natalizumab showed no effects on in vitro assays of 0:4-integrin-positive human tumour line proliferation/cytotoxicity. Xenograft transplantation models in SCID and nude mice with two cc4-integrin-positive human tumour lines (leukemia,melanoma) demonstrated no increase in turnour growth rates or metastasis resulting from natalizumab treatment.

TYSABRI induces increases in circulating lymphocytes, monocytes, eosinophils and nucleated red blood cells. During phase 3 clinical trials, cell counts were measured every 12 weeks. The largest cell increases were seen in lymphocytes, which were found to be elevated within 12 weeks after initiating TYSABRI treatment, reaching a plateau by 24 weeks. Although elevated, mea cell counts remained within the normal range. Observed increases persist during TYSABRI exposure, but are reversible, returning to baseline levels usually within 16 weeks after the last dose. Elevations of neutrophils were not observed. TYSABRI also induces mild decreases in hemoglobin levels that are frequently transient. These observations were not associated with clinical symptoms; therefore routine blood monitoring is not required.

Progressive Multifocal Leukoencephalopathy: Use of TYSABRI has been associated with an increased risk of progressive multifocal leukoencephalopathy (PML). PML can cause severe disability or death.

Cases of PML included natients who were treated with TYSABRI for over 2 years or who received intermittent doses of TYSABRI over an 18-month period. In clinical trials, two cases of PML were observed in 1869 patients with multiple sclerosis treated for a median of 120 weeks; the third case occurred among 1043 patients with Crohn's disease after the patient received 8 doses. These patients were concomitantly exposed to immunomodulators (e.g., interferon beta) or were immunocompromised due to treatment with immunos (e.g., azathioprine).

The absolute risk for PML in patients treated with TYSABRI cannot be precisely estimated and factors that might increase an individual patient's risk for PML have not been identified. There are no known interventions that can reliably prevent PML or adequately treat PML if it occurs. It is not known whether early detection of PMI, and discontinuation of TYSABRI will mitigate the disease. There is limited experience beyond 2 years of treatment. The relationship between the risk of PML and the duration of treatment is unknown

It is unclear whether the risk of PML is increased in MS natients treated with TYSABRI in combination with interferon beta compared to TYSABRI alone. Until more is known, TYSABRI should not be used in combination with other immunosuppressive or immunomodulatory agents, regardless of their class.

Short courses of corticosteroids can be used in combination with TYSABRI. In phase 3 MS clinical trials, concomitant treatment of relapses with a short course of corticosteroids was not associated with an increased rate of infection in patients treated with TYSABRI as compared with those on placebo

Healthcare professionals should be alert to any new signs or symptoms that may be suggestive of PML. TYSABRI should be suspended immediately at the first signs or symptoms suggestive of PML and an evaluation that includes a inium-enhanced magnetic resonance imaging (MRI) scan of the brain gadoli should be performed. Cerebrospinal fluid analysis for JC viral DNA may also be useful to confirm a diagnosis of PML. Pretreatment investigations (e.g., magnetic resonance imaging) may be helpful in the evaluation of patients who may develop signs or symptoms suggestive of PML

Immunosuppression: The safety and efficacy of TYSABRI in combination with antineoplastic or immunosuppressive agents have not been established int use of these agents with TYSABRI may increase the risk of infections, including opportunistic infections. In clinical studies for conditions other than MS, opportunistic infections (e.g., pneumocystis carinii pneumonia, pulmonary mycobacterium avium intracellulare, bronchopulmonary aspergillosis and burkholderia cepacia) have been uncommonly observed in patients receiving TYSABRI: some of these patients were receiving concur immunosuppressants (see Adverse Reactions). In pivotal clinical trials (1801 and 1802), concomitant treatment of relapses with a short course of corticosteroids was not associated with an increased rate of infection in patients treated with TYSABRI as compared with placebo.

Immunizations: No data are available on the effects of vaccination in natients receiving TYSABRI. Similarly, no data are available on the secondary transm of infection by live vaccines in patients receiving TYSABRI.

Special Peppleties

Pregnant Women: There are no adequate and well-controlled studies of TYSABRI therapy in pregnant women. In premarketing clinical trials, the extent of exposure is very limited. Because animal reproduction studies are not always predictive of human response, this drug should only be used during pregnancy if clearly needed. If a woman becomes pregnant while taking TYSABRI, discontinuation of TYSABRI should be considered.

In reproductive studies in monkeys and guinea pigs, there was no evidence of teratogenic effects or effects on survival or growth of offspring at doses up to 30 mg/kg (7 times the human clinical dose based on body weight comparison). In one of five studies that exposed monkeys or guinea pigs during pregnancy, the number of abortions in treated (30 mg/kg) monkeys was 33% vs. 17% in controls. No effects on abortion rates were noted in any other study. A study in pregnant cynomolgus monkeys treated at 2.3-fold the clinical dose demonstrated natalizumab-related changes in the fetus. These changes included mild anemia, reduced platelet count, increased spleen weights, and reduced liver and thymus weights associated with increased splenic extramedullary hematopoiesis, thymic atrophy and decreased hepatic hematopoiesis. In offspring born to mothers treated with natalizumab at 7-fold the clinical dose, platelet counts were also reduced. This effect was reversed upon clearance of natalizumab. There was no evidence of anemia in these offspring.

Nursing Women: It is unknown if natalizumab is excreted in human mille Because many drugs are excreted in human milk and the potential for serious adverse reactions is unknown, discontinuation of nursing or TYSABRI should be considered.

Pediatrics (<18 years): Safety and effectiveness of TYSABRI in pediatric MS patients have not been studied

Genatrics (> 65 years): Clinical studies of TVSABRI did not include sufficient numbers of patients to determine whether they respond differently than younger pati

ADVERSE REACTIONS

erse Drug Reaction Ov

Serious adverse drug reactions most frequently reported during treatment with TYSABRI™ (natalizumab) in clinical trials were infections (3.2% vs. 2.6% placebo, including unnary tract infection [0.8% vs. 0.3%] and pneumonia

[0.6% vs. 0%]); acute hypersensitivity reactions (1.1% vs. 0.3%, including anaphylaxis/anaphylactoid reaction [0.8% vs. 0%]); depression (1.0% vs. 1.0%, including suicidal ideation [0.6% vs. 0.3%]); and cholelithiasis (1.0% vs. 0.3%) (see Warnings and Precautions, Immune).

The most frequently reported adverse events leading to discontinuation of TYSABRI therapy were unlicaria (1%) and other hypersensitivity reactions (1%) (see Warnings and Precautions, General).

In clinical trials, cases of PML have been reported. PML can cause severe disability or death. Two cases occurred in MS patients who were being treated with concomitant interferon beta-1a for more than 2 years. One patient in other clinical trials who had a long history of treatment with immunosuppressants and associated leucopenia also developed PML (see Warnings and Precautions. Immune)

Clinical Trial Adverse Drug Reactions

Because clinical trials are conducted under very specific conditions, the adverse reaction rates observed in the clinical trials may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse drug reaction information from clinical trials is useful for identifying drug-related adverse events and for approximating rates.

Summary Listing of Adverse Events: In placebo-controlled trials in 1617 patients with multiple sclerosis treated with TYSABRI, the incidence of common events was balanced between the TYSABRI-treated patients and those who received placebo. Adverse events leading to discontinuation of therapy occurred in 5.8% of patients receiving TYSABRI and in 4.8% of patients receiving placebo. Events are listed in Table 1 by body system and frequency of occurrence in the TYSABRI group.

Table 1: All Adverse Events in Placebo-Controlled Studies of MS Occurring th Incidence ≥ 1.0% in TYSABRI Group and >0.5% in TYSABRI Group Than Placebo Group

System Organ Class	Preferred Term	Placebo	TYSABRI
		(n = 1135)	(n = 1617)
Infections and infestati	ons		
	Influenza	146 (12.9%)	225 (13.9%)
	Sinusitis	122 (10.7%)	184 (11.4%)
	Upper respiratory		
	tract infection viral	88 (7.8%)	134 (8.3%)
	Pharyngitis	59 (5.2%)	125 (7.7%)
	Gastroenteritis	21 (1.9%)	56 (3.5%)
	Tonsillitis	23 (2.0%)	51 (3.2%)
	Bladder infection	16 (1.4%)	38 (2.4%)
	Herpes zoster	16 (1.4%)	33 (2.0%)
	Respiratory tract		
	infection	15 (1.3%)	30 (1.9%)
	Gingival infection	6 (0.5%)	18 (1.1%)
Blood and lymphatic sy	stem disorders		
	Anemia	14 (1.2%)	30 (1.9%)
Immune system disord	ers		
	Seasonal allergy	35 (3.1%)	58 (3.6%)
Psychiatric disorders	Depressed mood	16 (1.4%)	37 (2.3%)
Nervous system disord	ers		
	Headache	436 (38.4%)	634 (39.2%)
	Dysesthesia	23 (2.0%)	42 (2.6%)
	Sinus headache	19 (1.7%)	38 (2.4%)
Cardiac disorders	Tachycardia	9 (0.8%)	23 (1.4%)
Vascular disorders	Hematoma	6 (0.5%)	17 (1.1%)
Respiratory, thoracic and	d mediastinal disorde	ITS	
	Cough	81 (7.1%)	130 (8.0%)
	Sinus congestion	22 (1.9%)	51 (3.2%)
	Epistaxis	13 (1.1%)	28 (1.7%)
Gastrointestinal disorde	ers		
	Abdominal pain	43 (3.8%)	75 (4.6%)
Musculoskeletal and co		ders	
	Muscle cramp	42 (3.7%)	82 (5.1%)
	Joint swelling	42 (3.7%) 13 (1.1%)	82 (5.1%) 32 (2.0%)
Reproductive system a	Joint swelling		
	Joint swelling	13 (1.1%)	32 (2.0%)
Reproductive system a	Joint swelling nd breast disorders Menstruation irregular	13 (1.1%) 12 (1.1%)	
	Joint swelling nd breast disorders Menstruation irregular	13 (1.1%) 12 (1.1%)	32 (2.0%)
Reproductive system a	Joint swelling nd breast disorders Menstruation irregular administration site co Fatigue	13 (1.1%) 12 (1.1%) onditions 305 (26.9%)	32 (2.0%) 37 (2.3%) 445 (27.5%)
Reproductive system a	Joint swelling nd breast disorders Menstruation irregular administration site co Fatigue Edema peripheral	13 (1.1%) 12 (1.1%) anditions 305 (26.9%) 25 (2.2%)	32 (2.0%) 37 (2.3%) 445 (27.5%) 62 (3.8%)
Reproductive system a	Joint swelling Ind breast disorders Menstruation irregular administration site co Fatigue Edema peripheral Chest pain	13 (1.1%) 12 (1.1%) proditions 305 (26.9%) 25 (2.2%) 35 (3.1%)	32 (2.0%) 37 (2.3%) 445 (27.5%) 62 (3.8%) 58 (3.6%)
Reproductive system a	Joint swelling Menstruation irregular administration site co Fatigue Edema peripheral Chest pain Rigors	13 (1.1%) 12 (1.1%) proditions 305 (26.9%) 25 (2.2%) 35 (3.1%) 12 (1.1%)	32 (2.0%) 37 (2.3%) 445 (27.5%) 62 (3.8%) 58 (3.6%) 55 (3.4%)
Reproductive system and	Joint swelling Ind breast disorders Menstruation irregular administration site co Fatigue Edema peripheral Chest pain Rigors Weight decreased	13 (1.1%) 12 (1.1%) proditions 305 (26.9%) 25 (2.2%) 35 (3.1%)	32 (2.0%) 37 (2.3%) 445 (27.5%) 62 (3.8%) 58 (3.6%)
Reproductive system a	Joint swelling Menstruation irregular administration site co Fatigue Edema peripheral Chest pain Rigors Weight decreased dural complications	13 (1.1%) 12 (1.1%) onditions 305 (26.9%) 25 (2.2%) 35 (3.1%) 12 (1.1%) 11 (1.0%)	32 (2.0%) 37 (2.3%) 445 (27.5%) 62 (3.8%) 58 (3.6%) 55 (3.4%) 27 (1.7%)
Reproductive system and	Joint swelling Ind breast disorders Menstruation irregular administration site co Fatigue Edema peripheral Chest pain Rigors Weight decreased	13 (1.1%) 12 (1.1%) proditions 305 (26.9%) 25 (2.2%) 35 (3.1%) 12 (1.1%)	32 (2.0%) 37 (2.3%) 445 (27.5%) 62 (3.8%) 58 (3.6%) 55 (3.4%)

ional inferi

Hypersensitivity: The incidence of hypersensitivity reactions was based on the investigator assessment that the event was urticaria or an allergic reaction. which may have included terms such as urticaria, itch, flushing, hypersensitivity or anaphylactoid reaction. In controlled clinical trials in MS patients hypersensitivity reactions occurred in up to 4% of patients. Serious systemic nsitivity reactions (e.g., anaphylactic/anaphylactoid) occurred in <1% (study 1801: 5/627) of MS patients. Hypersensitivity reactions usually occurred within two hours of the start of the infusion.


Immunogenicity: Persistent anti-natalizumab antibodies (detected on two occasions at least 6 weeks apart) were associated with decreased efficacy of TYSABRI and an increased incidence of hypersensitivity reactions. The majority of patients who became persistently antibodypositive had developed antibodies by 12 weeks

In controlled clinical trials in MS patients, persistent anti-natalizumab antibodies developed in approximately 6% of patients. Antibodies were detected on only one occasion in 4% of patients. Additional infusion-related reactions associated with persistent antibodies included rigors, nausea, vomiting and flushing. Approximately 90% of patients who became persistently antibody positive in 2-year clinical trials had developed antibodies by 12 weeks.

If, after 3 months of TYSABRI treatment, the presence of persistent dies is suspected, antibody testing should be performed. Antibodies may be detected and confirmed with sequential serum antibody tests Antibodies detected early in the treatment course (e.g., within 6 months) may be transient and disappear with continued dosing. Repeat testing between 6 weeks and 3 months after the initial positive result is recommended in natients in whom antihodies are detected to confirm that antibodies are persistent. In the presence of persistent antibodies, discontinuation of treatment with TYSABRI should be considered (see Figure 1).

Information regarding the availability and location of testing laborator be obtained by contacting Biogen Idec Canada at 1-888-827-2827.

Figure 1: Subject Relapse Rate Prior to and After Antibody Det Persistent Positives - Study 1801



Infections: In controlled clinical trials in MS patients, the rate of infection was approximately 1.5 per patient year in both TYSABRI- and placebo-treated patients. The nature of the infections was generally similar in TYSABRI- and placebo-treated patients. The majority of patients did not interrupt TYSABRI therapy during infections, and recovery occurred with appropriate treatment. In clinical trials, cases of PML have been reported (see Warnings and

Precautions, Immune: Adverse Drug Reaction Overview).

In other clinical trials, cases of opportunistic infections have been reported. While a causal role for natalizumab cannot be excluded, it is reasonable to conclude that comorbidities and concomitant medications played an important role in these infections. Should a serious opportunistic infection develop, TYSABRI therapy should be withheld until the infection has been successfully treated (see Warnings and Precautions, Immunosuppression).

Infusion-Related Reactions: An infusion-related reaction was defined in clinical trials as any adverse event occurring within 2 hours of the start of an infusion These events occurred in 23.1% of MS patients treated with TYSABRI (18.7% placebo). Events reported more commonly with TYSABRI than with placebo included headache, dizziness, fatigue, urticaria, pruritus and rigors.

Malignancies: No differences in incidence rates or the nature of malignancies between TYSABRI- and placebo-treated patients were observed over 2 years of treatment. Should a malignancy develop, TYSABRI therapy should be withheld at least until appropriate treatment has been initiated for the malignancy and the benefit and risks of resuming TYSABRI therapy have been deemed to be acceptable by the treating physician

Loss Common Clinical Trial Adverse Drug Reactions

The incidence of adverse drug reactions experienced by < 1% of subjects in natalizumab group and at least 0.1% higher in natalizumab compared to placeho are listed below:

Blood and ivmohatic system disorders: Anemia, thrombocytopenia, leukocytosis Cardiac disorders: Tachycardia, angina pectoris

Ear and labyrinth disorders: Vertigo

Gastrointestinal disorders: Flatulence, upper abdominal pain, abdominal distention, epigastric discomfort

General disorders and administration site conditions: Feeling hot, peripheral edema, lethargy, feeling abnormal, infusion site erythema, pain, thirst, hyperpyrexia, infusion site pruritus

Immune system disorders: Hypersensitivity, anaphylactoid reaction, anaphylactic reaction

Infections and infestations: Pharyngitis, sinusitis, herpes simplex, herpes zoster, rhinitis infective, bronchial infection, gastroententis, skin and subcutaneous tissue abscess, furuncie, pharyngitis streptococcal, bladder infection, breast abscess, dermatitis infected, herpes viral infection, oral infection, pharyngitis viral, tooth infection, urinary tract infection

Injury, poisoning and procedural complications: Overdose

investigations: Aspartate aminotransferase increased, neutrophil count increased, heart rate increased, neutrophil count decreased, white blood cell count increased, blood test abnorma

Musculoskeletal and connective tissue disorders: Myalgia, muscle cramp, muscle spasms, sensation of heaviness, joint stiffness, muscle tightness, muscle v reakness

Neoplasms benign, malignant and unspecified (including cysts and polyps): Cvs

Nervous system disorders: Tremor, paresthesia oral, sensory disturbance. paresis, psychomotor hyperactivity, syncope

Psychiatric disorders: Depression, agitation

Reproductive system and breast disorders: Irregular menstruation Respiratory, thoracic and mediastinal disorders: Cough, sinus congestion, wheezing, throat irritation

Skin and subcutaneous tissue disorders: Erythema, rash pruritic, acne, pruritus, urticaria, dry skin, onychorrhexis, skin irritation

Vascular disorders: Petechiae, poor venous access, thrombophlebitis, vasodilatation

DRUG INTERACTIONS

Drug-Drug Interactio

If a decision is made to stop treatment with TYSABRI," the physician needs to be aware that TYSABRI has pharmacodynamic effects (e.g., increased lymphocyte counts) for approximately 12 weeks following the last dose. For drugs such as interferon and glatiramer acetate, concomitant exposure of this

https://doi.org/10.1017/S0317167100116622 Published online by Cambridge University Press

duration was not associated with safety risks in clinical trials. This should be carefully considered on a case-by-case basis and a washout period of TYSABRI might be appropriate.

Should TYSABRI therapy be administered after treatment with another immunosuppressive drug, physicians should consider the half-life of the drug and the potential for persistent immunosuppressive effects of these products when considering if a washout period is needed and, if so, its duration

TYSABRI should not be diluted with anything other than 0.9% Sodium Chloride Injection, USP

Dree-Food Interactions

No information is available.

Drug-Laboratory Interactions

TYSABRI induces increases in circulating lymphocytes, monocytes, eosinophils and nucleated red blood cells. Observed increases persist during TYSABRI exposure, but are reversible, returning to baseline levels usually within 16 weeks after the last dose. Elevations of neutrophils are not observed.

DOSAGE AND ADMINISTRATION **Desing Consideration**

·TYSABRI* (natalizumab) should be administered by a healthcare professional. Patients should be observed during the infusion and for 1 hour after the infusion is complete for signs and symptoms of infusion reactions. Promptly discontinue the infusion upon the first observation of any signs or symptoms consistent with a hypersensitivity reaction.

Dilute only with 0.9% Sodium Chloride Injection, USP.

Recommended Dese and Desage Adjustment The recommended dose of TYSABRI is 300 mg IV infusion every 4 weeks. Do not administer TYSABRI as an IV push or bolus injection.

A daula le tratle. Dilution:

Parenteral Products:

Use aseptic technique when preparing TYSABRI solution for IV infusion. Each vial contains a single dose and is intended for single patient use only

TYSABRI is a colourless, clear to slightly opalescent concentrate. Inspect the TYSABRI vial for particulate material prior to dilution and administration. If visible particulates are observed and/or the liquid in the vial is discoloured. the vial must not be used. Do not use TYSABRI beyond the expiration date on the carton or vial.

To prepare the solution, withdraw 15 mL of TYSABRI concentrate from the vial using a sterile needle and syringe. Inject the concentrate into 100 mL 0.9% Sodium Chloride Injection, USP. No other IV diluents may be used to prepare the TYSABRI solution.

Gently invert the TYSABRI solution to mix completely. Do not shake, Inspect for particulate material prior to administration.

Following dilution, intravenously infuse TYSABRI solution. If immediate infusion is not possible, store the diluted solution at 2°C to 8°C. If stored at 2°C to 8°C, allow the solution to warm to room temperature prior to infusion and complete the infusion within 8 hours of dilution. DO NOT FREEZE.

Vial Size 15 mL

me of Diluent to be Mixed with Concentrate

100 mL 0.9% Sodium Chloride Injection, USP

Approximate Volume for Infusion

115 mL

Diluted Solution Concentration

2.6 mg

Infuse over approximately 1 hour. Observe patients during the infusion and for 1 hour after the infusion is completed for signs and symptoms of infusion reactions.

After the infusion is complete, flush with 0.9% Sodium Chloride Injection, USP. Other medications should not be injected into infusion set side ports or mixed with TYSABRI.

OVERDOSAGE

Safety of doses higher than 300 mg has not been adequately evaluated. The maximum amount of TYSABRI™ (natalizumab) that can be safely administe has not been determined

ACTION AND CLINICAL PHARMACOLOGY

a of Action

TYSABRI[®] (natalizumab) is a selective adhesion molecule (SAM) inhibitor and binds to the α 4-subunit of human integrin, which is highly expressed on the surface of all leukocytes, with the exception of neutrophils.

Specifically, natalizumab binds to the $\alpha 4\beta 1$ -integrin blocking the integrin with its cognate receptor, vascular cell adhesion molecule-1 (VCAM-1), and additional ligands such as osteopontin, and an alternatively spliced domain of fibronectin, connecting segment-1 (CS-1). Natalizumab blocks the interaction of 0x487-integrin with the mucosal addressin cell adhesion molecule-1 (MadCAM-1). Disruption of these molecular interactions prevents transmigration of mononuclear leukocytes across the endothelium into inflamed parenchymal tissue. A further mechanism of action of natalizumab may be to suppress ongoing inflammatory reactions in diseased tissues by inhibiting the interaction of cx4-expressing leukocytes with their ligands in the extracellular matrix and on parenchymal cells. As such, natalizumab may act to suppress inflammatory activity present at the disease site, and inhibit further recruitment of immune cells into inflamed tissues

In multiple sclerosis (MS), lesions are believed to occur when activated inflammatory cells, including T-lymphocytes, cross the blood-brain barrier (BBB). Leukocyte migration across the BBB involves interaction between adhesion molecules on inflammatory cells and endothelial cells of the vessel wall. The interaction between $\alpha 4\beta 1$ and its targets is an important component of pathological inflammation in the brain, and disruption of these interactions leads to reduced inflammation. Under normal conditions, VCAM-1 is not expressed in the brain parenchyma. However, in the presence of proinflammatory cytokines, VCAM-1 is upregulated on endothelial cells, and possibly on glial cells near the sites of inflammation. In the setting of central us system (CNS) inflammation in MS, it is the interaction of $\alpha 4\beta 1$ with VCAM-1, CS-1 and osteopontin that mediates the firm adhesion and transmigration of leukocytes into the brain parenchyma, and may perpetuate the inflammatory cascade in CNS tissue. Blockade of the molecular interactions of $\alpha 4\beta 1$ with its targets reduces inflammatory activity present in the brain in MS and inhibits further recruitment of immune cells into inflamed tissue, thus reducing the formation or enlargement of MS lesions.

A-23

Treatment with TYSABRI (natalizumab) led to an increase in circulating white blood cells and total lymphocytes that was maintained throughout the treatment period. This is due to the ability of natalizumab to inhibit adhesion of leukocytes to endothelial cells and diminish transmigration of these cells from the vascular space into inflamed tissues. These increases were not clinically significant and once treatment was discontinued, counts returned to baseline levels. Consistent with the mechanism of action of natalizumab and the lack of $\alpha 4$ on the surface of this cell type, there was no change in the number of circulating neutrophils.

Pharmacokinetic values determined after a single 300 mg dose of TYSABRI in healthy subjects are provided in Table 2. Similar values observed in MS patients after a single dose and after 6 months of dosing as monotherapy are given in Table 3. Some accumulation occurs over the 6-month dosing period.

Table 2: Pharmacokinetic Parameters, Single-Dose 300 md Natalizumah ous Infusion of 60 minutes as intra-

Median Values of Parameter	Study 1805	Study 1806
AUCt (µg/mL *hr)	19900	21500
Cmax (µg/mL)	110	94
T _{max} (hrs)	2.98	3.00
t _{1/2} (hr)	224	249
Vdis (mL/kg)	66.6	67.4
CL (mL/hr/kg)	0.212	0.179

Table 3: Summary of Pharmacokinetic Parameters Following 60-Minute 300 mg Natalizumab Infusions Given Monthly in MS Patients (Mean +/- s.d.)

Dose Number	Study	C _{max} (µg/mL)	Minimum (Trough) Conc. (ug/mL)	AUC(last) (µg x hr/mL)	Vd (mL/kg)	CL (mL/hr/kg)	t _{1/2} (hr)
1	C-1801	84.8 ± 22.3	none	17884 19165	77:36	0.23±0.09	249±105
6	C-1801	94.7 : 34.2	21.3 : 15.3*	19609 ± 5701	81:43	0.22±0.06	265 ± 98

Representative of concentration at the end of 6-months dosing (24-week measurement)

Sancial Pa s and Ca

Pediatrics: The pharmacokinetics of TYSABRI in pediatric MS patients have not been studied

Geriatrics: The pharmacokinetics of TYSABRI in MS patients over 65 years of age have not been established.

Hepatic insufficiency: The pharmacokinetics of TYSABRI in patients with hepatic insufficiency have not been studied.

Renal insufficiency: The pharmacokinetics of TYSABRI in patients with renal insufficiency have not been studied.

Gender: Results of a population pharmacokinetics study demonstrated that gender did not influence natalizumab pharmacokinetics.

Race: The effects of race on the pharmacokinetics of TYSABRI have not been studied.

Duration of Effect

TYSABRI has pharmacodynamic effects (e.g., increased lymphocyte counts) for approximately 12 weeks following the last dose.

STORAGE AND STABILITY

TYSABRI™ (natalizumab) single-use vials must be stored in a refrigerator between 2°C to 8°C. Do not use beyond the expiration date on the carton and vial label. Do not shake or freeze. Protect from light.

If not used immediately, store the TYSABRI solution for infusion at 2°C to 8°C. The administration of TYSABRI solution for infusion must be completed within 8 hours of dilution

SPECIAL HANDLING INSTRUCTIONS

TYSABRI[™] (natalizumab) is for single use only. One vial of TYSABRI should be diluted only with 0.9% Sodium Chloride Injection, USP before use. Any unused product or waste material should be disposed of in accordance with local requirements

DOSAGE FORMS, COMPOSITION AND PACKAGING

TYSABRI™ (natalizumab) concentrate is supplied as 300 mg natalizumab in a sterile, single-use vial free of preservatives.

Each 15 mL dose also contains (pH 6.1):

123 mg sodium chloride, USP/Ph.Eur

17.0 mg sodium phosphate, monobasic, monohydrate, USP

7.24 mg sodium phosphate, dibasic, heptahydrate, USP

3.0 mg polysorbate 80, USP/NF/Ph.Eur

Water for Injection, USP/Ph.Eu

Each package contains one vial

Product Monograph available on request.



Biogen Idec Canada Inc. 3 Robert Speck Parkway, Suite 300. ssauga, ON L4Z 2G5. TYSABRI. The Tysabri Care Program and ELAN are trademarks of

Elan Pharma International Ltd BIOGEN IDEC is a trademark of Biogen Idec MA Inc © 2006 Biogen Idec MA Inc. TYB1039

PAAB

See A-10, A-11, A-12, A-13



SUMMARY PRODUCT

Classi	ficatior	<u>a</u> Ana	Igesic	1
--------	----------	--------------	--------	---

Route of	Dosage Form /	Clinically Relevant
Administration	Strength	Nonmedicinal Ingredients
Oral	Capsules, 25 mg, 50 mg, 75 mg, 150 mg, 300 mg	Lactose monohydrate For a complete listing, see Dosage Forms, Composition and Packaging section.

INDICATIONS AND CLINICAL USE

Adults: LYRICA (pregabalin) is indicated for the management of neuropathic pain associated with: • Diabetic peripheral neuropathy and • Postherpetic neurolgia Geriatrics (>65 years of age): Pregabalin oral clearance tended to decrease with increasing age. This decrease in pregabalin oral clearance is consistent with age-related decreases in creatinine clearance. Reduction of pregabalin dose may be required in patients who have age-related compromised renal function (see WARNINGS AND PRECAUTIONS, Geriatrics)

CONTRAINDICATIONS

Patients who are hypersensitive to pregabalin or to any ingredient in the formulation or component of the container.

WARNINGS AND PRECAUTIONS

Tumorigenic Potential In standard preclinical in vivo lifetime carcinogenicity studies of pregabalin, a high incidence of hemangiosarcoma was identified in two different strains of mice (see **Preclinical Toxicology**). The clinical significance of this finding is uncertain. Clinical experience during pregabalin's premarketing development provides no direct means to assess its potential for inducing tumors in humans. In clinical studies across various patient populations, comprising 6396 patient-years of exposure in 8666 patients ranging in age from 12 to 100 years, new or worsening-preexisting tumors were reported in 57 patients. The most common malignant tumor diagnosed was skin carcinoma (17 patients) followed by breast carcinoma (8 patients), prostatic carcinoma (6 patients), carcinoma not otherwise specified (6 patients) and bladder carcinoma (4 patients). Without knowledge of the background incidence and recurrence in similar populations not treated with LYRICA (pregabalin), it is impossible to know whether the incidence seen in these cohorts is or is not affected by treatment. **Ophthalmological Effects** In controlled studies pregabalin treatment was associated with vision-related adverse events such as blurred vision (amblyopia) (6% pregabalin and 2% placebo) and diplopia (2% pregabalin and 0.5% placebo). Approximately 1% of pregabalin-treated patients discontinued treatment due to vision-related adverse events (primarily blurred vision). Of the patients who did not withdraw, the blurred vision resolved with continued of the patients who use for who who who who who the software with contribute doising in approximately half of the cases (see Post Marketing Adverse Drug Reactions). Prospectively planned ophthalmologic testing, including visual acuty testing, formal visual field testing and dilated funduscopic examination, was performed in over 3600 patients. In these patients, visual acuty was reduced in 7% of patients treated with pregabalin, and 5% of placebo-treated patients. Visual field changes were detected in 13% of pregabalin-treated, and 12% of placebo-treated patients. Funduscopic changes were observed in 2% of pregabalin-treated, and 2% of placebo-treated patients. At this time, clinical significance of the ophthalmologic findings is unknown. Patients should be informed that if changes in vision occur, they should notify their physician. If visual disturbance persists, further assessment, including discontinuation of pregabalin, should be considered. More frequent assessments should be considered for patients who are already routinely monitored for ocular conditions. Peripheral Edema In controlled clinical trials pregabalir treatment caused peripheral edema in 6% of patients (336/5508) compared with 2% of patients (42/2384) in the placebo group. In these studies, 0.5% (28/5508) of pregabalin patients and 0.2% (4/2384) of placebo patients withdrew due to peripheral edema (see ADVERSE REACTIONS, Peripheral Edema). In controlled clinical trials of up to 13 weeks in duration of patients without clinically significant heart or peripheral vascular disease, there was no apparent association between peripheral edema and cardiovascular complications such as hypertension or congestive heart failure. In the same trials, peripheral edema was not associated with laboratory changes suggestive of deterioration in renal or hepatic function. Higher frequencies of weight gain and peripheral edema were observed in patients taking both LYRICA (pregabalin) and a thiazolidinedione antidiabetic agent compared to patients taking either drug alone The majority of patients using thiazolidinedione antidiabetic agents in the overal safety database were participants in studies of pain associated with diabetic peripheral neuropathy. In this population, peripheral edema was reported in 3% (2/60) of patients who were using thiazolidinedione antidiabetic agents only, 8% (69/859) of patients who were treated with pregabalin only, and 19% (23/120) of patients who were on both pregabalin and thiazolidinedione antidiabetic agents. Similarly, weight gain was reported in 0% (0/60) of patients on thiazolidinediones only, 4% (35/859) of patients on pregabalin only; and 7.5% (9/120) of patients on both drugs. As the thiazolidinedione class of antidiabetic drugs can cause weight gain and/or fluid retention, possibly exacerbating or leading to heart failure, care should be taken when co-administering LVRICA and these agents. Because there are limited data on congestive heart failure patients with New York Heart Association (NYHA) Class III or IV cardiac status, LYRICA should be used with caution in these patients. Weight The carb as status, Ern Ac should be used with caution in these parents. Wrothin Cain Pregabatin treatment was associated with weight gain. In pregabatin controlled clinical trials of up to 13 weeks, a gain of 7% or more over baseline weight was observed in 5% of pracebatine treated patients and 2% of placebo-treated patients. Few patients treated with pregabatin (0.2%) withdrew from controlled trials due to weight gain (see ADVERSE REACTIONS, Weight Gain). Pregabatin associated weight gain was related to dose and duration of exposure, but did not appear to be associated with baseline BMI, gender or age. Weight gain was not limited to patients with edema (see WARNINGS AND PRECAUTIONS, Peripheral Edema). Although weight gain was not associated with clinically important changes in blood pressure in short-term controlled studies, the long-term cardiovascular effects of pregabalinassociated weight gain are unknown. Among diabetic patients, pregabalin-treated patients gained an average of 1.6 kg (range: -16 to 16 kg), compared to an average 0.3 kg (range: -10 to 9 kg) weight gain in placebo patients. In a cohort of 333 diabetic patients who received pregabalin for at least 2 years, the average weight gain was 5.2 kg. While the effects of pregabalin-associated weight gain on glycemic contro have not been systematically assessed, in controlled and longer-term open labe clinical trials with diabetic patients, pregabalin treatment did not appear to be associated with loss of glycemic control (as measured by HbArd). Dizziness and Somnolence In controlled neuropathic pain studies, pregabalin caused dizziness in ients (424/1831) compared to 7% in placebo (58/857). Sompolence was experienced by 14% (256/1831) and 4% (33/857) of the patients treated with pregabalin and placebo, respectively. These events begin shortly after the initiation of therapy and generally occur more frequently at higher doses. In these studies dizziness and somnolence led to withdrawal of 3.5% and 2.6% of the pregabalintreated patients, respectively. For the remaining patients (359 and 208, respectively, who experienced these events, dizziness and somnolence persisted until the last dose

alin in 43% and 58% of the patients, respectively (see ADVERSE REACTIONS, Tables 2 and 4, and Post-Marketing Adverse Drug Reactions) Accordingly, patients should be advised not to drive or operate complex machinery of engage in other hazardous activities until they have gained sufficient experience on pregabalin to gauge whether or not it affects their mental and/or motor performance pregabalin to gauge v adversely (see CONSUMER INFORMATION). Abrupt or Rapid Discontinuation Following abrupt or rapid discontinuation of pregabalin, some patients reported symptoms including insomnia, nausea, headache and diarrhea. Pregabalin should be r a minimum of one week rather than discontinued abruptly (see ADVERSE REACTIONS Adverse Events Following Abrunt or Banid Discontini Sexual Function/Reproduction Impairment of Male Fertility Preclinical Data In fertility studies in which male rats were orally administered pregabalin (50 to 2500 mg/kg) prior to and during mating with untreated females, a number of adverse reproductive and developmental effects were observed. These included decreased sperm counts and sperm motility, increased sperm abnormalities, reduced fertility, increased preimplantation embryo loss, decreased litter size, decreased fetal body weights and an increased incidence of fetal abnormalities. Effects on sperm and fertility parameters were reversible in studies of this duration (3-4 months). The noeffect dose for male reproductive toxicity in these studies (100 mg/kg) was associated with a plasma pregabalin exposure (AUC) approximately 3 times human exposure at the maximum recommended dose (MRD) of 600 mg/day. In addition, adverse effects on reproductive organ (testes, epididymides) histopathology were observed in male in reproductive organization (testes, epidophines) instructionally were considered in fine rats exposed to pregabalin (500 to 1250 mg/kg) in general toxicology studies of four weeks or greater duration. The no-effect dose for male reproductive organ histopathology in rats (250 mg/kg) was associated with a plasma exposure approximately 8 times human exposure at the MBD. In a fertility study in which female rats were given pregabalin (500, 1250 or 2500 mg/kg) orally prior to and during ating and early gestation, disrupted estrous cyclicity and an increased number days to mating were seen at all doses and embryolethality occurred at the highest dose. The low dose in this study produced a plasma exposure approximately 9 times that in humans receiving the MRD. A no-effect dose for female reproductive toxicity in rats was not established. The clinical significance of female fertility findings in animals is unknown. <u>Human Data</u> In a double-blind, placebo-controlled clinical trial to assess the effect of pregabalin on sperm motility, 30 healthy male subjects were exposed to pregabalin 600 mg/day for 3 months (one complete sperm cycle) Pregabalin did not exhibit significant detrimental effects on the reproductive function of healthy male subjects, as measured by semen analysis, when compared with placebo (n=16). However, due to the small sample size and short-term exposure to pregabalin (only one complete sperm cycle), no conclusions can be made regarding possible reproductive effects of pregabalin during long-term exposure. Effects or softer rale reproductive interes of programmers have not been adequately studied. Special Populations Renal Because pregabalin is eliminated primarily by renal the dose of pregabalin should be adjusted as noted for elderly patients with airment (see ACTION AND CLINICAL PHARMACOLOGY and DOSAGE AND ADMINISTRATION). Adjustment of Dose in Renally-Impaired Patients In patients with a medical history of significant renal insufficiency, daily dosages should be reduced accordingly (see Table in DOSAGE AND ADMINISTRATION, Dosing be reduced accordingly (see Table in Dovada Harvan Sharvan Turk, Daam Considerations) <u>Preclinical Data</u> Preglabalin was not treatogenic in mice, rats or rabbits. Pregabalin induced fetal toxicity in rats and rabbits at ≥39 times the mean human exposure at the maximum recommended clinical dose of 600 mg/day [AUC₀ 24 of 123 ug +hr/mL]. In the prenatal-postnatal toxicity study, pregabalin induced offspring developmental toxicity in rats at ≥5 times the maximum recommended human exposure. No developmental effects occurred at 2 times the maximum ecommended human exposure (see PRODUCT MONOGRAPH). Human Data Pregnant Women There are no adequate and well-controlled studies in pregnan women. Pregabalin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. *Labour and Delivery* The effects of pregabalin Jostines the poleritaritisk to the feats. Labour and Dentry The feats of plegaami on labour and delivery in pregnant women are unknown. In the prenatal-postnatal study in rats, pregabalin prolonged gestation and induced dystocia at exposures ≥47 times the mean human exposure [AUC_{0.84} of 123 µg hr/mL] at the maximum recommended chinical dose of 600 mg/day isee **PRDUCT MONGGRAPH**). *Nursing Women* It is not known if pregabalin is excreted in human breast milk; however, it is present in the milk of rats. Because of the potential for adverse reactions in nursing nfants from pregabalin, a decision should be made whether to discontinue nursing or o discontinue the drug, taking into account the importance of the drug to the mother to dis to discontinue the drug, taking into account the importance of the drug to the mother (see **PRODUCT MONOGRAPH**]. *Pediatrics (<18 years of age*) The statety and efficacy of pregabalin in pediatric patients (<18 years of age) have not been established. *Geriatrics (>65 years of age*) Of the 1831 patients who received pregabalin in neuropathic pain studies, 528 were 65 to 74 years of age, and 452 were 75 years of age or older. No significant differences in efficacy were observed between these patients and younger patients. Pregabalin oral clearance tended to decrease with increasing age. This decrease in pregabalin oral clearance is consistent with age-related decreases in creatinine clearance. Reduction of pregabalin dose may be required in patients who have age-related compromised renal function. In general, the incidence of adverse events did not increase with age. *Creatine Kinase Elevations* Pregabalin treatment was associated with creatine kinase elevations. Mean changes in creatine kinase from baseline to the maximum value were 60 U/ for pregabalin-treated patients and 28 U/L for the placebo patients. In all controllec trials across multiple patient populations, 2% of patients on pregabalin and 1% of placebo patients had a value of creatine kinase at least three times the upper limit of normal. Three pregabalin-treated subjects had events reported as rhabdomyolysis in premarketing clinical trails. The relationship between these myopathy events and pregabalin is not completely understood because the cases had documented factors that may have caused or contributed to these events. Prescribers should instruct patients to promptly report unexplained muscle pain, tenderness or weakness particularly if these muscle symptoms are accompanied by malaise or fever Pregabalin treatment should be discontinued if myopathy is diagnosed or suspected or if markedly elevated creatine kinase levels occur. Laboratory Changes, Decreased Platelet Count Pregabalin treatment was associated with a decrease in Decreased Platelet Countriegadalin treatment was associated with a decrease in platelet count. Pregabalin-treated subjects experienced a mean maximal decrease in platelet count of 20 x 10⁺/µL, compared to 11 x 10⁺/µL in placebo patients. In the overall database of controlled trials, 2% of placebo patients and 3% of pregabalin-treates experienced a near thirdly clinically significant decrease in platelets, defined as 20% below baseline value and <150 x 10⁺/µL. In randomized controlled trials, 2% pregabalin was not associated with an increase in bleeding related adverse events. ECG Changes, PR Interval Prolongation Pregabalin treatment was associated with mild PR interval prolongation. In analyses of clinical trial ECG data, the mean PR interval increase was 3-6 msec at pregabalin doses ≥300 mg/day. This mean change difference was not associated with an increased risk of PR increase ≥25% from baseline, an increased percentage of subjects with on-treatment PB >200 msec, or an increased risk of adverse events of second or third degree AV block. *Information for* Patients Dizziness and Somnolence Patients should be counseled that LYRICA (pregabalin) may cause dizziness, somnolence, blurred vision and other CNS signs and symptoms. Accordingly, they should be advised not to drive, operate complex machinery or engage in other hazardous activities until they have gained sufficient Received or cragget in the index descent of the rest o changes in vision occur, they should notify their physical use **WARMINGS ARU PRECAUTIONS, <u>Ophthalmologic Effects</u>). Abrupt or Rapid Discontinuation Patients should be advised to take LYRICA as prescribed. Abrupt or rapid discontinuation may result in insomia, nausea, headache or diarrhea. <u>Edema and</u> Weight Gain** Patients should be counseled that LYRICA may cause edema and ain. Patients should be advised that concomitant treatment with LYRICA and a thiazolidinedione antidiabetic agent may lead to an additive effect on edema and

weight gain. For patients with preexisting cardiac conditions, this may increase the risk of heart failure. Muscle Pain, Tenderness or Weakness Patients should be instructed to promptly report unexplained muscle pain, tenderness or weakne particularly if accompanied by malaise or fever. Concomitant Treatment with CNS Depressants, Alcohol Patients who require concomitant treatment with central nervous system depressants such as opiates or benzodiazepines should be informed that they may experience additive CNS side effects, such as somnolence. Patients should be told to avoid consuming alcohol while taking LYRICA, as LYRICA may potentiate the impairment of motor skills and sedation of alcohol. Pregnant Woman Patients should be instructed to notify their physician if they become pregnant or intend to become pregnant during therapy, and to notify their physician if they are breast-feeding or intend to breast-feed during therapy. Animal Studies in Male Reproduction In preclinical studies in rats, pregabalin was associated with an increased risk of male-mediated teratogenicity (see WARNINGS AND PRECAUTIONS, Sexual Function/Reproduction). The clinical Fraction round, <u>section runctuding production</u>. The clinical significance of this finding is uncertain; however, men being treated with LYRICA who plan to father a child should be informed of the potential risk of male-mediated teratogenicity. **Skin** Diabetic patients should be instructed to pay particular attention to skin integrity while being treated with LYRICA. Some animals treated with pregabalin developed skin ulcerations, although no increased incidence of skin lesions associated with skin ucerations, atmough no increased incidence of skin lesions associated with VPIICA was observed in clinical trials (see **PRODUCT MONOGRAPH**). Patients should be informed of the availability of a patient information leaflet, and they should be instructed to read the leaflet prior to taking LVRICA. <u>Preclinical Toxicology</u> *Carcinogenesis* A dose-dependent increase in the incidence of malignant vascular tumors (hemangiosarcomas) was observed in two strains of mice (B6C3F1 and CD-1) given pregabalin (200, 1000 or 5000 mg/kg) in the diet for two years. Plasma pregabalin exposure (AUC) in mice receiving the lowest dose that increased hemangiosarcomas was approximately equal to the human exposure at the maximum recommended dose (MRD) of 600 mg/day. A no-effect dose for induction of hemangiosarcomas in mice was not established. In an investigative study in female B6C3F1 mice, chronic treatment (24 months) with pregabalin at 1000 mg/kg caused an increased incidence of hemangiosarcoma, consistent with previous studies, but not at 50 or 200 mg/kg. Discontinuation of treatment after 12 months at 1000 mg/kg did not significantly reduce the incidence of hemangiosarcoma at 24 months. Evidence of carcinogenicity was not seen in two studies in Wistar rats following dietary administration of pregabalin for two years at doses (50, 150 or 450 mg/kg in males) administration of pregadamin for two years at cuses (so, 1 ao un 420 m/g/kg in males) and 100, 300 or 300 m/g/kg in famales) that were associated with Jasma exposures in males and females up to approximately 14 and 24 times, respectively, human exposure at the MRD. The clinical significance in humans of this finding in mice is unknown. Mutagenesis Pregadalin is not genotoxic based on results of a battery of in vitro and in vivo tests. Pregabalin was not mutagenic in bacteria or in mammalian cells in vitro, was not clastogenic in mammalian systems in vitro and in vivo, and did not induce unscheduled DNA synthesis in mouse or rat hepatocytes. Dermatopathy Skin lesions ranging from erythema to necrosis were seen in repeated-dose toxicology studies in both drag and how the studies of the set skin lesions is unknown. At studies in both rats and monkeys. The etiology of these skin lesions is unknown. At the maximum recommended human dose (MRD) of 600 mg/day, there is a 2-fold safety margin for the dermatological lesions. The more severe dermatopathies involving necrosis were associated with pregabalin exposures (as expressed by plasma AUCs) of approximately 3 to 8 times those achieved in humans given the MRD. No increase in incidence of skin lesions was observed in clinical studies. Ocular lesions Ocular lesions (characterized by retinal atrophy [including loss of hotoreceptor cells] and/or corneal inflammation/mineralization) were observed in wo lifetime carcinogenicity studies in Wistar rats. These findings were observed at plasma pregabalin exposures (AUC) >2 times those achieved in humans given the plasma pregatamin exposures (ACC) 22 times those actineva in normality given ime maximum recommended dose folom (griday A) no effect dose for ocular lesions was not established. Similar lesions were not observed in lifetime carcinogenicity studies in two strains of mice or in monkeys treated for 1 year. The clinical significance of this finding in rats is unknown. Monitoring and Laboratory Tests Routine therapeutic drug monitoring or clinical laboratory testing is not LYRICA (pregabalin) (see **ADVERSE REACTIONS**). drug m for natients treated with

ADVERSE REACTIONS

Adverse Drug Reaction Overview Clinical Trial Adverse Drug Reactions Ir all controlled and uncontrolled trials, more than 8666 patients have received LYRICA (pregabalin), with 83% of exposure at dosages of 300 mg/day or above and 32% at dosages of 600 mg/day or higher. Approximately 4010 patients had at least 6 months of exposure, 2415 had at least 1 year of exposure, and 939 had at least 2 years of exposure to pregabalin. In controlled trials, 1831 patients with neuropathic pain received pregabalin. Most Common Adverse Events in All Controlled Clinical Studies of Neuropathic Pain The most commonly observed adverse events (25% and twice the rate of that seen in placebo) in pregabalin-treated patients were dizziness, somnolence, peripheral edema and dry mouth. Adverse events were usually mild to moderate in intensity. *Discontinuation Due to Adverse Events* In all controlled studies, the discontinuation rate due to adverse events was 14% for patients receiving pregabalin and 7% for patients receiving placebo. The most common reasons for discontinuation due to adverse events (\geq 2%) in the pregabalin treatment groups were dizziness and somolence. Other adverse events that led to withdrawal more frequently in the pregabalin group than the placebo group were ataxia (1%) and asthenia, confusion, headache and nausea (<1% each). In controlled neuropathic pain studies, the discontinuation rate due to adverse events was 11% for pregabalin and 5% for placebo. The most common reasons for discontinuation due to adverse events (±2%) in the pregabalin treatment groups were dizziness and somnolence. Other adverse events that led to withdrawal more frequently in the pregabalin group than the placebo group were confusion (1%) and asthenia, peripheral edema and ataxia (<1% each). *Incidence of Adverse Events in Controlled Clinical Studies of Neuropathic Pain* In summaries of adverse events. investigator's terms for individual adverse events have been grouped into a smaller number of standardized categories using the COSTART IV dictionary. The prescriber should be aware that the percentages in Table 1 through Table 6 cannot be used to predict the frequency of adverse events in the course of usual medical practice where patient characteristics and other factors may differ from those prevailing during clinical studies. Similarly, the cited frequencies cannot be directly compared with figures obtained from other clinical investigations involving different treatments. uses or investigators. An inspection of these frequencies, however, does provide the prescriber with one basis to estimate the relative contribution of drug and non-drug factors to the adverse event incidences in the population studied. *Adverse Events* From Controlled Clinical Studies of Neuropathic Pain Diabetic Peripheral Neuropathy Table 1 lists all adverse events, regardless of causality, occurring $n \ge 2\%$ of patients with neuropathic pain associated with diabetic peripheral neuropathy receiving pregabalin for at least one of the pregabalin groups, and for which the incidence was greater than in the placebo group. A majority of pregabalin-treated patients in these studies had adverse events with a maximum intensity of mild or moderate. In these studies, 979 patients received pregabalin and 459 patients received placebo for up to 13 weeks.

Notice Development of the American State of the American State

			Pregabali	n (mg/day)	
Body System Preferred Term	Placebo (n = 459) %	75 (n = 77) %	150 (n = 212) %	300 (n = 321) %	600 (n = 369) %
Body as a whole					
Infection	6.1	3.9	7.5	8.4	4.6

	Pregabalin (mg/day)					
Body System Preferred Term	Placebo (n = 459) %	75 (n = 77) %	150 (n = 212) %	300 (n = 321) %	600 (n = 369) %	
Asthenia	2.4	3.9	1.9	4.4	7.3	
Pain	3.9	5.2	4.2	2.5	4.9	
Accidental injury	2.8	5.2	2.4	2.2	5.7	
Back pain	0.4	0.0	2.4	1.2	1.9	
Chest pain	1.1	3.9	1.4	1.2	1.6	
Face edema	0.4	0.0	0.9	0.9	2.2	
Digestive system						
Dry mouth	1.1	2.6	1.9	4.7	6.5	
Constipation	1.5	0.0	2.4	3.7	6.0	
Diarrhea	4.8	5.2	2.8	1.9	3.0	
Flatulence	1.3	2.6	0.0	2.2	2.7	
Vomiting	1.5	1.3	0.9	2.2	1.1	
Hemic and lymph	atic system					
Ecchymosis	0.2	2.6	0.5	0.6	0.3	
Metabolic and n	tritional dis	orders				
Peripheral edema	2.4	3.9	6.1	9.3	12.5	
Weight gain	0.4	0.0	4.2	3.7	6.2	
Edema	0.0	0.0	1.9	4.0	1.9	
Hypoglycemia	1.1	1.3	3.3	1.6	1.1	
Nervous system						
Dizziness	4.6	7.8	9.0	23.1	29.0	
Somnolence	2.6	3.9	6.1	13.1	16.3	
Neuropathy	3.5	9.1	1.9	2.2	5.4	
Ataxia	1.3	6.5	0.9	2.2	4.3	
Vertigo	1.1	1.3	1.9	2.5	3.5	
Confusion	0.7	0.0	1.4	2.2	3.3	
Euphoria	0.0	0.0	0.5	3.4	1.6	
Thinking abnormal ^a	0.0	1.3	0.0	0.9	3.0	
Abnormal gait	0.0	1.3	0.0	0.6	2.7	
Reflexes decreased	1.7	3.9	0.5	1.2	1.4	
Amnesia	0.2	2.6	0.9	0.0	2.2	
Hypesthesia	0.7	2.6	0.0	0.0	0.8	
Hyperalgesia	0.2	2.6	0.0	0.0	0.3	
Respiratory syste	m					
Dyspnea	0.7	2.6	0.0	1.9	1.9	
Skin and append	ages					
Pruritus	1.3	2.6	0.0	0.9	0.0	
Special senses						
Blurred vision [®]	1.5	2.6	1.4	2.8	1.5	
Conjunctivitis	0.2	2.6	1.4	0.6	0.3	

a Thinking abnormal primarily consists of events related to difficulty with concentration/attention but also includes events related to cognition and

language problems and slow thinking. b Investigator term; summary level term is amblyopia.

Discontinuation in Controlled Clinical Studies of Diabetic Peripheral Neuropathy Approximately 9% of patients receiving pregabalin and 4% receiving placebo discontinued from controlled diabetic peripheral neuropathy studies due to adverse events. The adverse events most commonly leading to discontinuation are presented in Table 2

Table 2. Adverse Events Most Frequently (≥2% of patients) Leading to Discontinuation in Placebo-Controlled Studies in Patients with Neuropathic Pain Associated with Diabetic Peripheral Neuropathy

	Nu	mber (%) of	Patients					
COSTART Preferred Term			Pregabali	egabalin (mg/day)				
	Placebo (n = 459)	75 (n = 77)	150 (n = 212)	300 (n = 321)	600 (n = 369)			
Dizziness	2 (0.4)	0 (0.0)	3 (1.4)	6 (1.9)	21 (5.7)			
Somnolence	0 (0.0)	0 (0.0)	0 (0.0)	5 (1.6)	15 (4.1)			

Postherpetic Neuralgia Table 3 lists all adverse events, regardless of causality, occurring in ≥2% of patients with neuropathic pain associated with postherpetic neuralgia receiving pregabalin for at least one of the pregabalin groups, and for which the incidence was greater than in the placebo group. A majority of pregabalin-treated patients in these studies had adverse events with a maximum support the second seco

Table 3. Incidence (%) of Treatment-Emergent Adverse Events in Placebo-Controlled Studies in Neuropathic Pain Associated with Postherpetic Neuralgia (Events in at Least 2% of Patients Receiving

Prega

Flatulence

1.0

abalin and More Frequent Than in Placebo-Treated Patients)
--

Tal

		Pregabalin (mg/day)					
Body System Preferred Term	Placebo (n = 398) %	75 (n = 84) %	150 (n = 302) %	300 (n = 312) %	600 (n = 154) %		
Body as a whol	e						
Infection	3.5	14.3	8.3	6.4	2.6		
Headache	5.3	4.8	8.9	4.5	8.4		
Pain	3.8	4.8	4.3	5.4	4.5		
Asthenia	4.0	3.6	5.0	2.6	5.2		
Accidental injury	1.5	3.6	2.6	3.2	5.2		
Flu syndrome	1.3	1.2	1.7	2.2	1.3		
Face edema	0.8	0.0	1.7	1.3	3.2		
Malaise	1.0	2.4	0.3	0.6	0.0		
Cardiovascular	system			-			
Vasodilatation	1.3	2.4	1.0	0.6	0.0		
Digestive system	m						
Dry mouth	2.8	7.1	7.0	6.1	14.9		
Constipation	2.3	3.6	4.6	5.4	5.2		
Diarrhea	4.0	2.4	4.3	3.5	4.5		

2.4

		Pregabalin (mg/day)					
Body System Preferred Term	Placebo (n = 398) %	75 (n = 84) %	150 (n = 302) %	300 (n = 312) %	600 (n = 154 %		
Vomiting	0.8	1.2	0.7	2.9	2.6		
Metabolic and n	utritional dis	orders					
Peripheral edema	3.5	0.0	7.9	15.7	16.2		
Weight gain	0.3	1.2	1.7	5.4	6.5		
Edema	1.3	0.0	1.0	2.2	5.8		
Hyperglycemia	0.8	2.4	0.3	0.0	0.0		
Nervous system							
Dizziness	9.3	10.7	17.9	31.4	37.0		
Somnolence	5.3	8.3	12.3	17.9	24.7		
Ataxia	0.5	1.2	2.0	5.4	9.1		
Abnormal gait	0.5	0.0	2.0	3.8	7.8		
Confusion	0.3	1.2	2.3	2.9	6.5		
Thinking abnormal ^a	1.5	0.0	1.7	1.3	5.8		
Incoordination	0.0	2.4	1.7	1.3	2.6		
Amnesia	0.0	0.0	1.0	1.3	3.9		
Speech disorder	0.0	0.0	0.3	1.3	3.2		
Insomnia	1.8	0.0	0.7	2.2	0.0		
Euphoria	0.0	2.4	0.0	1.3	1.3		
Nervousness	0.5	0.0	1.0	0.3	2.6		
Tremor	1.5	1.2	0.0	1.0	2.6		
Hallucinations	0.0	0.0	0.3	0.3	3.2		
Hyperesthesia	0.3	2.4	0.3	0.0	1.3		
Respiratory syst	em						
Bronchitis	0.8	0.0	1.3	1.0	2.6		
Pharyngitis	0.8	0.0	2.6	0.6	0.6		
Rhinitis	1.8	1.2	0.7	0.6	3.2		
Skin and append	lages						
Rash	3.0	2.4	2.0	2.9	5.2		
Special senses							
Blurred vision ^b	2.5	1.2	5.0	5.1	9.1		
Diplopia	0.0	0.0	1.7	1.9	3.9		
Abnormal vision	0.3	0.0	1.0	1.6	5.2		
Urogenital syste	m						
Urinary tract infection	1.5	0.0	2.3	1.6	3.2		

a Thinking abnormal primarily consists of events related to difficulty with concentration/attention but also includes events related to cognition and language problems and slow thinking.

b Investigator term; summary level term is amblyopia.

Discontinuation in Controlled Clinical Studies of Postherpetic Neuralgia Approximately 14% of patients receiving pregabalin and 7% receiving placebo discontinued from controlled postherpetic neuralgia studies due to adverse ev ents The adverse events most commonly leading to discontinuation are presented in Table 4.

Table 4. Adverse Events Most Frequently (≥2% of patients) Leading to Discontinuation in Placebo-Controlled Studies in Patients with Neuropathic Pain Associated with Postherpetic Neuralgia

	Nu	mber (%) of	Patients					
COSTART Preferred Term		Pregabalin (mg/day)						
	Placebo (n = 398)	75 (n = 84)	150 (n = 302)	300 (n = 312)	600 (n = 154)			
Dizziness	3 (0.8)	0 (0.0)	11 (3.6)	12 (3.8)	12 (7.8)			
Somnolence	1 (0.3)	0 (0.0)	6 (2.0)	12 (3.8)	10 (6.5)			
Confusion	1 (0.3)	0 (0.0)	2 (0.7)	5 (1.6)	8 (5.2)			
Peripheral edema	1 (0.3)	0 (0.0)	2 (0.7)	5 (1.6)	5 (3.2)			
Ataxia	0 (0.0)	0 (0.0)	1 (0.3)	5 (1.6)	4 (2.6)			
Abnormal gait	0 (0.0)	0 (0.0)	0 (0.0)	4 (1.3)	4 (2.6)			
Hallucinations	0 (0.0)	0 (0.0)	0 (0.0)	1 (0.3)	4 (2.6)			
Dry mouth	1 (0.3)	0 (0.0)	0 (0.0)	0 (0.0)	4 (2.6)			

Incidence of Most Common Dose-Related Treatment-Emergent Adverse Events Most common dose-related treatment-emergent adverse events are pr nted in Table 5 (diabetic peripheral neuropathy) and Table 6 (postherpetic neuralgia)

ble 5. Ir	nciden	ce (%)	of Most	Commo	n Dose-Re	lated Treat	nent-Emergen	t
A	dverse	Event	s in Pla	cebo-Co	ntrolled St	udies in Ne	uropathic Pair	£.

		Pregabalin (mg/day)				
Adverse Event Preferred Term	Placebo (n = 459) %	75 (n = 77) %	150 (n = 212) %	300 (n = 321) %	600 (n = 369) %	
Dizziness	4.6	7.8	9.0	23.1	29.0	
Somnolence	2.6	3.9	6.1	13.1	16.3	
Peripheral edema	2.4	3.9	6.1	9.3	12.5	
Asthenia	2.4	3.9	1.9	4.4	7.3	
Dry mouth	1.1	2.6	1.9	4.7	6.5	
Weight gain	0.4	0.0	4.2	3.7	6.2	
Constipation	1.5	0.0	2.4	3.7	6.0	
Blurred vision ^a	1.5	2.6	1.4	2.8	5.7	

term is amblyopi

Table 6. Incidence (%) of Most Common Dose-Related Treatment-Emergent Adverse Events in Placebo-Controlled Studies in Neuropathic Pain Associated with Postherpetic Neuralgia

Adverse Event Preferred Term		Pregabalin (mg/day)					
	Placebo (n = 398) %	75 (n = 84) %	150 (n = 302) %	300 (n = 312) %	600 (n = 154) %		
Dizziness	9.3	10.7	17.9	31.4	37.0		
Somnolence	5.3	8.3	12.3	17.9	24.7		

Adverse Event Preferred Term			Pregabalin (mg/day)				
	Placebo (n = 398) %	75 (n = 84) %	150 (n = 302) %	300 (n = 312) %	600 (n = 154) %		
Peripheral edema	3.5	0.0	7.9	15.7	16.2		
Dry mouth	2.8	7.1	7.0	6.1	14.9		
Blurred vision ^a	2.5	1.2	5.0	5.1	9.1		
Ataxia	0.5	1.2	2.0	5.4	9.1		
Weight gain	0.3	1.2	1.7	5.4	6.5		
Abnormal gait	0.5	0.0	2.0	3.8	7.8		

a Investigator term: summary level term is amblyopia

Adverse Events Following Abrupt or Rapid Discontinuation Following abrupt or rapid discontinuation of pregabalin, some patients reported symptoms including insomnia, nausea, headache and diarrhea. Pregabalin should be tapered gradually over a minimum of one week rather than discontinued abruptly (see WARNINGS AND PRECAUTIONS, Abrupt or Rapid Discontinuation) Drug Abuse and

AND FRECACIONS, <u>Actupe or napro Discontinuation</u> <u>Jurga Ausse and</u> <u>Degendence(Liability</u> in a study of recreational users [n=15] of sedative/hyponotic drugs, including alcohol, a single dose of LYRICA (pregabalin) 450 mg received subjective ratings of "good drug effect", "high", and "liking" to a degree that was similar to a single dose of diazepam 30 mg. In controlled clinical studies in over 5500 patients, 4% of LYRICA-treated patients and 1% of placebo-treated patients overall reported euphoria as an adverse event. However, in clinical trials of diabetic peripheral neuropathy, euphoria was reported as an adverse event by 1.8% of LYRICA-treated patients and 0% of placebo-treated patients, and in clinical trials of postherpetic neuralgia, euphoria was reported as an adverse event by 0.9% of LYRICA-treated patients and 0% of placebo-treated patients. In clinical studies, following abrupt

patients and 0% of placeborreated patients. In clinical studies, following adulpt or rapid discontinuation of pregabalin, some patients reported symptoms including insomnia, nausea, headache or diarrhea suggestive of physical dependence (see WARNINGS AND PRECAUTIONS, <u>Abrupt or Rapid Discontinuation</u>) Pregabalin is not known to be active at receptor sites associated with drugs of abuse. As with any CNS active drug, physicians should carefully evaluate patients for history of drug abuse and observe them for signs of LYRICA misuse or abuse (e.g., development of tolerance, dose escalation, drug-seeking behaviour). Other Events Observed During the Premarketing Evaluation of LYRICA Following is a list of treatment-emergent adverse events reported during premarketing assessment of LYRICA in clinical trials (over 8600 adult subjects) except those already listed in the previous tables or elsewhere in labeling. In the tabulations that follow, a COSTART-based dictionary of terminology has been used to classify reported adverse events. The frequencies presented, therefore, represent the proportion of the over 8600 adult individuals exposed to multiple doses of LYRICA who experienced an event of the type cited on at least 1 occasion while receiving LYRICA. It is important to emphasize that although the events reported occurred during treatment with LYRICA, they were not necessarily caused by it. Less Common Clinical Trial

Adverse Drug Reactions (24%) Events are further categories dy body system and listed in order of decreasing frequency according to the following definitions: frequent adverse events are those occurring on 1 or more occasions in at least 1/100 patients; infrequent adverse events are those occurring in 1/100 to 1/1000 patients; rare events are those occurring in fewer than 1/1000 patients.

Body System	Adverse Events						
Body as a	whole						
Frequent	Flu syndrome, back pain, allergic reaction, fever, generalized edema						
Infrequent	Neck pain, neoplasm, cellulitis, cyst, chills, malaise, overdose, moniliasis, hernia, viral infection, photosensitivity reaction, pelvic pain, abdomen enlarged, abscess, neck rigidity, lab test abnormal, drug level increased, carcinoma, sepsis, suicide attempt, reaction unevaluable Infection fungal, unexpected benefit, chills and fever, body						
Rare	Infection fungal, unexpected benefit, chills and fever, body odor, drug level decreased, halitosis, hangover effect, injection site reaction, hormone level altered, hypothermia, infection bacterial, injection site hemorrhage, intentional overdose, mucous membrane disorder, accidental overdose, adenoma, anaphylactoid reaction, ascites, chest pain substernal, death, sarcoidosis, sudden death, immune system disorder, increased drug effect, injection site pain, Lupus Erythematosus syndrome, medication error, sarcoma, shock, tolerance decreased						
Cardiovaso	cular						
Frequent	Hypertension, vasodilatation						
Infrequent	Palpitation, migraine, tachycardia, peripheral vascular disorder, electrocardiogram abnormal, cardiovascular disorder, angina pectoris, congestive heart failure, hemorrhage, myocardial infarct, hypotension, postural hypotension, vertricular extrasystoles, atrial fibrillation, coronary artery disorder, bradycardia, cerebrovascular accident, arrhythmia, cerebral ischemia, vascular disorder, sinus bradycardia, myocardial ischemia, bundle branch block, AV block first degree, arteriosclerosis, deep thrombophlebitis, phlebitis, arterial anomaly, heart failure, pulmonary embolus, retinal vascular disorder, varicose vein						
Bare	Heart arrest, vascular anomaly, occlusion, supraventricular tachy-						
	cardia, atrial arrhythmia, atrial flutter, cerebral infarct, coronary occlusion, thrombophlebitis, thrombosis, cardiomegaly, extrasys- toles, palior, AV block, AV block second degree, cardiomyopathy, peripheral gangrene, QI interval prolonged, retinal artery occlu- sion, supraventricular extrasystoles, cerebral hemorrhage, digitalis intoxication, ventricular arthythmia, aortic stenosis, bigeminy, cerebrovascular disorder, left heart failure, ventricular tachycardia, AV block complete, carotid occlusion, carditi thrombosis, cor pulmonale, embolus lower extremity, endocarditis, heart block, increased capillary fragility, intracranial aneurysm, nodal tachycar- dia, QI interval shortender, terlinal vein thrombosis, ST elevated, T inverted, vascular headache, vasculitis						
Digestive s							
Frequent	Nausea, diarrhea, anorexia, gastrointestinal disorder						
Infrequent	Gastroenteritis, tooth disorder, periodontal abscess, colitis, gastriis, liver function tests abnormal, increased salivation, thirst, nause and vomiting, rectal disorder, gingivitis, dvsphagia, stomatitis, mouth ulceration, cholelithiasis, rectal hemorrhage, gastrointestinal hemorrhage, glossitis, tooth caries, abnormal stools, cholecystitis, mellena, oral moniliasis, esophagitis, tongue disorder, cheilitis, tongue edema						
Rare	Eructation, pancreatitis, stomach ulcer, ulcerative stomatitis, esophageal stenosis, ficeal incontinence, gum hemorrhage, intestnaid obstruction, entertistic, peptic ulcer, enterocolitis, gum hyperplasia, hepatomegaly, liver fatty deposit, tenesmus, biliary pain, ficeal impaction, jaundice, periodontitis, ulcerative colitis, aphthous stomatis, cholestatic jaundice, gastrointestinal carcinoma, hemorrhagic gastritis, hepatitis, liver tenderness,						

1.3

1.6

3.2

Body System	Adverse Events
System	nausea, vomiting and diarrhea, salivary gland enlargement,
	stomach atony, bloody diarrhea, cardiospasm, duodenal ulcer,
	gamma glutamyl transpeptidase increased, hematemesis,
	hepatoma, intestinal perforation, intestinal stenosis, intestinal
	ulcer, leukoplakia of mouth, necrotizing pancreatitis, pancreas disorder, pseudomembranous colitis, sialadenitis, stomach ulcer
	hemorrhage, tongue discoloration
Endocrine	system
Infrequent	Diabetes mellitus, hypothyroidism
Rare	Goiter, prolactin increased, thyroid disorder, gonadotropic follicle
	stim hormone increase, hyperthyroidism, thyroiditis, adrenal insufficiency, parathyroid disorder, thyroid carcinoma, thyroid
	neoplasia, virilism
Hemic and	
Infrequent	Anemia, leukopenia, thrombocytopenia, lymphadenopathy,
	hypochromic anemia, leukocytosis, eosinophilia
Rare	Lymphocytosis, petechia, iron deficiency anemia, cyanosis,
	lymphedema, polycythemia, lymphoma like reaction, megaloblastic anemia, splenomegaly, purpura, thrombocythemia,
	thrombocytopenic purpura, chronic leukemia, coagulation disorder,
	erythrocytes abnormal, leukemoid reaction, lymphangitis,
	macrocytic anemia, pancytopenia, prothrombin decreased, rupture of spleen, sedimentation rate increased
Metabolic	and nutritional
Infrequent	Hyperglycemia, SGPT increased, hypoglycemia, hypokalemia,
	hypercholesteremia, SGOT increased, weight loss, hyperlipemia,
	amylase increased, hyperuricemia, alkaline phosphatase
	increased, creatinine increased, hyponatremia, gout, dehydration, BUN increased, healing abnormal
Rare	Hypercalcemia, hyperkalemia, hypocalcemia, bilirubinemia, alcohol
lidic	intolerance, hypoglycemic reaction, ketosis, calcium disorder, hypo-
	chloremia, hypomagnesemia, hypoproteinemia, NPN increased,
	uremia, acidosis, avitaminosis, enzymatic abnormality, gamma
	globulins increased, hypernatremia, hypophosphatemia, lactic acidosis, obesity
Musculosk	eletal system
Frequent	Arthralgia, myalgia, arthritis, leg cramps, myasthenia
Infrequent	Tendon disorder, arthrosis, joint disorder, bone disorder,
	tenosynovitis, bursitis, tendinous contracture, osteoporosis, tendon
	rupture, bone pain
Rare	Rheumatoid arthritis, osteomyelitis, rhabdomyolysis, myopathy, muscle atrophy, myositis, pyogenic arthritis, bone neoplasm,
	musculoskeletal congenital anomaly, pathological fracture
Nervous sy	stem
Frequent	Insomnia, anxiety, libido decreased, depersonalization, hypertonia,
	neuropathy
Infrequent	Reflexes decreased, sleep disorder, abnormal dreams, hostility, hallucinations, hyperkinesia, personality disorder, dysarthria,
	hyperesthesia, hypokinesia, circumoral paresthesia, libido
	increased, neuralgia, vestibular disorder, aphasia, movement
	disorder, hyperalgesia, apathy, hypotonia, convulsion, facial
Rare	paralysis, psychosis
nale	Drug dependence, neuritis, paranoid reaction, CNS depression, CNS neoplasia, manic reaction, neurosis, extrapyramidal
	syndrome, meningitis, hemiplegia, reflexes increased, akathisia,
	delirium, paralysis, withdrawal syndrome, brain edema, CNS
	stimulation, dyskinesia, encephalopathy, foot drop, grand mal convulsion, hypalgesia, peripheral neuritis, psychotic depression,
	addiction, arachnoiditis, cerebellar syndrome, cogwheel rigidity,
	dementia, dystonia, Guillain-Barre syndrome, intracranial
	hemorrhage, multiple sclerosis, myelitis, schizophrenic reaction, subarachnoid hemorrhage, torticollis
Respiratory	
Frequent	Sinusitis, rhinitis, dyspnea, cough increased, pneumonia, lung
	disorder
Infrequent	Asthma, epistaxis, laryngitis, voice alteration, respiratory disorder, sputum increased
Rare	Apnea, emphysema, aspiration pneumonia, hyperventilation,
	lung edema, pleural disorder, atelectasis, hemoptysis, hiccup,
	hypoxia, laryngismus, lung fibrosis, pleural effusion, lung function
	decreased, pulmonary hypertension, yawn, bronchiectasis, bronchiolitis, carcinoma of lung, hypoventilation, laryngeal
	neoplasia, nasal septum disorder, pneumothorax
Skin and a	
Infrequent	Pruritus, sweating, skin disorder, acne, dry skin, alopecia, skin
	ulcer, herpes simplex, urticaria, nail disorder, eczema, herpes
	zoster, skin benign neoplasm, fungal dermatitis, maculopapular rash, vesiculobullous rash, skin carcinoma, furunculosis, skin
	discoloration, skin hypertrophy, psoriasis, seborrhea, hirsutism
Rare	Skin nodule, angioedema, cutaneous moniliasis, skin atrophy,
	exfoliative dermatitis, pustular rash, ichthyosis, skin melanoma,
	subcutaneous nodule, sweating decreased, hair disorder, lichenoid dermatitis, melanosis, miliaria, purpuric rash, skin necrosis,
	Stevens Johnson syndrome
Special ser	ise
Frequent	Eye disorder, conjunctivitis, otitis media
Infrequent	Retinal disorder, tinnitus, eye pain, cataract specified, dry eyes,
	taste perversion, ear pain, lacrimation disorder, ear disorder,
	deafness, eye hemorrhage, photophobia, glaucoma, vitreous disorder, corneal lesion, otitis externa, refraction disorder,
	blepharitis, retinal edema, taste loss, abnormality of accommodation
Rare	Hyperacusis, keratitis, mydriasis, parosmia, ptosis, retinal
	hemorrhage, color blindness, retinal depigmentation, retinal
	detachment, corneal opacity, corneal ulcer, iritis, night
	hlindness ontic atronhy retinal decenaration externet NICC
	blindness, optic atrophy, retinal degeneration, cataract NOS, scleritis, strabismus, anisocoria, blindness, exophthalmos,
	scleritis, strabismus, anisocoria, blindness, exophthalmos, keratoconjunctivitis, ophthalmoplegia, papilledema
Urogenital Frequent	scleritis, strabismus, anisocoria, blindness, exophthalmos, keratoconjunctivitis, ophthalmoplegia, papilledema

Body Adverse Events System Infrequent Urinary frequency, urinary incontinence, cystitis, abnormal ion, urination impaired, dysuria, metrorrhagia, hematuria, vaginal moniliasis, prostatic disorder, vaginitis, dysmenorrhea. urinary urgency, kidney calculus, breast pain, menstrual disorder, amenorrhea, menorrhagia, kidney function abnormal, nephritis, urine abnormality, vaginal hemorrhage, urinary retention, urinary tract disorder, leukorrhea, breast neoplasm, menopause, oliguria, polyuria, albuminuria, pyuria Rare Breast carcinoma, penis disorder, papanicolau smear suspicious, fibrocystic breast, prostatic carcinoma, uterine fibroids enlarged, acute kidney failure, creatinine clearance decreased nephrosis, nocturia, polycystic kidney, bladder carcinoma, breast enlargement, cervicitis, cervix disorder, female lactation glycosuria, gynecomastia, hypomenorrhea, kidney pain, mastitis, pyelonephritis, kidney failure, breast abscess, epididymitis, orchitis, prostate neoplasia, prostatic specific antigen increase salpingitis, urogenital disorder, urolithiasis, uterine disorder, vulvovaginal disorder, balanitis, bladder calculus, calcium crystalluria, cervix neoplasm, dyspareunia, endometrial carcinoma, endometrial disorder, glomerulitis, hydronephrosis, ovarian cancer. unintended pregnancy, urethral pain, urethritis, urogenital anomaly, urogenital neoplasia, uterine hemorrhage

Comparison of Gender and Race The overall adverse event profile of pregabalin was similar between women and men. There are insufficient data to support a statement regarding the distribution of adverse experience reports by race. Peripheral Edema Incidence of peripheral edema in controlled neuropathic pain studies was 10.4% in the pregabalin group compared with 2.9% in the placebo group. In clinical trials, these events of peripheral edema were dose-related, mostly mild to moderate in intensity and rarely led to withdrawal. Peripheral edema was not associated with cardiovascular complications such as hypertension or congestive The associated with failutivascular complications solve as hyperiension to congestive hear failure and there was no evidence of hemodilution or changes in any laboratory parameters indicative of underlying organ dysfunction (see **WARNINGS AND PRECAUTIONS**, <u>Peripheral Edema</u>). Weight Gain in the controlled neuropathic pain studies, patients on pregabalin had a higher incidence (5.9%) of weight gain as defined by a \geq 7% increase from baseline weight as compared with the placebo group (1.6%). The mean change in the pregabalin group was an increase of 1.5 kg compared with 0.2 kg in the placebo group; few patients (0.1%) withdrew due to weight gain. This weight gain was dose-related, and not associated with clinically important changes in blood pressure or cardiovascular adverse events. There was no relationship between baseline body mass index and the incidence of >7% weight gain in the controlled trials. Based on the results of a controlled study of reproductive gain in the continued mass based on the resolits of a number study or inplication on pregabalin appeared to be reversible. In this study, there were no reports of peripheral edema (see WARNINGS AND PRECAUTIONS, <u>Weight Gain</u>) <u>Abnormal Hematologic and</u> <u>Clinical Chemistry Findings</u> In all controlled trials. 10% of patients on pregabalin and 0.5% of placebo patients had an increase in creatine kinase of >3x upper limit of normal. Renal dysfunction was generally not associated with the elevated creatine kinase in these patients. Mean changes in creatine kinase ranged from 9.6 to 26.3 U/L for pregabalin-treated patients and 4.8 U/L for the placebo patients (see DOSAGE AND ADMINISTRATION, Patients with Renal Impairment). Routine therapeuti drug monitoring or clinical laboratory testing is not required for patients treated with LYRICA (see **WARNINGS AND PRECAUTIONS**). <u>Post-Marketing Adverse</u> Drug Reactions The worldwide post-marketing experience to date with LYRICA is consistent with the clinical program. The most frequently reported adverse events from spontaneous post-marketing reports for LYRICA are shown below. There are insufficient data to support an estimate of their incidence or to establish causation Eye disorders: diplopia, vision blurred, visual disturbance. There have also been rare mmodation disorder, evelid edema and eve redness (see WARNINGS

Reports of accommodation usables, even a cell and any even and the cell and accommodation usables, and the cell and the nt, paresthesia, somnolence, speech disorder, tremor (see WARNINGS AND PRECAUTIONS, Dizziness and Somnolence). Psychiatric disorders: confusional state, depression, insomnia, psychotic disorder. There have been rare reports of psychotic disorders in patients receiving pregabalin. **Renal and urinary** disorders: urinary retention Respiratory, thoracic and mediastinal disorders: dyspnea Skin and subcutaneous tissue disorders: pruritus

DRUG INTERACTIONS

Overview Since pregabalin is predominately excreted unchanged in the urine noes negligible metabolism in humans (<2% of a dose recovered in urine as metabolites), does not inhibit drug metabolism in vitro, and is not bound to plasma proteins, LYRICA (pregabalin) is unlikely to produce, or be subject to, pharmacokinetic interactions. Pharmacokinetic In Vitro Studies: In vitro drug metabolism studies revealed that pregabalin at concentrations which were, in general, 10-fold greater than observed in Phase 2/3 clinical trials, does not inhibit human CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4 enzyme systems. In Vivo Studies: The drug interaction data described in this section were obtained Vivo Studies: The drug interaction data described in this section were obtained from studies involving healthy adults, patients with epilepsy, and patients with chronic pain disorders. Carbamazepine, valproic acid, lamotrigine, phenytoin, phenobarbital, and topiramate In vitro and in vivo studies showed that LYRICA is unlikely to be involved in significant pharmacokinetic drug interactions. Specifically, there are no clinically significant pharmacokinetic interactions between pregabalin and the following antiepileptic drugs: carbamazepine, valproic acid, lawtrigine, phenytoin, phenobarbital, and topiramate. Important pharmacokinetic interactions would also not be expected to occur between pregabalin and commonly used antiepileptic drugs. **Tiagabine:** The results of a population pharmacokinetic analysis anticipient and the results of a population pranticovine analysis indicated that in patients with partial seizures tagabain e had no clinically significant effect on pregabalin clearance. **Gabapentin:** The pharmacokinetics of pregabalin and gabapentin were investigated in 12 healthy subjects following concomitant single dose administration of 100 mg pregabalin and 300 mg gabapentin, and in 18 healthy subjects following concomitant multiple dose administration of 200 mg pregabalin q8h and 400 mg gabapentin q8h. Gabapentin pharmacokinetics following single and multiple dose administration were unaltered by pregabalin coadministration. The rate of pregabalin absorption was reduced by approximately 26% (single dose administration) and 18% (multiple dose administration) based or lower Cmay values; however, the extent of pregabalin absorption was unaffected by gabapentin coadministration. **Oral Contraceptives**: Pregabalin coadministration (200 mg TID) had no effect on the steady state pharmacokinetics of norethindrone and ethinyl estatolic († mg/s g, respectively) in healthy subjects. **Lorazepam**: Multiple dose administration of pregabalin (300 mg BID) in healthy subjects. **Lorazepam**: Multiple dose administration of pregabalin (300 mg BID) in healthy subjects **Lorazepam**; single dose administration of lorazepam (1 mg) had no clinically significant effect on the steady state pharmacokinetics of pregabalin. Oxycodone: Multiple dose administration of pregabalin (300 mg BID) in healthy subjects had no effect on the rate and extent of oxycodone single dose pharmacokinetics. Single dose administration of oxycodone (10 mg) had no clinically significant effect on the steady state pharmacokinetics of pregabalin. **Ethanol:** Multiple dose administration of pregabalin (300 mg BID) in healthy subjects had no effect on the rate and extent of ethanol single dose pharmacokinetics and single dose administration of ethanol (0.7 g/kg) had no clinically significant effect on the steady state pharmacokinetics

of pregabalin, Diuretics, Oral Hypoglycemics, and Insulin: A population pharmacokinetic analysis in patients with chronic pain showed no clinically significant effect on pregabalin clearance with the concomitant use of diuretics, or al hypoglycemics, and insulin. Pharmacodynamic Multiple oral doses of pregabalin co-administered with oxycodone, lorazepam, or ethanol did not result in clinically important effects on respiration. Pregabalin appears to be additive in the impairment of cognitive and gross motor function caused by oxycodone. Pregabalin may To cognitive and gross induct notion caused or doyclobine. Frequenting the regularity may potentiate the effects of ethanol and lorazepam. **Drug-Food Interactions**. The rate of pregabalin absorption is decreased when given with food resulting in a decrease in C_{max} by approximately 25% to 30% and an increase in T_{max} to approximately 3 hours. However, administration of pregabalin with food has no clinically relevant effect on However, administration of pregabating with food name chinicary relevant effect on the total amount of pregabating basehed. Therefore, pregabating has no known drug/herb interactions. <u>Drug-Leboratory Interactions</u> LYRICA (pregabatin) has no known drug/laboratory test interactions.

DOSAGE AND ADMINISTRATION

Dosing Considerations Patients with Impaired Renal Function Pregabalin is primarily eliminated from the systemic circulation by renal excretion as unchanged drug. In patients with a medical history of significant renal insufficiency, daily dosages should be reduced accordingly (see Dosage Adjustment Based on Renal Function, below). In accordance with cur clinical practice, if LYRICA (pregabalin) has to be discontinued, it is recommen this should be done gradually over a minimum of 1 week (see WARNINGS AND ans should be doine graduarly over a minimum of weak (see VARININGS AND) PRECAUTIONS, <u>Abory or Rapid Discontinuation</u>) Adults: Neuropathic pain associated with diabetic peripheral neuropathy The recommended starting dose for LYRICA is 150 mg/day, given in two or three divided doses (75 mg BID of 0 mg TID), with or without food in patients with a creatinine clearance rate of at least 60 mL/min. Efficacy of LYRICA has been demonstrated within the first week. Based on individual patient response and tolerability, the dose may be increased to 150 mg BID (300 mg/day) after one week. For patients who experience significant and ongoing pain and can tolerate pregabalin 300 mg/day well, maximum daily does of 600 mg (300 mg twice a day, BID) can be used. However, in clinical trials, LYRICA 600 mg/day did not provide additional significant efficacy and patients treated with this dose experienced markedly higher rates of adverse events and discontinued the trial more frequently. Neuropathic pain associated with postherpetic neuralgia The recommended starting dose for LYRICA is 150 mg/day, given in two or three divided doses (75 mg BID or 50 mg TID), with or without food in patients with a creatinine clearance rate of at least 60 mL/min. Efficacy of LYRICA has been demonstrated within the first week. Based on individual patient response and tolerability, the dose may be increased to 150 mg BID (300 mg/day) after one week. For patients who experience significant and ongoing pain and can tolerate pregabalin 300 mg/day well, maximum daily dose of 600 mg (300 mg twice a day, BID) can be used. However, in clinical trials, LYRICA 600 mg/day did not provide additional significant efficacy and patients treated with this dose experienced markedly higher rates of adverse events and discontinued the trial more frequently Dosage Adjustment Based on Renal Function LYRICA is primarily eliminated by al excretion. Therefore, the dose should be adjusted for patients with reduced renal BxXretion Thereiore, the dose should be adjusted for patients with reduced renal function. Pregabalin clearance is directly proportional to creatinine clearance. Therefore, dosing adjustment should be based on creatinine clearance (CL₂), as indicated in Table 7. To use this dosing table, an estimate of the patient's creatinine clearance (CL₂) as mL/min is needed. CL₂ in mL/min may be estimated from serum creatinine (mg/dL) determination using the Cockcroft and Gault equation:

[140 - age (years)] x weight (kg) (x 0.85 for female patients) CL~= 72 x serum creatinine (mg/dL)

Pregabalin is effectively removed from plasma by hemodialysis. Over a 4-hour hemodialysis treatment, plasma pregabalin concentrations are reduced by approximately 50%. For patients receiving hemodialysis, pregabalin daily dose should he adjusted based on renal function. In addition to the daily dose adjustment, a supplemental dose should be given immediately following every 4-hour hemodialysis treatment (see Table 7).

Table 7. Pregabalin Dosage Adjustment Based on Renal Function

Creatinine Clearance (CL _{cr}) (mL/min)	Total Pregabalin Daily Dose (mg/day)*			Dose Regimen
≥60	150	300	600	BID or TID
30-60	75	150	300	BID or TID
15-30	25-50	75	150	QD or BID
<15	25	25-50	75	QD
		age following		

Patients on the 25 mg QD regimen: take one supplemental dose of 25 mg or 50 mg Patients on the 25-50 mg QD regimen: take one supplemental dose of 50 mg or 75 mg Patients on the 75 mg QD regimen: take one supplemental dose of 100 mg or 150 mg

TID = Three divided doses; BID = Two divided doses; QD = Single daily dose a Total daily dose (mg/day) should be divided as indicated by dose regimen to provide mg/dose

b Supplementary dose is a single additional dose.

Geriatrics (>65 years): Pregabalin oral clearance tended to decrease with increasing age. This decrease in pregabalin oral clearance is consistent with age related decreases in creatinine clearance. Reduction of pregabalin dose may be regured in patients who have age-related compromised real function. *Pediatrics* (<18 years of age): The safety and efficacy of pregabalin in pediatric patients (<18 years of age) have not been established and its use in this patient population is not recommended. <u>Administration</u> LYRICA (pregabalin is given orally with or without food (see ACTION AND CLINICAL PHARMACOLOGY).

OVERDOSAGE

Signs, Symptoms and Laboratory Findings of Acute Overdosage in Humans The highest known dose of pregabalin received in the clinical development program was 15,000 mg in 1 patient. The types of adverse events experienced by patients who received an overdose were not clinically different from other patients receiving recommended doses of pregabalin. Treatment or Management of Overdose There is no specific antidote for overdose with pregabalin. If indicated, elimination of unabsorbed drug may be attempted by emesis or gastric lavage, usual precautions should be observed to maintain the airway. General supportive care of the patient is indicated including monitoring of vital signs and observation of the clinical status of the patient. A Certified Poison Control Center should be contacted for up-to-date information on the management of overdose with pregabalin. **Hemodialysis** Standard hemodialysis procedures result in significant clearance of pregabalin (approximately 50% in 4 hours) and should be considered in cases of overdose. Although hemodialysis has not been performed in the few known cases of overdose, it may be indicated by the patient's clinical state or in patients with significant renal impairment

ACTION AND CLINICAL PHARMACOLOGY

Mechanism of Action Pharmacodynamics LYRICA (pregabalin) binds with high nity to the alpha-delta protein (a calcium channel subunit) of brain tissues and has analgesic, antiepileptic and anxiolytic activity. Pregabalin is known chemically as (S)-3-(aminomethyl)-5-methylhexanoic acid. Although the mechanism of action of pregabalin is unknown, results with genetically modified mice and with compounds structurally-related to pregabalin indicate that selective binding to the alpha₂ delta protein is required for analgesic, antiepileptic and anxiolytic action in animal models. In vitro, pregabalin reduces the release of several neurotransmitters, suggesting a modulatory action on calcium channel function. Pregabalin does not mimic



ADVERTISERS INDEX

Biogen Idec Tysabri - A-10, A-11, A-12, A-13, A-22, A-23 **Boehringer Ingelheim** Aggrenox - A-8, A-19, A-20, A-21 Micardis - A-6, A-7, A-30 Elekta – IFC Kyphon – A-14 Merck Frosst Maxalt - A-3, A-30, A-31, A-32 Novo Nordisk - A-14 Pfizer Lyrica - A-9, A-24, A-25, A-26, A-27 Roche – A-15 Valeant Cesamet - A-5, A-28 CNSF/CJNS Board of Directors & Committee Chairs - A-16 Classified Ads - A-18, A-27, A-34, A-35

GABA at GABA₄ or GABA₆ receptors, nor does it augment GABA₄ responses like benzodiazepines or barbiturates. In contrast to vascular calcium channel blockers, pregabalin does not alter systemic blood pressure or cardiac function. Various in vitro **TID** (q8h) to Healthy Volunteers* benzodiazepines or barbiturates. In contrast to vascular calcium channel blockers, pregabalin does not alter systemic blood pressure or cardiac function. Various in vitro and in vivo results differentiate pregabalin from GABA uptake inhibitors or GABA transaminase inhibitors. In addition, pregabalin does not block sodium channels, it is not active at opiate receptors, it does not alter cyclooxygenase enzyme activity, it is not a servorini agonist, it is not a dopamine antagonist, and it is not an inhibitor of dopamine, servotonin or noradrenaline reuptake. Pregabalin treatment reduces pain-related behavior in neuropathic animal models of diabetes, peripheral nerve damage or chemotherapeutic insult and in a model of musculoskeletal-associated pain. Pregabalin given intrathecally prevents pain-related behaviors and reduces Values pain-related behavior caused by spinally administered agents, suggesting that it acts directly on tissues of the spinal cord or brain. **Pharmacokinetics** All pharmacological actions following pregabalin administration are due to the activity of the parent compound; pregabalin is not appreciably metabolized in humans. Mean steady-state plasma pregabalin concentration-time profiles following 75, 300 and 600 mg/day given in equally divided doses every 8 hours (TID) and 600 mg/day given in equally divided doses every 12 hours (BID) are shown in Table 8. Pregabalin pharmacokinetics are linear over the recommended daily dose range. Inter-subject pharmacokinetic variability for pregabalin is low (<20%).

Table 8. Pregabalin Mean (CV%) Steady-State Pharmacokinetic Parameter Values in Healthy Volunteers

Dose (mg)	Regimen	Daily Dose (mg/ day)	n	C _{maxss} (µg/ mL)	t _{max} (hr)	C _{minss} (µg/ mL)	AUC _{i0-6} (µg•hr/ mL)		C _{UF} (mL/ min)
25	TID ^b	75	8	1.39	0.9	0.45	6.7	5.9	64.1
25	110°	75		-19.5	-34.2	-25	-18.3	-17.3	-16.1
100	TID	000	6	5.03	0.8	1.94	25.2	6.3	68.9
100	TID	300		-21.3	-31	-33.6	-23	-19.6	-20.9
200	TID	600	11	8.52	0.9	3.28	41.7	6.3	81
				-14.8	-22.2	-29.2	-12.8	-13.6	-11.7
300	BID ^c	600	8	9.07	1.4	2.6	59	6.7	85.1
				-10.5	-57.1	-15.5	-6.4	-16.2	-6.4


Steady-state peak plasma concentration

Time of peak plasma concentration at steady state Steady-state trough plasma concentration

- AUC_{nut}: Area under the plasma concentration-time curve during one dosing interval
- at steady state Elimination half-life
- Oral clearance
- Percent coefficient of variation Total daily dose given in equally divided doses every 8 hours

c: Total daily dose given in equally divided doses every 12 hours Absorption: Pregabalin is rapidly absorbed when administered in the fasted state Absorption: rregatalin is rapidly assorbed when administerio in the tasteo state, with peak plasma concentrations occurring within 1.5 hours following both single-and multiple-dose administration. Pregabalin oral bioavailability is ≥90% and is independent of dose. C_{wan} (Figure 1) and AUC values increase proportionally following single- and multiple-dose administration. Following repeated administration, steady state is achieved within 24 to 48 hours. Multiple dose pharmacokinetics are predictable from single-dose data





Daily Dose (mg/day)

a: Solid line is the regression line going through the origin; individual (O) and mean (♠) values.

Distribution: In preclinical studies, pregabalin has been shown to readily cross the blood brain barrier in mice, rats and monkeys. Pregabalin is a substrate for system L transporter which is responsible for the transport of large amino acids across the blood-brain barrier. Pregabalin has been shown to cross the placenta in rats and is present in the milk of lactating rats. In humans, the apparent volume of distribution of pregabalin following oral administration is approximately 0.5 L/kg. Pregabalin is not bound to plasma proteins. At clinically efficacious doses of 150 Pregabalin is not bound to plasma proteins. At clinically efficacious doses of 150 and 600 mg/day, the average steady-state plasma pregabalini concentrations were approximately 1.5 and 6.0 µg/mL, respectively. **Metabolism:** Pregabalin undergoes negligible metabolism in humans. Following a dose of radiolabeled pregabalin, approximately 98% of the radioactivity recovered in the unine was unchanged pregabalin. The N-methylated derivative of pregabalin, the major metabolite of pregabalin found in unine, accounted for 0.9% of the dose. In preclinical studies, pregabalin found in unine, accounted for 0.9% of the dose. In preclinical studies, pregabalin classification of the N-methylated derivative pregabalin. The N-methylated derivative pregabalin is eliminated from the extension enclinean encoded, bus peel generation ac unchanged draw. Breachting extension encoded draw Breachting ac unchanged draw Breachting and the second draw Breachting ac unchanged draw Breachting extension encoded draw Breachting ac unchanged draw Breachting and the second draw Breachting and the second second draw Breachting and the second draw Breachting ac unchanged draw Breachting and the second draw Breachting ac unchanged draw Breachting and the second draw Breachting ac unchanged draw Breachting and the second draw Breachting ac unchanged draw Breachting and the second draw Breachting ac unchanged draw Breachting and the second draw Breachting ac unchanged draw Breachting and the second draw Breachting ac unchanged draw Breachting and the second draw Breachting ac unchanged draw Breachting and the second draw Breachting ac unchanged draw Breachting and the second draw Breachting ac unchanged draw Breachting and the second draw Breachting ac unchanged draw Breachting and the second draw Breachting ac unchanged draw Breachting and the second draw Breachting systemic circulation primarily by renal excretion as unchanged drug. Pregabalin mean $t_{1/2}$ is 6.3 hours. Pregabalin elimination is proportional to creatinine clearance. clearance is reduced in patients with impaired renal fu DOSAGE AND ADMINISTRATION) Special Populations and Conditions Pregabalin undergoes negligible metabolism, is not bound to plasma proteins and is eliminated predominately as unchanged drug by renal excretion. Clinically important differences in pregabalin pharmacokinetics due to race and gender have not been observed and are not anticipated. Pediatrics: Pharmacokinetics of pregabalin

osserved and are not anticipated. **Pediatrics:** "narmacokinetics of pregadani have not been studied in paediatric patients. Geniatrics: "Pregabalin oral clearance tended to decrease with increasing age. This decrease in pregabalin oral clearance is consistent with age-related decreases in creatinine clearance. Reduction of pregabalin dose may be required in patients who have age-related compromised renal function (see WARNINGS AND PRECAUTIONS and DOSAGE AND ADMINISTRATION). Gender: A population pharmacokinetic analysis of the Phase 2/3 clinical program showed that the relationship between daily dose and pregabalin

drug exposure is similar between genders when adjusted for gender-related differences in creatinine clearance. **Race:** A population pharmacokinetic analysis of the Phase 2/3 clinical program showed that the relationship between daily dose and pregabalin drug exposure is similar among Caucasians, Blacks and Hispanics. **Renal** Insufficiency: Because renal elimination is the major elimination pathway, dosage reduction in patients with renal dysfunction is necessary. Pregabalin is effectively removed from plasma by henoidalysis. Following a 4-hour hemoialaysis reatment, plasma pregabalin concentrations are reduced by approximately 50%. For patients on hemodialysis, dosing must be modified (see **DOSAGE AND ADMINISTRATION**). STORAGE AND STABILITY

Store at 15°C-30°C

DOSAGE FORMS, COMPOSITION AND PACKAGING

Each capsule of LYRICA (pregabalin) contains 25, 50, 75, 150 or 300 mg pregabalin, lactose monohydrate, maize starch and talc. The capsule shells contain gelatin and titanium dioxide. In addition, the orange capsule shells contain red iron oxide and the white capsule shells contain sodium lauryl sulfate and colloidal silicon dioxide. Colloidal silicon dioxide is a manufacturing aid, which may not be present. The markings on the capsules are in black ink, which contains shellac, black iron oxide ropylene glycol, potassium hydroxide and wate


Capsules are packaged in HDPE bottles containing 60 capsules, and PVC/aluminum

pregabalin

PHARMACEUTICAL INFORMATION

Drug Substance Proper name:

emical name: Molecular formula Molecular mass: Structural formula:



NH₂

Precabalin is a white crystalline solid. It is soluble in water and in both basic and acidic aqueous solutions

Product Monograph available upon request

Last revised: June 3, 2005.

Physicochemical

Last revised, unle 3, 2000.
References: I. U.YRICA Product Monograph, Pfizer Canada Inc., June 2005.
2. Freynhagen R et al. Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-bind, multicentre, placebo-controlled trial of flexible-and fixed-dose regimens. *Pain* 2005; 115:254-63.
3. Data on file, Pfizer Canada Inc., study 1008-96.
4. van Seventer R et al. Efficacy and tolerability of twice-daily pregabalin for treating pain and related sleep interference in postherpetic neuralgia: pregabalin for treating pain and related sleep interference in postherpetic neuralgia a 13-week, randomized trial. *Clin Med Res Opin* 2006; 22(2):375-84.



Working for a healthier world C 2007

Pfizer Canada Inc

Kirkland, Queber H9J 2M5

PAAB

TM Pfizer Inc, used under license LYRICA is a registered trademar C.P. Pharmaceuticals Internation Pfizer Canada Inc., Licensee (R&D)



THERAPEUTIC CLASSIFICATION

Antiemetic Agent

ACTION

CESAMET (nabilone) is a synthetic cannabinoid with antiemetic properties which have been found to be of value in the management of some patients with nausea and vomiting associated with cancer chemotherapy. It also has sedative and psychotropic effects.

After oral administration, comparable peak plasma levels of nabilone and of its carbinol metabolite were attained within 2 hours. The combined plasma concentrations of nabilone and of its carbinol metabolite accounted for, at most, 10 to 20% of the total radiocarbon concentration in plasma. The plasma half-life of nabilone was approximately 2 hours, while that of the total radiocarbon was of the order of 35 hours Of the two major possible metabolic pathways, stereo-specific enzymatic reduction and direct enzymatic oxidation, the latter appears to be the more important in man. The drug and its metabolites are eliminated mainly in the feces (approximately 65%) and to a lesser extent in the urine (approximately 20%). The major excretory pathway is the biliary system.

INDICATIONS

NCESAMET is indicated for the management of severe nausea and vomiting associated with cancer chemotherapy.

CONTRAINDICATIONS

NCESAMET is contraindicated in patients with known sensitivity to marijuana or other cannabinoid agents, and in those with a history of psychotic reactions.

WARNINGS

*CESAMET should be used with extreme caution in patients with severe liver dysfunction and in those with a history of non-psychotic emotional disorders. "CESAMET should not be taken with alcohol, sedatives, hypnotics, or other psychotomimetic substances.

^NCESAMET should not be used during pregnancy, in nursing mothers or in pediatric patients, since its safety under these conditions has not been established.

PRECAUTIONS

Since "CESAMET will often impair the mental and/or physical abilities required for the performance of potentially hazardous tasks, such as driving a car and operating machinery, the patient should be warned accordingly and should not be permitted to drive or engage in dangerous tasks until the effects of nabilone are no longer present. Adverse psychiatric reactions can persist for 48 to 72 hours following cessation of treatment.

Since "CESAMET elevates supine and standing heart rates and causes postural hypotension, it should be used with caution in the elderly and in patients with hypertension or heart disease.

Drug Interactions: Potential interactions between ^NCESAMET, and diazepam: sodium secobarbital; alcohol; or codeine, were evaluated. The depressant effects of the combinations were additive. Psychomotor function was particularly impaired with concurrent use of diazepam.

ADVERSE REACTIONS

The most frequently observed adverse reactions to nabilone and their incidences reported in the course of clinical trials were as follows: drowsiness (66.0%), vertigo (58.8%), psychological high (38.8%), dry mouth (21.6%), depression (14.0%), ataxia (12.8%), blurred vision (12.8%), sensation disturbance (12.4%), anorexia (7.6%), asthenia (7.6%), headache (7.2%), orthostatic hypotension (5.2%), euphoria (4.0%) and hallucinations (2.0%).

The following adverse reactions were observed in less than 1% of the patients who were administered nabilone in the course of the clinical trials: tachycardia, tremors, syncope, nightmares, distortion in the perception of time, confusion, dissociation, dysphoria, psychotic reactions and seizures.

SYMPTOMS AND TREATMENT OF OVERDOSE

Signs and Symptoms: Signs and symptoms which might be expected to occur are psychotic episodes including hallucinations, anxiety reactions, respiratory depression and coma (experience with cases of overdosage of more than 10 mg/day has not yet been reported).

Treatment: Overdosage may be considered to have occurred, even at prescribed dosages, if disturbing psychiatric symptoms are present. In these cases, the patient should be observed in a quiet environment and supportive measures, including reassurance, should be used. Subsequent doses should be withheld until patients have returned to their baseline mental status; routine dosing may then be resumed if clinically indicated. In such instances, a lower initiating dose is suggested

If psychotic episodes occur, the patient should be managed conservatively, if possible. For moderate psychotic episodes and anxiety reactions, verbal support and comforting

may be sufficient. In more severe cases, antipsychotic drugs may be useful; however, the utility of antipsychotic drugs in cannabinoid psychosis has not been systematically evaluated. Support for their use is drawn from limited experience using antipsychotic agents to manage cannabis overdoses. Because of the potential for drug-drug interactions (eg, additive CNS depressant effects due to nabilone and chlorpromazine), such patients should be closely monitored.

Protect the patient's airway and support ventilation and perfusion. Meticulously monitor and maintain, within acceptable limits, the patient's vital signs, blood gases, serum electrolytes, etc. Absorption of drugs from the gastrointestinal tract may be decreased by giving activated charcoal, which, in many cases, is more effective than emesis or lavage; consider charcoal instead of or in addition to gastric emptying. Repeated doses of charcoal over time may hasten elimination of some drugs that have been absorbed. Safeguard the patient's airway when employing gastric emptying or charcoal

The use of forced diuresis, peritoneal dialysis, hemodialysis, charcoal hemoperfusion, or cholestyramine has not been reported. In the presence of normal renal function, most of a dose of nabilone is eliminated through the biliary system.

Treatment for respiratory depression and comatose state consists in symptomatic and supportive therapy. Particular attention should be paid to the occurrence of hypothermia. If the patient becomes hypotensive, consider fluids, inotropes, and/or vasopressors.


DOSAGE AND ADMINISTRATION

The usual adult dosage of *CESAMET (nabilone) is 1 mg or 2 mg twice a day. The first dose should be given the night before initiating administration of chemotherapeutic medication. The second dose is usually administered 1 to 3 hours before chemotherapy. If required, administration of "CESAMET can be continued up to 24 hours after the chemotherapeutic agent is given. The maximum recommended daily dose is 6 mg in divided doses.

"CESAMET® is available in a 0.5 mg strength for dose adjustment within the therapeutic range. Dose adjustment may be required for the purposes of response and tolerance in individual patients. Overdosage may occur even at prescribed dosages, if disturbing psychiatric symptoms are present. In these cases, the patient should be observed in a quiet environment and supportive measures, including reassurance, should be used. Subsequent doses should be withheld until patients have returned to their baseline mental status; routine dosing may then be resumed if clinically indicated. In such instances, a lower initiating dose is suggested. *CESAMET contains nabilone in a capsule dosage form and is intended only for oral administration

STRUCTURAL FORMULA AND CHEMISTRY

Molecular Formula: C₂₄H₃₆O₃ Molecular Weight: 372 U.S.A.N: Nabilone



Chemical Name:

(+)-trans-3-(1,1-dimethyl-heptyl)-6,6a,7,8,10,10a-hexahydro-1-hydroxy-6,6-dimethyl-9H-dibenzo(b,d),pyran-9-one.

Description: Composition

Each 1 mg NCESAMET® capsule contains 1 mg of nabilone, starch, povidone, gelatin, FD&C blue #2 (indigo carmine), red iron oxide and titanium dioxide. Each 0.5 mg "CESAMET® capsule contains: 0.5 mg of nabilone, starch, povidone, gelatin, titanium dioxyde, D&C red # 33, D&C yellow # 10, FD&C red # 40.

Stability and storage Recommendations

Store at controlled room temperature at 15-30°C.

AVAILABILITY

"CESAMET® 1 mg capsule: each capsule contains 1 mg of nabilone and are available in bottles of 20 capsules.

CESAMET® 0.5 mg capsule; each capsule contains 0.5 mg of nabilone and are available in bottles of 50 capsules.

NCESAMET legally is considered to be a narcotic and is subject to the controls which apply to those drugs.

Product Monograph available upon request



www.valeantcanada.com

Valeant Canada Limited PAAB 4787, Rue LEVY St, Montreal, Quebec H4R 2P9

White crystalline powder





PHARMACOLOGIC CLASSIFICATION Cholinesterase inhibitor INDICATIONS AND CLINICAL USE ARICEPT (donepezil hydrochloride) is indicated for the symptomatic treatment of patients with mild-to-moderate dementia of the Alzheimer's type. Efficacy of ARICEPT in patients with mild-to-moderate Alzheimer's disease was established in two 24-week and one 54-week placebo-controlled trials. ARICEPT tablets should only be prescribed by (or following consultation with) clinicians who are experienced in the diagnosis and management of Alzheimer's disease. CONTRAINDICATIONS ARICEPT (donepezil hydrochloride) is contraindicated in patients with known hypersensitivity to donepezil hydrochloride or to piperidine derivatives. WARNINGS AND PRECAUTIONS Cardiovascular: Because of their pharmacological action, cholinesterase inhibitors may have vanotonic effects on heart rate (e.g., bradycardia). The potential for this action may be particularly important to patients with "sick sinus syndrome" or other supraventricular cardiac conduction conditions. In clinical trials in Alzheimer's disease, most patients with serious cardiovascular conditions were excluded. Patients such as those with controlled hypertension (DBP<95 mmHg), right bundle branch blockage and pacemakers were included. Therefore, caution should be taken in treating patients with active coronary artery disease and congestive heart failure. Syncopal episodes have been reported in association with the use of ARICEPT. It is recommended that ARICEPT should not be used in nations with cardiac conduction abnormalities (except for right bundle branch block) including "sick sinus syndrome" and those with unexplained syncopal episodes. Gastrointestinal: Through their primary action, cholinesterase inhibitors may be expected to increase gastric acid secretion due to increased cholinergic activity. Therefore, patients at increased risk for developing ulcers. e.g., those with a history of ulcer disease or those receiving concurrent nonsteroidal anti-initianmatory drugs (NSAIDs), including high doses of acetylsalicylic acid (ASA), should be monitored for symptoms of active or occult gastrointestinal bleeding. Clinical studies of ARICEPT have shown no increase relative to placebo in the incidence of either peptic ulcer disease or gastrointestinal bleeding use ADVERSE REACTIONS section). ARICEPT, as a predictable consequence of its pharmacological properties, has been shown to produce, in controlled clinical trials in patients with Alzheimer's disease diarrhea, nausea and vomiting. These effects, when they occur, appear more frequently with the 10 mg dose than with the 5 mg dose. In most cases, these effects have usually been mild and transient, sometimes lasting 1 to 3 weeks, and have resolved during continued use of ARICEPT (see ADVERSE REACTIONS section). Treatment with the 5 mp/day dose for 4-6 weeks prior to increasing the dose to 10 mp/day is associated with a lower incidence of gastrointestinal intolerance. Genitourinary: Although not observed in clinical trials of ARICEPT, cholinomimetics may cause bladder outflow obstruction. Hepatic: There is limited information regarding the pharmacokinetics of ARICEPT in hepatically impaired Alzheimer's disease patients. Close monitoring for adverse effects in patients with hepatic disease being treated with ARICEPT is therefore recommended. Neurologie: Seizures: Some cases of seizures have been reported with the use of ARICEPT in clinical trials and from spontaneous Adverse Reaction reporting. Cholinomimetics can cause a reduction of seizure threshold, increasing the risk of seizures. However seizure activity may also be a manifestation of Alzheimer's disease. The risk/benefit of ARICEPT treatment for patients with a history of seizure disorder must therefore be carefully evaluated. ARICEPT has not been studied in patients with Parkinsonian features. The efficacy and safety of ARICEPT in these patients are unknown. Peri-Operative Considerations: Anesthesia: ARICEPT, as a cholinesterase inhibitor. is likely to exaggerate succinvloholine-type muscle relaxation during anesthesia. Renal: There is limited information regarding the pharmacokinetics of ARICEPT in renally impaired Alzheimer disease patients. Close monitoring for adverse effects in patients with renal-disease being treated with ARICEPT is therefore recommended. Respiratory: Because of their cholinomimetic action, cholinesterase inhibitors should be prescribed with care to patients with a history of asthma or obstructive pulmonary disease. ARICEPT has not been studied in patients under treatment for these conditions and should therefore be used with particular caution in such patients. Special Populations: Pregnant and Nursing Women: The safety of ARICEPT during pregnancy and lactation has not been established and therefore, it should not be used in women of childbearing potential or in nursing mothers unless, in the opinion of the physician, the potential benefits to the patient outweigh the possible hazards to the fetus or the infant. Teratology studies conducted in pregnant rats at doses of up to 16 mg/kg/day and in pregnant rabbits at doses of up to 10 mg/kg/day did not disclose any evidence for a teratogenic potential of ARICEPT. Pediatrics: There are no adequate and well-controlled trials to document the safety and efficacy of ARICEPT in any illness occurring in children. Therefore, ARICEPT is not recommended for use in children Geriatrics (>85 years of age): In controlled clinical studies with 5 and 10 mg of ARICEPT, 536 patients were between the ages of 65 to 84 and 37 patients were aged 85 years or older. In Alzheimer's disease patients, nausea, diarrhea, vomiting, insomnia, fatigue and anorexia increased with dose and age and the incidence appeared to be greater in female patients. Since cholinesterase inhibitors as well as Alzheimer's disease can be associated with significant weight loss, caution is advised regarding the use of ARICEPT in low body-weight elderly patients, especially in those 285 years old. Use in Elderly Patients with Comorbid Disease: There is limited safety information for ARICEPT in patients with mildto-moderate Alzheimer's disease and significant comorbidity. The use of ARICEPT in Alzheimer's disease patients with chronic illnesses common among the geriatric population should be considered only after careful risk/benefit assessment and include close monitoring for adverse events Caution is advised regarding the use of ARICEPT doses above 5 mg in this patient population. ADVERSE REACTIONS Adverse Drug Reaction Overview: Alzheimer's Disease: A total of 747 patients with mild-to-moderate Alzheimer's disease were treated in controlled clinical studies with ARICEPT (donepezil hydrochloride). Of these patients, 613 (82%) completed the studies. The mean duration of treatment for all ARICEPT groups was 132 days (range 1–356 days). Adverse Events Leading to Discontinuation: The rates of discontinuation from controlled clinical trais of ARICEPT due to adverse events for the ARICEPT 5 mg/day treatment groups were comparable to those of placebo-treatment groups at nately 5%. The rate of discontinuation of patients who received the 10 mg/day dose after only a 1-week initial treatment with 5 mg/day ARICEPT was higher at 13%. The most common adverse events leading to discontinuation, defined as those occurring in at least 2% of patients and at twice the incidence seen in placebo patients, are shown in Table 1

Table 1. Most Frequent Adverse Events Leading to Withdrawal From Controlled Clinical Trials by Dose Group

Dose Group	Placebo	5 mg/day ARICEPT	10 mg/day ARICEPT
Number of Patients Randomized	355	350	315
Events / % Discontinuing			
Nausea	1%	1%	3%
Diarrhea	0%	<1%	3%
Vomiting	<1%	<1%	2%

Most Frequent Adverse Clinical Events Seen in Association with the Use of ARICEPT. The most common adverse events, defined as those occurring at a frequency of al least 5% in patients receiving 10 mg/dsy and hvice the placeborate, are largely predicted by MRCEPT's coholinominetic effects. These include masses darrhats insomnia - wonting, muscle cranp, talgue and anoresi. These adverse events were often of mild intensity and transient, resolving during continued ARICEPT treatment without the need for dose modification. There is evidence to suggest that the frequency of these common adverse events may be affected by the duration of treatment with an initial 5 mg daily dose prior to increasing the dose to 10 mg/dsy. An open label study was conducted with 269 gatients who received placebo in the 15- and 30-week studies. These patients received a 5 mg/dsy dose for 6 weeks point to initialing treatment with 10 mg/dsy. The rates of common adverse events were lower than those seen in controlled clinical trial patients who received 10 mg/dsy after only a 1-week initial treatment period with a 5 mg daily dose, and were comparable to the rates noted in patients treated only with 5 mg/dsy. See Tale 2 for a comparison of the most common adverse events flowing: - and 6-week initial treatment periods with 5 mg/dsy. RefCEPT.

Table 2. Comparison of Rales of Adverse Events in Patients Treated with 10 mg/day after 1 and 5 Weeks of Initial Treatment with 5 mg/day

No Initial treatment		1-Week Initial Irea	tment with 5 mg/day	6-Week Initial treatment with 5 mg/da	
Adverse Event	Placebo (n=315)	5 mg/day (n=311)	10 mg/day (n=315)	10 mg/day (n=269)	
Nausea	6%	5%	19%	5%	
Diarrhea	5%	8%	15%	9%	
Insomnia	6%	6%	14%	6%	
Fatique	3%	4%	8%	3%	
Vomiting	3%	3%	8%	5%	
Muscle Cramps	2%	6%	8%	3%	
Anorexia	2%	3%	7%	3%	

Clinical Trial Adverse Drug Reactions: The events cited reflect experience gained under closely monitored conditions of clinical trials in a highly selected patient population. In actual clinical practice or in other clinical trials. These frequency estimates may not apply, as the conditions of use. reporting behaviour and the kinds of patients treated may differ. Table 3 lists treatment-emergent signs and symptoms (TESS) that were reported in at least 2% of patients from placebo-controlled clinical trials who received ABICEPT and for which the rate of occurrence was greater for ABICEPT than placebo-cassigned patients. In general, adverse events occurred more frequently in tenade patients and with advancing age

Body System / Adverse Events	Placebo (n=355)	ARICEPT (⊫747)	Body System / Adverse Events	Placebo (a=355)	ARICEPT (=747)
Percent of Patients			Netabolic and Nutritional		
with any Adverse Event	72	74	Weight Decrease	1	3
Body as a Whole			Musculoskeletal System		
Headache	9	10	Muscle Cramos	2	6
Pain, various locations	8	9	Arthritis	1	2
Accident	6	7	Nervous System		
Fatigue	3	5	Insomnia	6	9
Cardiovascular System			Dizziness	6	8
Syncope	1	2	Depression	đ	3
Digestive System			Abnormai Dreams	0	3
Nausea	6	11	Somnolence	4	2
Diarrhea	5	10	Urseenital		•
Vomiting	3	5	Frequent Urination	1	2
Anorexia	2	4			•
Hemic and Lymphatic Systems					
Ecchymosis	3	4			

Long-Term Safety: Patients were exposed to ARICEPT in 2 open-label extension studies (n=885) of over 2 years. In 1 of the studie 763 patients who previously completed 1 of 2 placebo-controlled studies of 15 or 30 weeks duration continued to receive ARICEPT and were evaluated for safety and neuropsychological evaluations for up to 152 weeks: the safety profile of ARICEPT in this extension study remained consistent with that observed in placebo-controlled trials. Following 1 and 2 years of treatment, 76% (n=580) and 49% (n=374) of these patients, respectively, were still receiving therapy (cumulative Weeks 48 and 108). Postmarket Adverse Drug Reactions: Voluntary reports of adverse events temporally associated with ARICEPT that have been received since market introduction, that are not listed above, and for which there is inadequate data to determine the causal relationship with the drug include the following; abdominal pain agitation, cholecystitis, confusion, convulsions, hallucinations, heart block (all types), hemolytic anemia, hepatitis, hyponatremia, pancreatitis and rash. Vascular dementia: The initial safety profile from controlled clinical trials in Vascular dementia patients indicates that the rate of occurrence of adverse events overall was higher in Vascular dementia patients (91%) than in Alzheimer's disease patients (75%), however this was seen in both ARICEPT-treated subjects, and placebo-treated subjects, and may relate to the greater number of comorbid medical conditions in the Vascular dementia population. A comparison of the Alzheimer's disease and Vascular dementia studies shows that the type of ARICEPT-associated adverse events was similar in the 2 patient populations. A total of 827 patients with Vascular dementia were treated in controlled clinical studies with ARICEPT. Of these patients, 639 (77%) completed the studies. The mean duration of treatment for all ARICEPT. groups was 152 days (range 1-428 days). In controlled clinical trials in Vascular dementia patients, the rates of discontinuation due to adverse events were 10.6 % for ARICEPT 5 mg and 19% for ARICEPT 10 mg compared to 9.9% for placebo. The most common adverse event leading to discontinuation, defined as those occurring in at least 2% of patients and at twice the incidence seen in placebo patients, was nausea. Other less common events leading to discontinuation include cerebrovascular accident, confusion, dizziness, diarrhea and vomiting. The most common serious adverse events were cerebrovascular accident (3 4%) and pneumonia (1.6%). The most common adverse events were intection (14.4%), diarrhea (13.9%), accidental injury (13.0%) and nausea (11.3%). Most adverse events were judged by the investigator to be mild to moderate in intensity and not related to study medication. DRUG INTERACTIONS Concomitant Use with Other Drugs: Use with Anticholinergics: Because of their mechanism of action, cholinesterase inhibitors have the potential to interfere with the activity of anticholinergic medications. Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinvicholine, similar neuromuscular blocking agents or cholinergic agonsts such as bethanechol. Use with Other Psychoactive Drugs: Few patients in controlled clinical trials received neuroleptics. antidepressants or anticonvulsants. There is thus limited information concerning the interaction of ARICEPT with these drugs. Drug-Drug Interactions Pharmacokinetic studies, limited to short-term, single-dose studies in young subjects evaluated the potential of ARICEPT for interaction with theophylline, cimetidine, warfarin and digoxin administration. No significant effects on the pharmacokinetics of these drugs were observed. Similar studies in elderly patients were not done. Drugs Highly Bound to Plasma Proteins: Drug displacement studies have been performed in vitro between donepezil, a highly bound drug (96%) and other drugs such as furosemide, digoxin, and warfarin. Donepezil at concentrations of 0.3 - 10 µg/mL did not affect the binding of furosemide (5 µg/mL). doponi, Ca gran, and watani Boyani. To huma albumin. Similari the binding of dopepezi to human blumin vas not affected doponi, Ca gran, land watani B grani. To huma albumin. Similari the binding of dopepezi to human blumin was not affected by furosemide, digoxin and watanin. Effect of ARICEPT on the Metabolism of Other Drags: In vitro studies show a low rate of donepezi binding to CYP 3A4 and CYP 2D6 isoenzymes (mean Ki about 50-130 µM), which, given the therapeutic plasma concentrations of donepezil (164 nM), indicates little likelihood of interferences. In a pharmacokinetic study involving 18 healthy volunteers, the administration of ARICEPT at a dose of 5 mg/day for 7 days had no clinically significant effect on the pharmacokinetics of ketoconazole. No other clinical trials have been conducted to investigate the effect of ARICEPT on the clearance of drugs metabolized by CYP 3A4 (eg. cisapride. terfenadine) or by CYP 2D6 (eg. imipramine). It is not known whether ARICEPT has any potential for enzyme induction. Effect of Other Drugs on the Metabolism of ARICEPT: Ketoconazole and quinidine, inhibitors of CYP450, 3A4 and 2D6 respectively, inhibit donegezil metabolism in vitro. In a pharmacokinetic study, 18 healthy volunteers received 5 mp/day ARICEPT together with 200 mg/day ketoconazole for 7 days. In these volunteers, mean donepezil plasma concentrations were increased by about 30%-36%. Inducers of CYP 2D6 and CYP 3A4 (eg. phenytoin, carbamazepine, dexamethasone, rifampin and phenobarbital) could increase the rate of elimination of ARICEPT. Pharmacokinetic studies demonstrated that the metabolism of ARICEPT is not significantly affected by concurrent administration of digoxin or cimetidine. Drug-Food Interactions: Food does not have an influence on the rate and extent of donepezil hydrochloride absorption. Drug-Herb Interactions: Interactions with herbal products have not been established Drug-Laboratory Interactions: Interactions with laboratory tests have not been established. DOSAGE AND ADMINISTRATION Dosing considerations: ARICEPT (donepezil hydrochloride) or ARICEPT RDT should only be prescribed by (or following consultation with) clinicians who are experienced in the diagnosis and management of Alzheimer's disease. Recommended Dose and Dosage Adjustment: Adults: The recommended initial dose of ARICEPT or ARICEPT RDT is 5 mg taken once daily. Therapy with the 5 mg dose should be maintained for 4-6 weeks before considering a dose increase, in order to avoid or decrease the incidence of the most common adverse reactions to the drug (see ADVERSE REACTIONS section) and to allow plasma levels to reach steady state. Based on clinical judgement, the 10 mg daily dose may be considered following 4–6 weeks of treatment at 5 mg/day. The maximum recommended dose is 10 mg taken once daily. Following initiation of therapy or any dosage increase, patients should be closely monitored for adverse effects. Special Populations: Adverse events are more common in individuals of low body weight, in patients ≥85 years old and in females. It is recommended that ARICEPT be used with caution in these patient populations. In elderly women of low body weight, the dose should not exceed 5 mg/day. In a population of cognitively-impaired individuals, safe use of this and all other medications may require supervision. ARICEPT should be taken once daily in the morning or evening. It may be taken with or without food. Administration: ARICEPT tablets should be swallowed whole with water. ARICEPT RDT should be placed on the tongue and allowed to disintegrate before swallowing with water. AVAILABILITY OF DOSAGE FORMS ARICEPT is supplied as film-coated tablets containing 5 mg (while tablets) or 10 mg (yellow tablets) of donepezil hydrochloride. The name ARICEPT and the strength are embossed on each tablet. ARICEPT is available in high-density polyethylene (HDPE) bottles of 30 tablets and in blister strips boxed as 28 tablets (combination of 2 strips of 14 tablets). ARICEPT RDT is supplied as uncoated rapidly disintegrating tablets containing 5 mg (white tablets) or 10 mg (yellow tablets) of donepezil hydrochloride. The name ARICEPT and the strength are embossed on each tablet. ARICEPT RDT is available in blister strips boxed as 28 tablets. STORAGE AND STABLITY: ARICEPT ROT should not be removed from blisters until immediately prior to administration

Product Monograph available upon request.

References

1. Seltzer B et al. Efficacy of donepezil in early-stage Alzheimer disease. Arch Neurol 2004;61:1852-1856

2. Rogers SL et al. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology 1998:50:136-145.



® Eisai Go. Ltd., owner / Pfizer Canada Inc., Licensee © 2007 Pfizer Canada Inc., Kirkland, Quebec H9J 2M5





riptan tablets (as rizatriptan benzoate) 5 mg and 10 mg



rizatriptan wafers (as rizatriptan benzoate)

5 mg and 10 mg

Migraine Therapy 5-HT, Receptor Agonist ACTIONS AND CLINICAL PHARMACOLOGY

Mechanism of Action

MAXLT[®] (right plant) are a selective 5-hydroxytryptamine_{1B1D} (5-HT_{1B1D}) receptor agonist. Rizatriptan binds with high affinity to human cloned 5-HT_{1B1D} receptors. It has weak affinity for other 5-HT, receptor subtypes (5-HT_{1A} 5-HT_{1F}, 5-HT_{1F}) and the 5-HT₇ receptor, but has no significant activity at 5-HT₂, 5-HT₁, alpha- and beta-adrenergic, dopaminergic, histaminergic, muscarinic or benzodiazepine receptors.

oppanningrig:, instaminergic, muscannic or benzoliazepine receptors. Current theories on the etiology of migraine headaches suggest that symptoms are due to local cranial vasodilatation and/or to the release of vasoactive and pro-inflammatory peptides from sensory nerve endings in an activated trigominal system. The therapeutic activity of reatripidan in migraine can most likely be attributed to agonist effects at 5-HT₁₀₁₀ receptors on the extraceretral, intracranial blood vessels that become direated during a migraine attack and on nerve terminals in the trigominal system. Activation of these recentors results in cranial usesal constrictions. Joibilition of these receptors results in cranial vessel constriction, inhibition of neuropeptide release and reduced transmission in trigeminal pain pathways.

Pharmacokinetics Absorption

Absorption Rizatriptan is completely absorbed following oral administration. The mean oral absolute bioavailability of the MAXALT* Tablet is about 45%, and mean peak plasma concentrations (C_{max}) are reached in approximately 1-1.5 hours (T_{max}). The presence of a migraine headache did not appear to affect the absorption or pharmacokinetics of rizatriptan. Food has no significant effect on the bioavailability of rizatriptan but delays the time to reach peak concentration by an hour. In clinical trials, MAXLT* was administered without regard to food. The plasma half-life of rizatriptan in males and females averages 2-3 hours.

When MAXALT® 10 mg was administered every 2 hours for three doses on four consecutive days, the plasma concentrations of rizatriptan within each day were approximately 3-fold greater than those seen with a single 10 mg dose and no plasma accumulation of the drug occurred from day to day. cose and no plasma accumulation of the drug occurred from day to day. The bioavailability and C_{max} of rizatriptan were similar following administration of MAXALT[®] tablets and MAXALT RPD[®] Wafers, but the rate of absorption is somewhat slower with MAXALT RPD[®] Wafers, with T_{max} averaging 1.6.2.5 hours. AUC of rizatriptan is approximately 30% higher in females than in males.

Distribution

The mean volume of distribution is approximately 140 liters in male subjects and 110 liters in female subjects. Rizatriptan is minimally bound (14%) to plasma proteins.

Metabolism

Metabolism The primary route of rizatriptan metabolism is via oxidative deamination by monoamine oxidase-A (MAO-A) to the indole acetic acid metabolite, which is not active at the 5-HT_{RPD} receptor. N-monodesmethyl-rizatriptan, a metabolite with activity similar to that of parent compound at the 5-HT_{RPD} receptor. Is formed to a minor degree. Plasma concentrations of N-monodesmethyl-rizatriptan are approximately 14% of those of parent compound, and it is eliminated at a similar rate. Other minor metabolites, the N-oxide, the 6-hydroxy compound, and the sulfate conjugate of the 6-hydroxy metabolite are not active at the 5-HT_{Therp} receptor.

Rizatripan is not an inhibitor of the activities of human liver cytochrome P450 isoforms 3A4/5, 1A2, 2C9, 2C19, or 2E1; rizatriptan is a competitive inhibitor (Ki=1400 nM) of cytochrome P450 2D6, but only at high, clinically irrelevant concentrations.

Excretion

The total radioactivity of the administered dose recovered over 120 hours in urine and feces was 82% and 12%, respectively, following a single 10 mg oral administration of "C-rizatriptan. Following oral administration of "C-rizatriptan, rizatriptan accounted for about 17% of circulating plasma radioactivity. Approximately 14% of an oral dose is excreted in urine as unchanged rizatriptan while 51% is excreted as indole acetic acid mathbility. metabolite, indicating substantial first pass metabolism.

MAXALT® is not recommended for use in patients under 18 years of age (see PRECAUTIONS, Pediatric Use). In a single study in adolescents (n=291), there were no significant differences with respect to headache relief at 2 hours between MAXALT* and placebo treated groups.

Gender

The mean AUC₀,..., and C_{max} of rizatriptan (10 mg orally) were about 30% and 11% higher in females as compared to males, respectively, while T_{max} occurred at approximately the same time.

Hepatic Impairment

Hepatic Inpairment Following oral administration in patients with hepatic impairment caused by mild to moderate alcoholic cirrhosis of the liver, plasma concentrations of rizatriptan were similar in patients with mild hepatic insufficiency compared to a control group of healthy subjects; plasma concentrations of rizatriptan were approximately 30% greater in patients with moderate hepatic insufficiency (see PRECAUTIONS). Since there are no data in patients with severe hepatic impairment (Child-Pugh grade C, nizatriptan is contraindicated in this population (see CONTRAINDICATIONS).

Renal Impairment

In patients with renal impairment (creatinine clearance 10-60 mL/min/1.73 m2), In pacents whit reason inplanment (becamine obstance in-control information) in the AUC, and inclusion of significantly different from that in healthy subjects. In hemodialysis patients (creatinine clearance < 2 ml/min/1.73 m²), however, the AUC for rizzbriptan was approximately 44% greater than that in patients with normal renal function (see PRECAUTIONS).

Race

Pharmacokinetic data revealed no significant differences between African American and Caucasian subjects. The effect of race on the pharmacokinetics of rizatriptan has not been systematically evaluated.

Clinical Studies MAXALT® Tablets

The efficacy of MAXALT® Tablets was established in four multicenter, randomized, placebo-controlled trials. Patients enrolled in these studies were primarily female (84%) and Caucasian (88%), with a mean age of 40 years (range of 18 to 71). Patients were instructed to treat a moderate to severe headache. Headache response (defined as a reduction of moderate sever headache. Headache response (defined as a reduction or moderate or severe headache pain ton or mild headache pain), was assessed (or up to 2 hours (Study 1) or up to 4 hours after dosing (Studies 2, 3 and 4). Associated symptoms of nausea, photophobia, and phonophobia and maintenance of response up to 24 hours postdose were evaluated. A second dose of MXAL T^a Tablets was allowed 2 to 24 hours after dosing for treatment of recurrent headache in Studies 1 and 2. Additional analoesics and/or antiemetics were allowed 2 hours after initial treatment for rescue in all four studies.

In all studies, the percentage of patients achieving headache response If an studies, the percentage of hypathics achieving fleatable response 2 hours after treatment was significantly greater in patients who received either MXXLT® 5 or 10 mg compared to those who received placebo. In a separate study, doese of 2.5 mg were not different from placebo. Doese greater than 10 mg were associated with an increased incidence of adverse effects. The results from the 4 controlled studies using the marketed formulation are summarized in Table II.

Table II Response Rates¹ 2 Hours Follow Treatment of Initial Headache

Study Placebo		dy Placebo MAXALT® Tablets 5 mg	
1	35% (n=304)	62%* (n=458)	71%**** (n=456)
21	37% (n=82)		77%* (n=320)
3	23% (n=80)	63%* (n=352)	÷ .
4	40% (n=159)	60%* (n=164)	67%* (n=385)

¹ Pain response is defined as a reduction in headache severity

from grade 3 or 2 (severe or moderate pain) to grade 1 or 0

(mild or no pain) • p value < 0.05 in comparison with placebo

p value < 0.05 in comparison with 5 mg

* Results for initial headache only

Comparisons of drug performance based upon results obtained in different clinical trials are never reliable. Because studies in different clinical trials are never reliable. Because studies are conducted at different times, with different samples of patients, by different investigators, employing different criteria and/or different interpretations of the same criteria, under different conditions (dose, dosing regimen, etc.), quantitative estimates of treatment response and the timing of response may be expected to vary considerably from study to study.

For patients with migraine-associated photophobia, phonophobia, and nausea at baseline, there was a decreased incidence of these symptoms following administration of MAXALT® compared to placebo.

		Table 1		
P	harmacokinetic Para	meters of a Single Dose	of Rizatriptan in Fe	males (n = 12)
		Arithmetic Mean (± SD)	
	MAXALT [®]	MAXALT RPD*	MAXALT [®]	MAXALT RPD [®]

	5 mg Tablet	5 mg Wafer	10 mg Tablet	10 mg Wafer	
AUC(0) (ng+hr/mL)*	34.5 ± 13.0	33.2 ± 9.8	73.9 ± 23.4	75.9 ± 24.7	
Cmax (ng/mL) ^a	10.4 ± 3.9	11.1 ± 4.7	21.3 ± 6.9	20.3 ± 7.9	
T _{max} (hr)	1.0 ± 0.6	$1.6 \pm 0.8^{\circ}$	1.5 ± 0.8	2.5 ± 1.4*	
t1/2 (hr) ^b	1.7	1.6	1.7	1.7	
Plasma Clearance (mL/min) ^c	1050.5 ± 224.5	1121.2 ± 241.6	1081.6 ± 239.4	1099.3 ± 251.7	

Potency-normalized

Fuse userance of 1-mg stable, heavy-labeled I.V. dose of rizatriptan given concomitantly with oral dose
 * p < 0.05 compared to tablet formulation

Special Populations

Elderiv

Rizatriptan pharmacokinetics in healthy elderly non-migraineur volunteers (age 65-77 years) were similar to those in younger non-migraineur volunteers (age 18-45 years).

Adolescents (12-18 years)

The mean AUC0_{0,...} and $C_{\rm max}$ of rizatriptan (10 mg orally) were about 12% and 19% higher in adolescents (n=12) as compared to historical data in adults, respectively

Registered Trademark of Merck & Co., Inc. Used under license.

Efficacy was unaffected by the presence of aura; by the gender, or age of the patient: to by concomitant use of common migratine prophylactic drugs (e.g., beta-blockers, calcium channel blockers, tricyclic antidepressants) or oral contraceptives. There were insufficient data to assess the impact of race on efficacy.

The long-term efficacy of MAXALT* 5 mg and 10 mg was investigated in a total of 1854 patients in optional extension phases of three Phase III studies. The extension phases were single blind (except in one study where only 10 mg MAXALT* was used) and patients were randomized to either 5 mg or 10 mg MAXALT* or standard care. Approximately 16,150 attacks

were treated with MAXALT[®] 5 mg and approximately 24,043 with MAXALT[®] 10 mg over a period of up to 12 months (median number of attacks treated per patient was approximately 17). Headache response was sustained (as judged by the proportion of attacks treated with MAXLT[®] per patient resulting in headache relief).

MAXALT RPD® Wafers

The efficacy of MAXALT RPD® in the acute treatment of migraine attacks The encody of MAXALT RPD* in the active treatment of inigratine attacks was established in two multicenter, randomized, placebo-controlled trials that were similar in design to the trials of MAXALT* Tablets. In one study (n=311), by 2 hours postdosing, headache response rates in patients treated with MAXALT RPD* were approximately 66% for rizatripan 5 mg and 10 mg, compared to 47% in the placebo group. In a larger study (n=547), by 2 hours postdosing, headache response rates were 59% in patients treated with MAXALT RPD* 5 mg, and 74% after 10 mg, compared patients treated with MAAL 1HrD-5 mg, and 74% after 10 mg, compared to 28% in the placebe group. Headacher response was statistically significant as early as 30 minutes following dosing with the 10 mg wafer. The 10 mg dose was superior to 5 mg at 2 hours. MAXALT RPD* also relieved the functional disability, nausea, placebable, and phonophobia which accompanied the migraine episodes.

INDICATIONS AND CLINICAL USE

MAXALT® (rizatriptan benzoate) is indicated for the acute treatment of migraine attacks with or without aura in adults.

MAXALT® is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic, ophthalmoplegic or basilar migraine (see CONTRAINDICATIONS). Safety and effectiveness of MAXALT® have not been established for cluster headache, which is present in an older, predominantly male population.

CONTRAINDICATIONS

MAXALT® (rizatriptan benzoate) is contraindicated in patients with history, symptoms, or signs of ischemic cardiac, cerebro-vascular or peripheral vascular syndromes, valvular heart disease or cardiac arrhythmias (especially tachycardias). In addition, patients with other significant underlying addition, patients with other significant underlying cardiovascular diseases (e.g., atherosclerotic disease, congenital heart disease) should not receive MAXALTS-ischemic cardiac syndromes include, but are not restricted to, angina pectoris of any type (e.g., stable angina of effort and vasospastic forms of angina such as the Prinzmetal's variant), all forms of myocardial Infarction, and silent myocardial ischemia. Cerebrovascular syndromes include, but are not limited to, strokes of any type as well as transient ischemic attacks (TIAS). Peripheral vascular disease includes, but s not limited to, lschemic bowel disease, or Raynaud's syndrome (see WARNINGS). (see WARNINGS)

Because MAXALT® may increase blood pressure, it is contraindicated in patients with uncontrolled or severe hypertension (see WARNINGS).

MAXALT® is contraindicated within 24 hours of treatment with another 5-HT₁ agonist, or an ergotamine-containing or ergot-type medication like dihydroergotamine or methysergide. MAXALT[®] is contraindicated in patients with hemiplegic, ophthalmoplegic or basilar migraine.

Concurrent administration of MAO inhibitors or use of rizatriptan within 2 weeks of discontinuation of MAO inhibitor therapy is contraindicated (see PRECAUTIONS, Drug Interactions).

Because there are no data available, MAXALT* is contraindicated in patients with severe hepatic impairment.

MAXALT® is contraindicated in patients who are hypersensitive to rizatriptan or any component of the formulation.

WARNINGS

MAXALT® (rizatriptan benzoate) should only be used where a clear diagnosis of migraine has been established.

Risk of Myocardial Ischemia and/or Infarction and Other Adverse Cardiac Events

MAXALT's has been associated with transient chest and/or neck pain and tightness which may resemble angina pectoris. Following the use of other 5-HT, agonists, in rare cases these symptoms have been identified as being the likely result of coronary vasospasm or myocardial ischemia. Rare cases of serious coronary evants or arrhythmia have occurred follow use of other 5-HT, agonists, and may therefore also occur v MAXALT[®]. Because of the potential of this class of compou o occur with use of other 5-HT, agonists, and may therefore also occur with MXALT.⁵ Because of the potential of this class of compounds (5-HT_{RPD} agonists) to cause coronary vasopasm, MAALT⁵ should not be given to patients with documented ischemic or vasopastic coronary artary disease (see CONTRAINDICATIONS). It is strongly recommended that MAXALT⁸ not be given to patients in whom unrecognized coronary artary disease (AAD) is predicted by the presence of risk factors (e.g., hypertension, hypercholesterolemia, smoker, obesity, diabetes, strong family history of CAD, female with surgical or physiological menopause, or male over 40 years of age) unless a cardiovascular evaluation provides satisfactory clinical evidence that the patient is reasonably free of coronary artery and ischemic myocardial disease or other significant underlying cardiovascular evaluation, the patient's medical history, electrocardiographic or other investigations reveal findings indicative of, or consistent with, coronary artery vasospasm or myocardial ischemia, MAXALT⁸ should not be administered (see CONTRAINDICATIONS).

administered (see CONTRAINDICATIONS). For patients with risk factors predictive of CAD, who are considered to have a satisfactory cardiovascular evaluation, the first dose of rizatriptan should be administered in the setting of a physician's office or similar medically staffed and equipped facility. Because cardiac ischemia can occur in the absence of clinical symptoms, consideration should be given to obtaining on the first occasion of use an electrocardiogram (ECG) during the interval immediately following MAXALT?, in these patients with risk factors. However, an absence of drug-induced cardiovascular effects on the occasion of the initial dose dose not preclude the possibility of such effects occurring with subsequent administrations.

Intermittent long-term users of MAXALT* who have or acquire risk factors predictive of CAD, as described above, should receive periodic interval cardiovascular evaluation as they to use MAXALT

If symptoms consistent with angina occur after the use of MAXALT³, ECG evaluation should be carried out to look for ischemic changes.

The systematic approach described above is intended to reduce the likelihood that patients with unrecognized cardiovascular disease will be indivertently exposed to MAXALT^{e.}

Cardiac Events and Fatalities Associated with 5-HT, Agonists

Variate trents and retaines Associated with 5-h1, Agonists MAXALT³ may cause coronary artery vasospasm. Serious adverse cardiac events, including acute myocardial infarction, life-threatening disturbances of cardiac rhythm, and death have been reported within a few hours following the administration of 5-HT, agonists. Considering the extent of use of 5-H1, agonists in patients with migraine, the incidence of these events is extremely low.

Premarketing Experience with MAXALT®

Among the approximately 4200 patients who were treated with at least a single oral dose of either 5 or 10 mg rizatriptan in premarketing clinical trials of MAXALT*, electrocardiac adverse experiences were observed in 33 natients. One natient was reported to have chest pain with possible ischemic ECG changes following a single dose of 10 mg

Cerebrovascular Events and Fatalities Associated with 5-HT1

Cerebral hemorrhage, subarachnoid hemorrhage, stroke, and othe cerebrovascular events have been reported in patients treated with 5-HT agonists; and some have resulted in fatalities. In a number of cases, it appears possible that the cerebrovascular events were primary, the agonist having been administered in the incorrect belief that the symptoms experienced were a consequence of migraine, when they were not. It should be noted that patients with migraine may be at increased risk of certain cerebrovascular events (e.g., stroke, hemorrhage, transient ischemic attack). Special Cardiovascular Pharmacology Studies with Another

5-HT, Agonist

In subjects (n=10) with suspected coronary artery disease undergoing angiography, a 5-HT, agonist at a subcutaneous dose of 1.5 mg produced an 8% increase in aortic blood pressure, an 18% increase in pulmonary artery blood pressure, and an 8% increase in systemic vascular resistance. In addition, mild chest pain or tightness was reported by four subjects. Clinically significant increases in blood pressure were experienced by binnee of the subjects (two of whom also had chest pain/discomfort). Diagnostic angiogram results revealed that 9 subjects had normal coronary arteries and one had insignificant coronary artery disease

in an additional study with this seme drug, migraine patients (n=35) free of cardiovascular disease were subjected to assessments of myocardial perfusion by positron emission tomography while receiving a subcutaneous 1.5 mg dose in the absence of a migraine attack. Reduced coronary vasodilatory reserve (~10%), increased coronary resistance (~20%), and decreased hyperemic myocardial blood flow (~10%) were noted. The relevance of these findings to the use of the recommended oral dose of this 5-HT₁ agonist is not known.

Similar studies have not been done with MAXALT*. However, owing to the common pharmacodynamic actions of 5-HT, agonists, the possibility of cardiovascular effects of the nature described above should be considered for any agent of this pharmacological class

Hypersensitivity

Rare hypersensitivity (anaphylaxis/anaphylactoid) reactions may occur in patients receiving 5-HT, agonists such as MAXALT® Such reactions can be life threatening or fatal. In general, hypersensitivity reactions to drugs are more likely to occur in individuals with a history of sensitivity to multiple allergens. Owing to the possibility of cross-reactive hypersensitivity reactions, MAXALT® should not be used in patients having a history of hypersensitivity to chemically-related 5-HT₁ receptor agonists.

Other Vasospasm-Related Events

5-HT₁ agonists may cause vasospastic reactions other than coronary artery vasospasm. Extensive post-market experience has shown the use of another 5-HT, aconist to be associated with rare occurrences of peripheral vascular ischemia and colonic ischemia with abdominal pain and bloody diarrhea

Increase in Blood Pressure

Increase in Biood Pressure Significant elevation in blood pressure, including hypertensive crisis, has been reported on rare occasions in patients receiving 5-HT, agonists with and without a history of hypertension. In healthy young male and female subjects who received maximal doese of MAXALT® (10 mg every 2 hours for 3 doese), slight increases in blood pressure (approximately 2-3 mmHg) were observed. Rizatriptan is contraindicated in patients with uncontrolled or severe hypertension (see CONTRAINDICATIONS).

PRECAUTIONS

General

MAXALT* (rizatriptan benzoate) should be administered with caution to patients with diseases that may alter the absorption, metabolism, or excretion of drugs (see ACTIONS AND CLINICAL PHARMACOLOGY, Special Populations)

For a given attack, if a patient has no response to the first dose of rizatriptan, the diagnosis of migraine should be reconsidered before administration of a second dose.

Cardiovascular

Discomfort in the chest, neck, throat and jaw (including pain, pressure heaviness and tightness) has been reported after administration of rizatriptan. Because drugs in this class may cause coronary artery vasospasm, patients who experience signs or symptoms suggestive of angina following dosing should be evaluated for the presence of CAD or a predisposition to Prinzmetal's variant angina before receiving additional doses of medication, and should be monitored electrocardiographically if dosing is resumed and similar symptoms recur. Similarly, patients who using is resumed and similar symptoms recuir similarly, patients who experience other symptoms or signs suggestive of decreased arterial flow, such as ischemic bowel syndrome or Raynaud's syndrome following MAXALT® administration should be evaluated for atteresclerosis or predisposition to vasospasm (see CONTRAINDICATIONS and WARNINGS). **Neurologic Conditions**

Care should be taken to exclude other potentially serious neurologic with migraine or who experience a headache in patients not previously diagnosed with migraine or who experience a headache that is atypical for them. There have been rare reports where patients received 5-HT agonists for severe headache that were subsequently shown to have been secondary to an evolving neurological lesion. For newly diagnosed patients or patients presenting with atypical symptoms, the diagnosis of migraine should be reconsidered if no response is seen after the first dose of MAXALT®.

Seizures

Caution should be observed if MAXALT[®] is to be used in patients with a history of epilepsy or structural brain lesions which lower the convulsion threshold. **Psychomotor Effect**

Dizziness, somnolence and asthenia/fatigue were experienced by some patients in clinical trials with MAXALT* (see ADVERSE EVENTS). Patients

should be advised to avoid driving a car or operating hazardous machinery until they are reasonably certain that MAXALT $^{\infty}$ does not adversely affect them

Renaliv Impaired Patients

Rizatriptan should be used with caution in dialysis patients due to a decrease in the clearance of rizatriptan, resulting in approximately 44% increase in plasma concentrations (see ACTIONS AND CLINICAL PHARMACOLOGY, Special Populations, and DOSAGE AND ADMINISTRATION)

Hepatically Impaired Patients

Rizatriptan should be used with caution in patients with moderate hepatic insufficiency due to an increase in plasma concentrations of approximately 30% (see ACTIONS AND CLINICAL PHARMACOLOGY, Special Populations, and DOSAGE AND ADMINISTRATION. Since there are no data in patients with severe hepatic impairment, rizatriptan is contra-indicated in this population (see CONTRAINDICATIONS and DOSAGE AND ADMINISTRATION

Binding to Melanin-Containing Tissues

The propensity for rizatriptan to bind melanin has not been investigated. Based on its chemical properties, rizatriptan may bind to melanin and accumulate in melanin-rich tissue (e.g., eye) over time. This raises the possibility that rizatriptan could cause toxicity in these tissues after extended use. There were, however, no adverse ophthalmologic changes extended use: There were, however, in adverse opinitalinoogic charges related to treatment with rizatriptian in the one-year dog toxicity study. Atthough no systematic monitoring of ophthalmologic function was undertaken in clinical triats, and no specific recommendations for ophthalmologic monitoring are offered, prescribers should be aware of the possibility of long-term ophthalmologic effects.

Phenviketonurics

Phenylketonuric patients should be informed that MAXALT RPD* Wafers contain phenylalanine (a component of aspartame). Each 5 mg wafer contains 1.05 mg phenylalanine, and each 10 mg wafer contains 2.10 mo phenvlalanine

Laboratory Tests

No specific laboratory tests are recommended for monitoring patients prior to and/or after treatment with MAXALT^{*}.

Drug Interactions

Progranoloi

MAXALT® should be used with caution in patients receiving propranolol, since the pharmacokinetic behavior of rizatriptan during co-administration since the pharmacokinetic behavior of rizztriptan during co-administration with propranolol may be unpredictable. In a study of concurrent administration of propranolol 240 mg/day and a single dose of rizztriptan 10 mg in healthy subjects (n=11), mean plasma AUC and C_{max} for rizztriptan were increased by 70% and 75%, respectively, during propranolol administration. In one subject, a 4-lold increase in AUC and 5-fold increase in C_{max} was observed. This subject was not distinguishable from the others based on demographic characteristics. The AUC of the active N-monodesmethyl metabolite of rizztriptan was not affected by progranolol (see DOSAGE AND ADMINISTRATION).

Ergot-Containing Drugs

Ergot-containing drugs have been reported to cause prolonged vasospastic reactions. Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and rizatripatan within 24 hours is contraindicated (see CONTRAINDICATIONS).

Other 5-HT, Agonists

The administration of rizatriptan with other 5-HT, agonists has not been evaluated in migraine patients. Because their vasospastic effects may be additive, co-administration of rizatriptan and other 5-HT, agonists within 24 hours of each other is contraindicated (see CONTRAINDICATIONS).

Selective Serotonin Reuptake Inhibitors (SSRIs)

SSRIs (e.g., fluxetine, fluxoxamine, parovetine, sertraine) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when co-administered with 5-HT, agonists. If concomitant treatment with rizatritotan and an SSRI is cinically warranted, appropriate observation of the patient for acute and long-term adverse events is advised. No clinical or pharmacokinetic interactions were observed when MAXALT® 10 mg was administered with paroxetine.

Monoamine Oxidase Inhibito

Monoamine Oxidase Inhibitors Rizatriptan is principally metabolized via monoamine oxidase, 'A' subtype (MAO-A). In a drug interaction study, when MAXALT* 10 mg was administered to subjects (n=12) receiving concomitant therapy with the selective, reversible MAO-A inhibitor, moclobemide 150 mg Li.d., there were mean increases in rizatriptan AUC and C_{max} of 119% and 41%, respectively; and the AUC of the active N-monodesmethyl metabolite of rizatriptan was increased more than 400%. The interaction would be expected to be greater with irreversible MAO-B inhibitors. Drug interaction studies were not conducted with selective MAO-B inhibitors. The specificity of MAO-B inhibitors diminishes with higher doses and varies among patients. Therefore, co-administration of rizatriptan in patients taking MAO-A or MAO-B inhibitors is corritaridicated (see CONTBANDICATIONS). A or MAO-B inhibitors is contraindicated (see CONTRAINDICATIONS

Nadoloi/Metooroioi

In a drug interactions study, effects of multiple doses of nadolol 80 mg or metoprolol 100 mg every 12 hours on the pharmacokinetics of a single dose of 10 mg rizatriptan were evaluated in healthy subjects (n=12). No pharmacokinetic interactions were observed.

Oral Contraceptives

In a study of concurrent administration of an oral contraceptive during 6 days of administration of MAXALT® (10-30 mg/day) in healthy female volunteers (n=18), rizatriptan did not affect plasma concentrations of ethinyl estradiol or norethindrone

Drug/Laboratory Test Interactions

MAXALT* is not known to interfere with commonly employed clinical laboratory tests

Impairment of Fertility

In a fertility study in rats, altered estrus cyclicity and delays in time to a continue source in ratio, anered estruis cyclicity and delays in time to mating were observed in females treated orally with an equivalent of 337 times the maximum recommended daily dose (MRDD) of 20 mg in humans. The no-effect dose was 22 times the MRDD. There was no impairment of fertility or reproductive performance in male rats treated with up to 825 times the MRDD.

Use in Pregnancy

In a reproduction study in rats, birth weights and pre- and post-weaning In a reproduction study in rats, birth weights and pre- and post-wearing weight gain were reduced in the offspring of females treated prior to and during mating and throughout gestation and lactation. These effects occurred in the absence of any apparent maternal toxicity (maternal plasma drug exposures were 22 and 337 times, respectively, the exposure in humans receiving the maximum recommended daily dose (MRDD) of 20 mg). The developmental no-effect dose was equivalent to 2.25 times human exposure at the MRDD. In empryofetal development studies ino teratogenic effects were observed when pregnant rats and rabbits were administered does at the equivalent of 337 times and 168 times, respectively, the human MRDD, during organogenesis. However, fetal weights were decreased in conjunction with decreased maternal weight gain at these same doses. The developmental no-effect dose in both rats and rabbits was 22 times the human MRDD. Toxicokinetic studies demonstrated placental transfer of drug in both species.

There are no adequate and well-controlled studies in pregnant women: therefore, rizatriptan should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Use in Nursing Mothers

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when MAXALT[®] is administered to women who are breast-feeding. Rizatriptan is extensively excreted in rat milk, at a level of 5-fold or greater than maternal nlasma levels

Pediatric Use

MAXALT® is not recommended for use in patients under 18 years of age. In a randomized placebo-controlled trial of 291 adolescent for third international aged 12-17 years, the efficacy of MAXAL[®] Tablets (5 mg) was not different from that of placebo (see ACTIONS AND CLINICAL PHARMACOLOGY, Special Populations).

Use in the Elderly

The safety and effectiveness of MAXALT® has not been adequately studied in individuals over 65 years of age. The risk of adverse reactions to this drug may be greater in elderly patients, as they are more likely to have decreased hepatic function, be at higher risk for CAD, and experience blood pressure increases that may be more pronounced. Clinical studies with MAXALT® did not include a substantial number of natients over 65 years of age (n=17). Its use in this age group is, therefore, not recommended

ADVERSE REACTIONS

Serious cardiac events, including some that have been fatal, have occurred following use of $5-HT_1$ agonists. These events are extremely rare and most have been reported in patients with risk factors predictive of CAD. Events reported have included coronary artery vasospasm, transient myocardial ischemia, myocardial infarction, ventricular tachycardia, and ventricular fibriliation (see Contraindications, Warnings, and Perchanal Precautions).

Experience in Controlled Clinical Trials with MAXALT® (rizatrintan

Typical 5-HT₁ Agonist Adverse Reactions

As with other 5-HT1 agonists, MAXALT® has been associated with sensations of heaviness, pressure, tightness or pain which may be intense. These may occur in any part of the body including the chest, throat, neck, jaw and upper limb.

Acute Safety

Adverse experiences to rizatriptan were assessed in controlled clinical trials that included over 3700 patients who received single or multiple doses of MAXALT* Tablets. The most common adverse events during treatment with MAXALT* rabiets. These events appeared to be dose-related. In long-term extension studies where patients were allowed to treat multiple attacks for up to 1 year. 4% (59 out of 1525 patients) withdrew because of adverse experiences.

Multitive because or adverse events regardless of drug relationship (incidence ≥ 1% and greater than placebo) after a single dose of MAXALT* Tablets and MAXALT RPD* Wafers, respectively. Most of the adverse events appear to be dose-related. The events cider affect experience gained under closely monitored conditions of clinical trials in a highly selected patient population. In actual clinical practice or in other clinical trials, these frequency estimates may not apply, as the conditions of use, reporting behavior, and the kinds of patients treated may differ.

Table III

Incidence (≥ 1% and Greater than Placebo) of Adverse Experiences After a Single Dose of MAXALT* Tablets or Placebo (Prior to Subsequent Dose) in Phase III Controlled Clinical Trials'

	%(of Patients	
	Placebo	MAXALT* 5 mg	MAXALT [®] 10 mg
Number of Patients	627	977	1167
Symptoms of Potentially Cardiac Origin			
Chest Sensations*	1.0	1.6	3.1
Neck/Throat/Jaw Sensations*	0.6	1.4	2.5
Upper Limb Sensations*	1.3	1.7	1.8
Palpitations	0.2	0.9	1.0
Body as a Whole			
Asthenia/Fatigue	2.1	4.2	6.9
Abdominal Pain	1.0	1.7	2.2
Digestive System			
Dry Mouth	1.3	2.6	3.0
Nausea	3.5	4.1	5.7
Vomiting	2.1	1.6	2.3
Nervous System			
Dizziness	4.5	4.2	8.9
Headache	0.8	1.8	2.1
Insomnia	0.3	1.0	0.3
Paresthesia	1.0	1.5	2.9
Somnolence	3.5	4.2	8.4
Tremor	1.0	1.3	0.3
Skin and Skin Appendage			
Flushing	1.0	0.6	1.1

1.0 0.6 * The term "sensations" encompasses adverse events described as as pain, discomfort, pressure, heaviness, constriction, tightness

heat/burning sensation, paresthesia, numbness, tingling, weakness and strange sensations.

Data from Studies 022, 025, 029 and 030

Table IV

Incidence (≥ 1% and Greater than Placebo) of Adverse Experiences After a Single Dose of MAXALT RPD* Wafers or Placebo (Prior to Subsequent Dose) in Phase III Controlled Clinical Trials'

	% of Patients			
	Placebo	MAXALT RPD* 5 mg	MAXALT RPD® 10 mg	
Number of Patients	283	282	302	
Symptoms of Potentially Cardiac Origin				
Chest Sensations*	0.4	1.4	1.7	
Neck/Throat/Jaw Sensations*	0.4	1.4	2.0	
Upper Limb Sensations*	0.4	0.7	2.0	
Palpitations	0.4	0.4	1.0	
Tachycardia	1.1	1.4	0.3	
Body as a whole				
Asthenia/Fatigue	0.4	2.1	3.6	
Digestive System				
Dry Mouth	2.1	6.4	6.0	
Nausea	5.7	6.4	7.0	
Dyspepsia	0.7	1.1	2.0	
Acid Regurgitation	0	1.1	0.7	
Salivation Increase	0	0	1.3	
Musculoskeletal System	1			
Regional Heaviness	D	0	1.0	
Nervous System				
Dizziness	3.9	6.4	8.6	
Headache	0.7	1.8	2.0	
Insomnia	0	1.4	0.7	
Mental Acuity Decreased	0	1.1	0.3	
Paresthesia	0.4	1.4	3.0	
Somnolence	2.8	4.3	5.3	
Tremor	0.7	1.1	0	
Hypesthesia	0	1.4	0.7	
Nervousness	0.4	1.1	0.7	
Respiratory System				
Pharyngeal Discomfort	0	1.1	0.7	
Skin and Skin Appendag	e			
Sweating	0.7	1.1	1.0	
Special Senses				
Blurred Vision	0	0.4	1.3	
Taste Perversion	1.1	1.4	2.3	

*The term "sensations" encompasses adverse events described as pain, disconfort, pressure, heaviness, constriction, tightness, heat/burning sensation, paresthesia, numbress, tingling, weakness and strange sensations Data from Studies 039 and 049.

MAXALT* was generally well tolerated. Adverse experiences were typically mild in intensity and were transient. The frequencies of adverse experiences in clinical trials did not increase when up to three doses were taken within 24 hours. The incidences of adverse experiences were not affected by age, gender or use of prophylactic medications. There were insufficient data to assess the impact of race on the incidence of adverse events.

Long-Term Safety

Long-term extension studies, a total of 1854 patients treated 16,150 migraine attacks with MAXALT* 5 mg Tablets and 24,043 attacks with MAXALT* 10 mg Tablets over a period of up to 1 year. In general, the types of clinical adverse experiences observed in the extension studies were similar to those observed in the acute studies. However, the incidences of most clinical adverse events were approximately 3-fold incidences of most clinical adverse events were approximately 3-fold higher in extension, as expected, based on increased observation time. The most common adverse events per attack (defined as occurring at an incidence of at least 1%) for MAVALT* 5 mg and 10 mg, respectively, were as follows: raused (3%, 4%), diztiness (2%, 2%), sominience (2%, 4%), asthemia/fatigue (2%, 2%), headache (1%, 2%), vorniting (1%, <1%), chest pan (<1%, 1%) and paresthesa (<1%, 2%), vorniting (1%, <1%), placebo controls in the extension studies, the role of MAXALT* in causation cannot be reliably determined causation cannot be reliably determined.

Other Events Observed in Association with the Administration of $\ensuremath{\mathsf{MAXALT}}^4$

MAXALT* In the section that follows, the frequencies of less commonly reported adverse clinical events are presented. Because the reports include events observed in open studies, the role of MAXALT* in their causation cannot be reliably determined. Furthermore, variability associated with adverse event reporting, the terminology used to describe adverse events, etc. limit the value of the quantitative frequency estimates provided. Event frequencies are calculated as the number of patients who used MAXALT* S sm g and 10 mg Tablets in Phase II and III studies (n=3716) and reported an event divided by the total number of patients exposed to MAXALT*. All reported events are included evend those afready listed in the previous table, those too general to be informative, and those not reasonably associated with the use of the drug. Events are further classified within body system categories and enumerated in order of decreasing frequency body system categories and enumerated in order or utcreasing metupercy using the following definitions: frequent adverse events are those ofcimed as those occurring in at least 1/100 patients; intrequent adverse experiences are those occurring in 1/100 to 1/1000 patients; and rare adverse experiences are those occurring in fewer than 1/1000 patients.

Body as a Whole

Frequent were warm sensations, chest pain and chills/cold sensations Infrequent were heat sensitivity, facial edema, hangover effect, adominal distention, edema/swelling and malaise. Rare were fever, orthostatic effects, and syncope.

Cardiovascular

Frequent was palpitation. Infrequent were tachycardia, cold extremities, hypertension, arrhythmia, and bradycardia. Rare were angina pectoris and blood pressure increased

Digestive

Frequent was diarrhea. Infrequent were dyspepsia, thirst, acid regurgitation, dysphagia, constipation, flatulence, and tongue edema Rare were anorexia, appelite increase, gastritis, paralysis (tongue), eructation and glosodynia.

Metabolic

Infrequent was dehydration

Musculoskeletal

Infrequent were muscle weakness, stiffness, myalgia, muscle cramp, musculoskeletal pain, and arthralgia.

Neurological/Psychiatric

Frequent were hypesthesia and mental acuity decreased. Infrequent were nervousness, vertigo, insomnia, activity depression, euphoria, disorientation, ataxia, dysarthria, confusion, dream abnormality, gait abnormality, irritability, memory impairment, agitation, hyperesthesia, sleep disorder, speech disorder, migraine and spasm. Rare were dysesthesia, depersonalization, akinesia/bradykinesia, apprehension, hyperkinesia, hypersomnia, and hyporeflexia

Respiratory

Frequent were dyspnea and pharyngeal discomfort. Infrequent were pharyngitis, irritation (nasal), congestion (nasal), dry throat, upper respiratory infection, yawning, respiratory congestion, dry nose, epistaxis, and sinus disorder. Rare were cough, hiccups, hoarseness, rhinorrhea, sneezing, tachyonea, and pharyngeal edema.

Special Senses

Frequent was taste perversion. Infrequent were blurred vision, tinnitus, dry vers, burning eve, eve pain, eve irritation, ear pain, and tearing. Rare were hyperacusis, smell perversion, photophobia, photopsia, itching eye, and eve swelling

Skin and Skin Appendage

Infrequent were sweating, pruritus, rash, and urticaria. Rare were erythema, acne, and photosensitivity

Urogenital System

Frequent was hot flashes. Infrequent were urinary frequency, polyuria, and menstruation disorder. Rare was dysuria

The adverse experience profile seen with MAXALT RPD* Wafers was similar to that seen with MAXALT* Tablets.

Post-Marketing Experience

The following additional adverse reactions have been reported very rarely and most have been reported in patients with risk factors predictive of CAD: Myocardial ischemia or infarction, cerebrovascular accident

The following adverse reactions have also been reported:

Hypersensitivity: Angioedema (e.g., facial edema, tongue swelling, pharyngeal edema), wheezing, urticaria, rash, toxic epidermal necrolysis. Special Senses: Dysgeusia.

Drug Abuse and Dependence

Although the abuse potential of MAXALT* has not been specifically Annough the aduse potential of wAAAL " as hot been specifically assessed, no abuse of tolerance to, with that and no of drug-seeking behavior was observed in patients who received MAXALT " in clinical trials or their extensions. The 5-HT_{18:10} agonists, as a class, have not been seeceibled with drug abuse associated with drug abuse

SYMPTOMS AND TREATMENT OF OVERDOSAGE

No overdoses of MAXALT[®] (rizatriptan benzoate) were reported during clinical trials

Rizatriptan 40 mg (administered as either a single dose or as two doses with a 2-hour interdose interval) was generally well tolerated in over 300 patients; dizziness and somnolence were the most common drugrelated adverse effects

In a clinical pharmacology study in which 12 subjects received rizatriptan, In a climical priaring output of the second S-second systelic pause (on ECG monitor) immediately after a painful venipuncture. The venipuncture occurred two hours after the subject had received a total of 80 mg rizatriptan (administered over four hours).

In addition, based on the pharmacology of rizatriptan, hypertension or other in addition, based on the pharmacology of rizampian, hypertension of other more serious cardiovascular symptoms could occur after overdosage. Gastrointestinal decontamination (i.e., gastric lavage followed by activated charcoal) should be considered in patients suspected of an overdose with MAXALT[®]. The elimination half-life of rizatriptan is 2 to 3 hours (see ACTIONS AND CLINICAL PHARMACOLOGY). Clinical and electro-cardiographic monitoring should be continued for at least 12 hours, even if chicked ventures are not behaviord. clinical symptoms are not observed.

There is no specific antidote to rizatriptan. In cases of severe intoxication, intensive care procedures are recommended, including establishing and maintaining a patent airway, ensuring adequate oxygenation and ventilation, and monitoring and support of the cardiovascular system

The effects of hemo- or peritoneal dialysis on serum concentrations of rizatriptan are unknow

DOSAGE AND ADMINISTRATION

 $MAXALT^{\$}$ (rizatriptan benzoate) is recommended only for the acute treatment of migraine attacks. $MAXALT^{\$}$ should not be used prophylactically.

Controlled trials have not established the effectiveness of a second dose if the initial dose is ineffective.

The safety of treating, on average, more than four headaches in a 30-day period has not been established.

ADULTS

MAXALT[®] Tablets and MAXALT RPD[®] Wafers

The recommended single adult dose is 5 mg. The maximum recommended single dose is 10 mg. There is evidence that the 10 mg dose may provide a greater effect than the 5 mg dose (see ACTIONS AND CLINICAL PHARMACOLOGY, Clinical Studies). The choice of dose should therefore be made on an individual basis, weighing the possible benefit of the 10 mg dose with the potential risk for increased adverse events.

For MAXALT RPD." Wafers, administration with liquid is not necessary. The wafer is packaged in a blister within an outer aluminum pouch. Patients he want is packaged in a baser within an other animum poor r adving should be instructed not to remove the bister from the outer pouch until just prior to dosing. The blister pack should then be peeled open with dry hands and the wafer placed on the tongue, where it will dissolve and be swallowed with the saliva

Redosina

Doses should be separated by at least 2 hours; no more than a total of 20 mg (Tablets or Wafers) should be taken in any 24-hour period **Patients Receiving Propranolol**

A single 5 mg dose of MAXALT^{*} should be used. In no instances should the total daily dose exceed 10 mg per day, given in two doses, separated by at least two hours (see PRECAUTIONS, Drug Interactions).

Renal Imnairment

In hemodialysis patients with severe renal impairment (creatinine clearance In hemodaysis patients with severe renal impairment (creatinne clearance < 2 mL/min/1.73 m?), the AUC of rizitriptian was approximately 44% greater than in patients with normal renal function (see ACTIONS AND CLINICAL PHARMACOLOGY, Special Populations). Consequently, if treatment is deemed advisable in these patients, the 5 mg MAXALT* Tablet or Water should be administered. No more than a total of 10 mg should be taken in any 24-hour period. Repeated dosing in renally impaired patients has not been evaluated.

Hepatic Impairment

MAXALT* is contraindicated in patients with severe hepatic impairment (Child-Pugh grade C) due to the absence of safety data. Plasma concentrations of inzatriptica were approximately 30% greater in patients with moderate hepatic insufficiency (see ACTIONS AND CLINICAL PHARMACOLOGY, Special Populations). Consequently, if treatment is deemed advisable in the presence of moderate hepatic impairment, the 5 mg MXALT* Tablet or Wafer should be administered. No more than a total of 10 mg should be taken in any 24-hour period. Repeated dosing in hepatically impaired patients has not been evaluated

Patients with Hypertension

MAXALT^{*} should not be used in patients with uncontrolled or severe hypertension. In patients with mild to moderate controlled hypertension, atients should be treated cautiously at the lowest effective dose COMPOSITION

Tablets

Each compressed tablet contains either 5 mg or 10 mg of rizatriptan (corresponding to 7.265 mg or 14.53 mg of the benzoate salt, respectively) and the following non-medicinal ingredients: ferric oxide (red), lactose monohydrate, magnesium stearate, microcrystalline cellulose and pregelatinized starch

Wafers

Each lyophilized wafer contains either 5 mg or 10 mg of rizatriptan (corresponding to 7.265 mg or 14.53 mg of the benzoate salt, respectively) and the following non-medicinal ingredients: aspartame. gelatin, glycine. mannitol and peppermint flavor.

STABILITY AND STORAGE RECOMMENDATIONS

Tablets Store the tablets at room temperature (15°C-30°C)

Wafers

Store the wafers at room temperature (15°C-30°C).

The patient should be instructed not to remove the blister from the outer aluminum sachet until the patient is ready to consume the outer alumin the wafer inside.

AVAILABILITY OF DOSAGE FORMS

MAXALT* 5 mg are pale pink, capsule-shaped compressed tablets, embossed with the code MSD on one side and 266 on the other. Available in blister packages of 6 tablets.

MAXALT* 10 mg are pale pink, capsule-shaped compressed tablets, embossed with the code MSD 267 on one side and MAXALT on the other. Available in blister packages of 6 tablets.

MAXALT RPD* 5 mg are white to off-white, round, rapidly disintegrating tablets, with a flat or slightly irregular surface, debossed with a modified triangle on one side, and with a peppermint flavor. Each wafer is individually packaged in a blister inside an aluminum pouch (sachet). Available in blister packages of 6 wafers.

MAXLT RPS ⁴¹ 0 mg are white to off-white, round, rapidly disintegrating tablets, with a flat or slightly irregular surface, debossed with a modified square on one side, and with a peppermint flavor. Each wafer is individually packaged in a blister inside an aluminum pouch (sachet). Available in blister packages of 6 wafers.

PRODUCT MONOGRAPH AVAILABLE ON REQUEST

(1012-a.3.06)

34380402

Member R&D



www.merckfrosst.com



for a better tomorrow.

MERCK FROSST CANADA LTD. P.O. BOX 1005, POINTE-CLAIRE DORVAL, QUEBEC H9R 4P8

MICARDIS_® (telmisartan) 40 mg and 80 mg Tablets THERAPEUTIC CLASSIFICATION:

Angiotensin II AT₁ Receptor Blocker INDICATIONS AND CLINICAL USE

MICARDIS» (telmisartan) is indicated for the treatment of mild to moderate essential hypertension. MICARDIS» may be used alone or in combination with thiazide diuretics. The safety and efficacy of concurrent use with angiotensin converting enzyme inhibitors have not been established. Information on the use of telmisartan in combination with beta blockers is not available

CONTRAINDICATIONS

is contraindicated in patients who are hypersensitive to any components of this product (see Composition) WARNINGS

Pregnancy:

WARNINGS Pregnancy: Drugs that act directly on the renin-angiotensin system can cause fetal and neonatal morbidity and mortality when administered to pregnant women. If pregnancy is detected, MICARDIS- (telmisartan should be discontinued as soon as possible. The use of drugs that act directly on the renin-angiotensin system during the second and third timesters of pregnancy has been associated with tetal and nonnatal injury, including hypotension, neonatal skull hypoplasia, anuria, reversible or inversible renal failure, and death. Oligohydramnics has also been reported, presumably resulting from decreased tetal renal function, oligohydramnics in this setting has been associated with tetal and contractures, cranolocial deformation, and hypoplastic lung development. Prenaturity, intrauterine growth relaration, and patent ductus arteriosus have also been reported, although it is not clear whether these occurrences were due to exposure to the drug. These adverse effects do not appear to have resulted from intrauterine drug exposure that has been limited to the first timester. Mothers whose entryose and fetuses are exposed to an angiotensin II receptor antagonist only during the first timester should be so informed. Nonetheless, when patients become pregnant, physicians should have the patient discontinue the use of MCAPLOS as soon as possible unless it is considered life saving for the mother. Rareh, probably less often than once in every thousand pregnancies, no atternative to neek of pregnancy strais lesting (ST), a non-stress test (NSI), or biophysical profiling (BP) may be appropriate, depending upon the week of pregnancy and hyperkalemi. If oligon's coursions may ot appear until after the texts has sustained inversible injury. Infants with histories of in utere exposure to an angiotensin II AIT: receptor antagonist should be closely observed for hypotension, oliguria, and hyperkalemi. If oliguria course, attention should be erecet toward support biodic during perfauits as to and loses of up to

Hypotension:

nypotension: In patients who are volume-depleted by diuretic therapy, dietary salt restriction, dialysis, diarrhea or vomiting, symptomatic hypotension may occur after initiation of therapy with MICARDISs. These conditions should be corrected prior to administration of MICARDISs. In these patients, because of the potential fall in blood pressure, therapy should be started under close medical supervision. Similar considerations apply to patients with ischemic heard or cerebrovascular disease, in whom an excessive fall in blood pressure could result in myocardial infarction or cerebrovascular accident.

PRECAUTIONS

Verteral: **Hepatic Impairment:** As the majority of telmisartan is eliminated by biliary excretion, patients with biliary obstructive disorders or hepatic insufficiency have reduced clearance of telmisartan. Three-to four-fold increases in C_{max} and AUC were observed in patients with liver impairment as compared to healthy subjects. MICARDIS» (telmisartan) should be used with caution in these patients (see DOSAGE AND ADMINISTRATION).

DOSAGE AND ADMINISTRATION. Renal Impairment: As a consequence of inhibiting the renin-angiotensin-aldosterone system, changes in renal function may be anticipated in susceptible individuals. In patients whose renal function may depend on the activity of the renin-angiotensin-aldosterone system, such as patients with bilateral renal attery stenosis, unilateral renal attery stenosis to a solitary kidney, or severe congestive heart fairue, treatment with agents that inhibit this system has been associated with oligina, progressive azotemia, and rarely acute renal failure and/or death. There is no experience with long-term use of MICAPDIS, feltimisarian in patients, concomitant diuretic use may further increase the risk. Use of telmisarian should include appropriate assessment of renal function in these types of patients. **Valvular Stenosis:** There is concern on theretical grounds that patients with aortic stenosis might be at a particular risk of decreased coronary pertission, because they do not develop as much afterfold reduction. **Hyperkalemia:** Drugs such as MICAPDIS, that affect the renin-angiotensin-adosterone system can cause hyperkalemia. Monitoring of serum potassium in patients at risk is recommended. Based on experience with the use of other drugs that affect the renin-angiotensin system, concomitant use with potassium-spaning diuretics, potassium supplements, salt substitutes containing potassium. **Use in Nursing Mothers:** It is not known whether telmisartan is excreted in human milk, but telmisartan was shown to be present in the milk of lacitating ratis. Because of the potential for adverse effects on the runsing infant, a decision should be made whether to discontine nursing or discontinue the drug, taing in account the importance of the drug to the mother. **Use in Children**: Safety and effectiveness in pediatric patients have no toene established. **Use in Children**: Safety and effectiveness in pediatric patients have no toene established. **Use in Children**: Safety and effectiveness Renal Impairment: As a consequence of inhibiting the renin-angiotensin-aldosterone system, changes in renal function may be

Drug Interactions:

Drug Interactions: Wararim (IICARDIS, telmisartan) administered for 10 days slightly decreased the mean wararim trough plasma concentration; this decrease did not result in a change in International Normalized Ratio (INR). Coadministration of MICARDIS₁₀ also did not result in a clinically significant interaction with acetaminophen, amiodipine, glyburide, hydrochitorothiazide or ibuproten. For digoxin, median increases in digoxin peak plasma concentration (49%) and in turolph concentration (20%) were observed. It is recommended that digoxin plasma levels be monitored when initiating, adjusting or discontinuing MICARDIS₁₀. Lithium: Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with angiotensi converting enzyme inhibitors. Very rare cases have also been reported with angiotensin II receptor antagonists. Therefore, serum lithium level monitoring is advisable during concomitant use.

ADVERSE EVENTS MICARDISe (telmisartar

AUVERSE EVENTS. MICARDS, Hemissram has been evaluated for safety in 27 clinical trials involving 7.968 patients. Of these 7.968 patients, 5.788 patients were treated with MICARDIS[®] monotherapy including 1.058 patients treated for ≥1 year and 1.395 patients treated in placebo-controlled trials. In 3.400 patients, discontinuation of therapy due to adverse events was required in 2.8% of MICARDIS[®] patients and 6.1% placebo patients. The following potentially serious adverse reactors have been reported rarely with telmisstant in controlled clinical synope and hypotension. In placebo-controlled trials, no serious adverse event was reported with a frequency of greater that 0.1% in MICARDIS[®]-treated patients.

In placebe controlled trials, no serious adverse event was reported with a trequency or greater use u. I to it in reconcisionation and the series of the ser

symptonics. Psychiatric System: Common: Anxiety, depression, nervousness. Respiratory System: Common: Upper respiratory tract infections including pharyngitis and sinusitis, bronchitis, coughing, dyspnea, rhinitis. Skin and Appendages Systems: Common: Skin disorders like eczema, rash.

CLINICAL LABORATORY FINDINGS

n hemoglobin has been observed which occurs more often during treatment with telmisartan than

PLACEBO-CONTROLLED TRIALS

The overall incidence of adverse events reported with MICARDIS₈ (41.4%) was usually comparable to placebo (43.9%) in placebo controlled trials. Adverse events occurring in 1% or more of 1,395 hypertensive patients treated with MICARDIS₈ monotherapy in placebo controlled clinical trials, regardless of drug relationship, include the following:

Adverse Event, by System	MICARDIS® Total n=1,395 %	Placebo n=583 %
Body as a Whole		
Back pain	2.7	0.9
Chest pain	1.3	1.2
Fatigue	3.2	3.3
Influenza-like symptoms	1.7	1.5
Pain	3.5	4.3

Central & Peripheral Nervous System		
Dizziness	3.6	4.6
Headache	8.0	15.6
Somnolence	0.4	1.0
Gastrointestinal System		
Diarrhea	2.6	1.0
Dyspepsia	1.6	1.2
Nausea	1.1	1.4
Vomiting	0.4	1.0
Musculoskeletal System		
Myalgia	1.1	0.7
Respiratory System		
Coughing	1.6	1.7
Pharyngitis	1.1	0.3
Sinusitis	2.2	1.9
Upper respiratory tract infection	6.5	4.6
Heart Rate and Rhythm Disorders		
ECG abnormal specific	0.2	1.0
Palpitation	0.6	1.0
Cardiovascular Disorders, General		
Hypertension	1.0	1.7
Oedema peripheral	1.0	1.2

The incidence of adverse events was not dose-related and did not correlate with the gender, age, or race of patients. In addition, the following adverse events, with no established causality, were reported at an incidence of <1% in placebo-controlled clinical trials

In addition, the following adverse events, with no established causality, were reported at an incidence of <1% in placebo-controlled clinical trials. Autonomic Nervous Systems Disorders: sweating increased. Body as a Whole: abdome enlarged, allergy, cyst nos, fall, fever, leg pain, rigors, syncope. Cardiovascular Disorders, General: hypotension, hypotension-postural, leg edema. Central & Peripheral Nervous System Disorders: hypotension, migraine-aggravated, muscle contraction-involuntary. Gastrointestinal System Disorders: anorexia, appetite increased, flatulence, gastrointestinal disorder nos, gastroenteritis, gastroeschapeal reflux, melena, mouth dry, abdomial pain. Heart Rate & Rhythm Disorders: arthythmia, fachycardia. Metabolic & Nutritional Disorders: mytoria, appetite increased, flatulence, gastrointestinal disorder nos, gastroenteritis, dato and the stabetes mellitus, hypokalemia. Musculoskeletal System Disorders: mytoria, appravated, arthrosis, bursits, fascitis plantar, tendinitis. Mys Cho Pericardial & Valve Disorders: mytorial infarction. Psychiatric Disorders: anemia. Red Blood Cell Disorders: anemia. Red Blood Cell Disorders: amenia. Meander Blosders: Barder Stabetes mellitis.

Red Biolog Cell Disorders: anemia. Reproductive Disorders, Farmale: vaginitis. Resistance Mechanism Disorders: abscess, infection, bacterial, moniliasis genital, otitis media. Respiratory System Disorders: bronchospasm, epistaxis, pneumonia, bronchitis. Skin & Appendage Disorders: rash, skin dry. Urinary System Disorders: dysuria, hematuria, micturition disorder, urinary tract infection. Vascular (Extracardiac) Disorders: cerebrovascular disorder, purpura. Vision Disorders: vision aborders: vision aborders.

Vision Disorders: vision abnorm Clinical Laboratory Findings:

Crinical Laboratory mixings: In placebo-controlled clinical trads involving 1,041 patients treated with MICARDIS+ monotherapy, clinically relevant changes in standard laboratory test parameters were rarely associated with administration of MICARDIS+. Creatinine, Blood Urera Nitrogen: Increases in BUN (=11.2 mg/dL) and creatinine (=0.5 mg/dL) were observed in 1.5% and 0.6% of MICARDIS+ treated patients; the corresponding incidence was 0.3% each for placeto-treated patient. These increases occurred primarily with MICARDIS+ in combination with hydrochlorothiazide. One telmisartan-treated patient discontinued therapy due to increases in relations on theory and the patients in the procession of the patient discontinued therapy due to increases in

MICAPDIS--treated patients; the corresponding incore were use use an inspected variable discontinued therapy due to increases in creatinine and blood urea nitrogen. Hemoglobin, Hematocrit: Clinically significant changes in hemoglobin and hematocrit (<10 mg/dL and <30% respectively) were rarely observed with MICAPDIS treatment and did not differ from rates in placebo-treated patients. No patients descontinued therapy due to anemia. Serum Uric Acid: An increase in serum uric acid (≥2.7 mg/dL) was reported in 1.7% of patients treated with MICAPDIS- with more thready one to anemia. Serum Uric Acid: An increase in serum uric acid (≥2.7 mg/dL) was reported in 1.7% of patients treated with MICAPDIS- with the MICAPDIS- with a discontinued thready to be anemia. Liver Function Tests: Clinically significant elevations in ASI and ALI (>3 times the upper limit of normal) occurred in 0.1% and 0.5% respectively of patients treated with MICAPDIS- songared to 0.8% and 1.7% of patients receiving placebo. No telmisartan-treated patients (0.4%) respectively of patients treated with MICAPDIS- treated patients (0.6%, 0.3%, respectively). Clinically significant elevations in serum potassium (≥4.-1.4 mEg/L) occurred rarely and with a lower frequency in MICAPDIS-treated patients (0.3%, 0.1%, respectively) than in placebo patients (0.6%, 0.3%, respectively). Clinically significant elevations in serum orbitoserol water reported in a total of 6 telmisartan-treated patients (0.4%) and no placebo chreated patients were 0.6% and 0.8%. **Cholesterol**: In placebo-treated patients were 0.6% and 0.8%. **Cholesterol**: In a locabo-controlled triaks, marked patients with 0.4% of patients are reported at baseline. The corresponding rates for placebo-treated patients were 0.6% and 0.8%. **Cholesterol**: In placebo-treated patients were 0.6% and 0.8%.

To compare the contraction of television of the market, cases of erythema, pruritus, faintness, insomnia, depression, stomach upset, vomiting, hypotension, bradycardia, tadycardia, dysprocea, eosinophila, thrombocytopenia, weakness and lako of efficacy have been reported rarely. As with other angiotensini II antagonistis rare cases of angio-eodema, pruvitis, rash and urticaria thave been reported. Cases of muscle pain, muscle weakness, myositis and rhabdomyolysis have been reported in patients receiving angiotensin II receptor blockers.

SYMPTOMS AND TREATMENT OF OVERDOSAGE

Limited data are available with regard to overdosage in humans. The most likely manifestation of overdosage would be hypotension and/or tachycardia. If symptomatic hypotension should occur, supportive treatment should be instituted. Telmisartan is not removed by hemodialysis.

DOSAGE AND ADMINISTRATION The recommended dose of MICARDIS». (telmisartan) is 80 mg once daily. The antihypertensive effect is present within 2 weeks and maximal reduction is generally attained after four weeks. If additional blood pressure reduction is required, a thiazide diuretic may be added.

pressure reduction is required, a finance quireter (may be added). No initial dosign adjustment is necessary for elderly patients or for patients with renal impairment, but greater sensitivity in some older individuals cannot be ruled out. Markedy reduced telmisartan plasma levels were observed in patients on hemodialysis. For patients with hepatic impairment, a starting dose of 40 mg is recommended (see PRECAUTIONS, Hepatic Impairment). MICARDIS+ should be taken consistently with or without food. Composition:

Composition: MICARDIS: Tablets contain the following inactive ingredients: sodium hydroxide, meglumine, povidone, sorbitol, and magnesium stearate. Stability and Storage Recommendations: MICARDIS: Tablets are hygroscopic and require protection from moisture. Tablets are packaged in blisters and should be stored at room temperature, 15 to 30°C (59-86°F). Tablets should not be removed from blisters until immediately prior to administration.

Tables should not be reinforce minimized and initiated and provide doministration. **AVALUABLITY OF DOSAGE FORMS** MICARDIS- is available as white, oblong-shaped, uncoated tablets containing telmisatan 40 mg or 80 mg. Tablets are marked with the Boehringer Ingelheim logo on ore side, and on the other side, with a decorative score and either 51H or 52H for the 40 mg and 80 mg strengths, respectively. MICARDIS- have a strength of the other side of the advectory of 28 tablets as 4 cards containing 7 tablets each.

Product Monograph available upon request. References:

References: 1. Mailion JM *et al.* ABPM Comparison of the Antihypertensive Profiles of the Selective Angiotensin II Receptor Antagonists Telmisartan and Losartan in Patients With Mild-to-Moderate Hypertension. *Journal of Human Hypertension* 1939;13(10):657–664. 2. Lacoucière Y. *et al.* A Multicenter, 14-Week Study of Telmisartan and Ramipril in Patients With Mild-to-Moderate Hypertension Using Ambulatory Blood Pressure Monitoring. *American Journal of Hypertension* 2006;19:104–112. 3. MiGARDIS- Product Monograph, Boehringer Ingelheim (Canada) Ltd. October 2005. 4. Cozaer[®] Product Monograph, E.I. du Port de Nemours and Company. 5. Diovan[®] Product Monograph, Novaritis, 6. Avapro[®] Product Monograph (Canada), Sanofi-Synthelabo. 7. Atacand[®] Product Monograph, AstraZeneca Pharma Inc. 8. Teveten[®] Product Monograph, Solvay Pharma Inc.



GOOD MORNING. MICARDIS.

Boehringer Ingelheim Boehringer Ingelheim (Canada) Ltd. 5180 South Service Rd Burlington, Ontario L7L 5H4

PAAB

W

Fellowship in Stereotactic & Functional Neurosurgery



Fellowship in Stereotactic & Functional Neurosurgery

The Division of Neurosurgery at Dalhousie University is offering a one year Clinical Fellowship in Stereotactic & Functional Neurosurgery. Functional neurosurgical procedures for Atlantic Canada (population 2,500,000) are performed at the QEII Health Sciences Center/Dalhousie University. The Division of Neurosurgery is affiliated with the multimillion dollar Brain Repair Centre, with facilities ranging from basic science laboratories to a human 4T MRI.

Fellows will participate in the evaluation and treatment of patients with a broad range of functional neurosurgical disorders including:

- Movement disorders
- Complex pain
- Epilepsy
- Spasticity
- Angina

Fellows will have training in different techniques including:

- Deep brain stimulation, with and without microelectrode recording
- Motor Cortex Stimulation
- Spinal cord stimulation
- Intrathecal therapy
- Ablative procedures
- Selective mesial temporal resections
- Extratemporal resections for epilepsy
- Neurotransplantation
- Vagus nerve stimulation

Fellows are expected to be involved in clinical research projects. Opportunities for those interested in basic science research are also available. Candidates must have completed their neurosurgical training and be eligible for licensure in Nova Scotia, This position is to commence July 01, 2008. Interested candidates should send three letters of reference along with their cover letter outlining why they wish to study stereotactic and functional neurosurgery, by August 31, 2007.

To:

Rob Brownstone, MD, PhD, FRCSC Division of Neurosurgery, QEII Health Sciences Center 3816-1796 Summer Street, Halifax, NS B3H3A7 Phone: (902) 473-6850 Fax: (902) 473-6852 Email: madonna.munden@dal.ca

Websites: www.neurosurgery.medicine.dal.ca www.brainrepair.ca www.neuraltransplantation.dal.ca www.motorcontrol.med.dal.ca

Baystate 📠 Health

baystatehealth.com

CHILD NEUROLOGIST

Baystate Children's Hospital is seeking a 4th and 5th Child Neurologist to join a well-established academic practice. You will enjoy opportunities to practice general pediatric neurology in a setting that has a 55-bed NICU, 10-bed PICU, and extensive clinical neurophysiology services, including digital ambulatory and video EEG and polysomnography. Candidates must be BC/BE and fellowship-trained in pediatric neurology. Additional training in epilepsy and perioperative EEG/ECOG monitoring is desirable.

Baystate is one of New England's largest integrated multi-institutional healthcare systems and offers a coordinated continuum of hospital, physician services, and home healthcare services. The campus is located in the beautiful Connecticut River valley of Western Massachusetts, at the foothills of the Berkshires with convenient access to coastal New England, Vermont and metropolitan Boston and New York. The area also supports a rich network of academic institutions including the University of Massachusetts and Amherst, Smith, Hampshire and Mount Holyoke Colleges. The Baystate continuum includes Baystate Medical Center, Franklin Medical Center and Baystate Mary Lane Hospital. Baystate Health is ranked in the top 50 most highly integrated healthcare networks in the United States.

The new Neurodiagnostics and Sleep Center at Baystate Medical Center in Springfield offers the latest state-of-the-art technology for polysomnography sleep studies (16 channel) and respiratory sleep studies (4 and 5 channel). With approximately 9,000 square feet and 14 testing rooms, it is the largest sleep center in Western Massachusetts.

Interested applicants should submit a CV and cover letter to:

John Larson, Senior Manager Physician Recruitment 759 Chestnut Street, Suite S1578, Springfield, MA 01199 Telephone: (413) 794-2571; Fax: (413) 794-5059 Email: john.larson@bhs.org. EOE/AA

Western Campus of Tufts University School of Medicine

NEUROLOGIST NANAIMO, VANCOUVER ISLAND

The perfect climate for your future!

Nanaimo Regional General Hospital, a 234 acute-bed regional referral hospital, has a vacancy for a Neurologist. The successful applicant will hold FRCPC qualifications and establish a private fee-for-service practice. MOCAP call back funding will be available. MRI, CT, EEG and EMG are all available on-site.

Vancouver Island's second largest city, Nanaimo is situated midway on the east coast, 115 kilometers north of Victoria and is in close proximity to Vancouver. The community offers a variety of educational and cultural opportunities for families. Recreational activities abound including year-round golf, spectacular winter skiing within one hour's drive, and all manner of water sport activities.

Nanaimo offers an attractive quality of life where the outdoor living is easy all year!

We invited interested candidates to contact: Brenda Warren, Coordinator Medical Admin. 1200 Dufferin Crescent, Nanaimo, BC V9S 2B7 Tel: 250.755-7687 Fax: 250.716.7747 Email: brenda.warren@viha.ca www.viha.ca www.nanaimo.ca

COGNITIVE DISORDERS AND VASCULAR DEMENTIA - CLINICIAN-SCIENTIST



The **Department of Clinical Neurosciences** and the **Hotchkiss Brain Institute of the University of Calgary** and **Calgary Health Region** invite applications for a full-time position as a clinician-scientist at the level of Assistant Professor or higher. The successful candidate will be a practicing neurologist with clinical and research training in cognitive disorders and stroke. This new position offers an extraordinary opportunity to develop an independent research program at the interface of cognitive impairment and stroke in a multidisciplinary scholarly environment. The successful candidate will join the cognitive assessment program and become a member of one of the leading investigative and clinical stroke care programs in North America. Duties will include teaching, patient care and trainee supervision, but time for research will be protected (75% level).

Excellent facilities for clinical neuroscience and population health research, supported by state-of-the-art clinical and experimental imaging facilities, provide an environment conducive to leading-edge research. The Calgary Stroke Program provides care to the 1.8 million residents of Southern Alberta and is involved in NIH funded multi-centre trials.

Qualifications include an MD, specialist certification in Neurology and eligibility for licensure in the Province of Alberta. Research training in cognitive disorders and stroke neurology and demonstrated commitment to research are essential. The ability to establish an independent research program as demonstrated by a portfolio of significant scholarly work is also required. Attractive start-up support is available, but within three years, the successful candidate will be expected to compete successfully for external salary support and research funds from the Alberta Heritage Foundation for Medical Research, Canadian Institutes of Health Research, or Heart and Stroke Foundation.

Calgary is a vibrant multicultural city located near the Rocky Mountains, Banff National Park and Lake Louise.

Please forward a curriculum vitae, statement of research interests and the names of three referees by May 31, 2007 to:

Dr. Sam Wiebe, Head

Division of Neurology Department of Clinical Neurosciences Foothills Medical Centre 1403 – 29th Street N.W. Calgary, AB T2N 2T9 Canada

In accordance with Canadian immigration requirements, priority will be given to Canadian citizens and permanent residents of Canada. The University of Calgary respects, appreciates, and encourages diversity.

NAME CHANGE

Canadian Congress of Neurological Sciences

0

Canadian Neurological Sciences Federation

Recently our name was officially changed to the Canadian Neurological Sciences Federation to better reflect the fact that we represent a federation of four professional societies.



CANADIAN NEUROLOGICAL Sciences Federation Fédération Des sciences

NEUROLOGIQUES DU CANADA



www.ucalgary.ca

Join us in Edmonton, Alberta for the

42nd Annual Congress presented by the

Canadian Neurological Sciences Federation (CNSF) June 19-22, 2007

NOTES AND ANNOUNCEMENTS

NEW DEAN APPOINTED TO FACULTY OF MEDICINE

University of Calgary President and Vice-Chancellor Dr. Harvey Weingarten announced the appointment of a new Dean of the U of C's Faculty of Medicine.

Dr. Tom Feasby has been appointed Dean of Medicine for a five-year term, effective July 1, 2007. He will replace Dr. Grant Gall, who is stepping down after ten years as Dean.

Feasby's appointment marks a homecoming of sorts: he was Head of the Faculty's Department of Clinical Neurosciences from 1991 to 2003.

Feasby is currently the Associate Dean, Clinical Affairs in the Faculty of Medicine & Dentistry at the University of Alberta and Vice-President, Academic Affairs of Capital Health in Edmonton.

His record of research excellence is reflected in more than 100 research publications in areas such as neurologic diseases and the appropriateness of health care interventions, his supervision of numerous graduate students, and his involvement in professional societies and organizations including the CIHR Institute of Health Services and Policy Research, the Canadian Academy of Health Sciences and the American Academy of Neurology. Feasby's outstanding administrative skills have also helped strengthen research groups and health care organizations throughout Canada.

THE CANADIAN NEUROLOGICAL SCIENCES FEDERATION ANNUAL CONGRESS CHANGES

Our 2007 Congress in Edmonton is June 19-22. Highlights of some of the changes:

- 1 Chair John Stewart, Vice Chair Mike Tymianski and the Scientific Program Committee are working hard to ensure this year's program is one of the best ever, with a more interactive scientific program. Of particular significance is the fact the Congress has been shortened by one day. Details are available on the CNSF website: cnsfederation.org. Additionally, we have enhanced and improved the Congress social events. Details are also on our web site. Poster presentations this year will be digital and contained in a more compact exhibit area; allowing for ease of viewing and commentary.
- 2 All Congress materials will be provided to registrants on a CD, one to two weeks prior to the Congress. Everyone, therefore, will receive all Congress materials--not just for the Courses/sessions they attend. We are asking registrants to either bring the CD and their laptop to the Congress and/or to print their required materials ahead of time. No Course materials will be distributed at the Congress. This change will save close to \$20,000 and also has obvious environmental benefits.
- 3 Congress Abstracts will be mailed with the May issue of the Journal. There will not be another distribution of the Abstract book on site, as in previous years, so bring your Abstract book with you for reference during poster and platform sessions. This is in response to numerous negative comments about receiving two copies, saves us approximately \$10,000 and again has a positive environmental impact.
- 4 The "overall Congress evaluation" will be on line through Survey Monkey. This means we should be able to capture more feedback and relevant data to assist us in planning future meetings. We NEED you to fill in the evaluations! Specific instructions on how to fill in the evaluations will be provided at a later date.

SO, PLEASE VISIT THE CNSF WEB SITE ASAP, AND CHECK OUT THE GREAT PROGRAM AND EVENTS.

REGISTER FOR THE CONGRESS AND YOUR ACCOMMODATIONS AT WWW.CNSFEDERATION.ORG.

The CNSF Board, Committee Chairs and Secretariat look forward to seeing you in Edmonton.

The Canadian Neurological Sciences Federation is pleased to recognize our Sponsors* for 2007. These organizations partner with CNSF to determine the causes of, and develop treatment for diseases and injuries of the nervous system, and in the care of patients with these diseases and injuries. Along with support of the Canadian Journal of Neurological Sciences and other initiatives the CNSF maintains throughout the year, these organizations graciously provide unrestricted educational grants to the Annual Congress, this year in Edmonton, Alberta; June 19th – 22, 2007.

Platinum





Gold







Silver

Hoffman La-Roche

Bronze

Talecris Biotherapeutics Prestwick Pharmaceuticals



Bayer Inc. Merck Frosst Codman Neuro & Depuy Spine XLTek Roxon Medi-Tech Medtronic of Canada Teva Neuroscience Valeant Canada Ltd. Canada Microsurgical Carl Zeiss Canada



*Confimed as of April 3, 2007

Helping him make connections 1,2#



CHOOSE ARICEPT®

ARICEPT is indicated for the symptomatic treatment of patients with mild-to-moderate dementia of the Alzheimer's type. ARICEPT does not change the underlying course of the disease.

The most common adverse events with ARICEPT 10 mg/d after proper dose escalation include nausea, diarrhea, insomnia, vomiting, muscle cramps, fatique and anorexia (occurring in at least 5% of patients). These events are usually mild and transient, resolving with continued ARICEPT treatment without the need for dose modification.

- + In a 24-week, randomized, double-blind, placebo-controlled study of ARICEPT in 153 mild AD patients (MMSE 21-26). Patients received either ARICEPT 5 mg/d for the first 6 weeks and 10 mg/d thereafter, (n=96), or placebo (n=57). 37% of ARICEPT-treated patients experienced a 4 point ADAS-cog improvement and 10% experienced a 7 point improvement versus 16% and 7% respectively with placebo.
- ‡ In a 24-week, multicentre, randomized, double-blind, placebo-controlled trial, 473 patients were randomized to receive ARICEPT 5 mg/d, ARICEPT 10 mg/d or placebo. Following the 24-week, double-blind phase, all patients underwent a 6-week, single-blind placebo washout. Patients treated with either dose of ARICEPT demonstrated significantly less decline on the CIBIC-plus versus placebo (CIBIC-plus value at endpoint for ARICEPT 5 mg/d and 10 mg/d were 4.15 and 4.07 respectively versus 4.51 with placebo, p=0.0047 and p<0.0001).

Product Monograph available on request



Eisai Co. Ltd., owner Pfizer Canada Inc., Licensee 2007 Pfizer Canada Inc. Kirkland, Quebec H9I 2M5 PAAB (R&D)





First Alzheimer's Therapy in Canada

https://doi.org/10.1017/S0317167100116622 Published online by Cambridge University Press

For brief prescribing information see page A-29